

CITATION REPORT

List of articles citing

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

DOI: 10.1002/ana.22366

Annals of Neurology, 2011, 69, 292-302.

Source: <https://exaly.com/paper-pdf/51484773/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2207	Essential voice tremor: treatment with propranolol. 1985 , 35, 106-8		66
2206	Regional variation in cerebral perfusion during acute hypertension. 1987 , 37, 94-9		20
2205	Recherche de bandes oligoclonales dans le LCR. 2011 , 2, 285-290		2
2204	Natural history of multiple sclerosis: early prognostic factors. 2011 , 29, 279-92		24
2203	Longitudinal extensive transverse myelitis—it's not all neuromyelitis optica. 2011 , 7, 688-98		108
2202	Dalfampridine: a new agent for symptomatic management of multiple sclerosis. 2011 , 68, 2335-40		7
2201	Multiple sclerosis in childhood and adolescence. 2011 , 311 Suppl 1, S53-7		8
2200	Subcutaneous recombinant interferon- β 1a (Rebif [®]): a review of its use in the treatment of relapsing multiple sclerosis. 2011 , 71, 1865-91		18
2199	Development of biomarkers for multiple sclerosis as a neurodegenerative disorder. 2011 , 95, 670-85		40
2198	Managed approaches to multiple sclerosis in special populations. 2011 , 17, S1-19; quiz S20-1		3
2197	No cerebral or cervical venous insufficiency in US veterans with multiple sclerosis. 2011 , 68, 1521-5		30
2196	Measures of acute and chronic lesions visualized by conventional magnetic resonance imaging. 91-111		
2195	Measures of neurological impairment and disability in multiple sclerosis. 56-64		
2194	The use of MRI in multiple sclerosis clinical trials. 198-212		
2193	Treatment for patients with primary progressive multiple sclerosis. 604-613		
2192	Use of MRI in the clinical management of multiple sclerosis. 645-653		
2191	Blurred vision and pain in the eye. 2011 , 195, 329-32		2

2190	Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis. 2011 , 2011, 740505	21
2189	Prevalence of grey matter pathology in early multiple sclerosis assessed by magnetization transfer ratio imaging. 2011 , 6, e24969	35
2188	Revised McDonald Criteria Make Diagnosis Simpler, Faster. 2011 , 11, 36-38	3
2187	Statins for multiple sclerosis. 2011 , CD008386	17
2186	Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis. 2011 ,	2
2185	[Diagnosis of pediatric multiple sclerosis initially presenting with tumefactive demyelinating lesion using ¹ H-magnetic resonance spectroscopy]. 2011 , 51, 688-93	
2184	Role of tumour necrosis factor (TNF)- α and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis. 2011 , 166, 338-45	23
2183	Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice. 2011 , 371, 170-3	21
2182	Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. 2011 , 240-241, 104-8	28
2181	Predictors of multiple sclerosis in children and implications for early initiation of treatment. 2011 , 10, 1039-41	
2180	MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. 2011 , 10, 1065-73	132
2179	[Diagnosis of multiple sclerosis 2010 revision of the McDonald criteria]. 2011 , 82, 1302-9	7
2178	The radiologically isolated syndrome: look (again) before you treat. 2011 , 11, 498-506	14
2177	The Wilson films--MS tremor. 2011 , 26, 2471-2	2
2176	Diagnostic criteria in multiple sclerosis: headed in the right direction but still a ways to go. <i>Annals of Neurology</i> , 2011 , 69, 234-6	9.4 3
2175	Reply. <i>Annals of Neurology</i> , 2011 , 70, 183-184	9.4
2174	Reply. <i>Annals of Neurology</i> , 2011 , 70, 181-182	9.4 1
2173	Cerebrospinal fluid analysis in the 2010 revised McDonald's multiple sclerosis diagnostic criteria. <i>Annals of Neurology</i> , 2011 , 70, 183; author reply 183-4	9.4 7

2172	2010 revisions to McDonald criteria for diagnosis of multiple sclerosis: impact of 3-Tesla magnetic resonance imaging. <i>Annals of Neurology</i> , 2011 , 70, 182-3	9.4	13
2171	Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. <i>Annals of Neurology</i> , 2011 , 70, 520; author reply 521	9.4	42
2170	Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America. 2011 , 4, 349-60		13
2169	The puzzle of multiple sclerosis: gray matter finds its place. 2011 , 11, 1565-8		5
2168	Multiple Sklerose – Neue Therapieoptionen. 2011 , 40, 419-421		
2167	Was gibt es Neues bei der Multiplen Sklerose?. 2011 , 38, 190-202		1
2166	Novel therapeutic approaches to autoimmune demyelinating disorders. 2011 , 17, 3191-201		2
2165	Idiopathic inflammatory demyelinating disorders of the central nervous system in children. 2011 , 22, 223-37		4
2164	Relapses do not matter in relation to long-term disability: no (they do). 2011 , 17, 1415-6		14
2163	Intrinsic damage to the major white matter tracts in patients with different clinical phenotypes of multiple sclerosis: a voxelwise diffusion-tensor MR study. 2011 , 260, 541-50		54
2162	Magnetic resonance techniques in multiple sclerosis: the present and the future. 2011 , 68, 1514-20		106
2161	Multiple sclerosis: the evolving diagnostic criteria for multiple sclerosis. 2011 , 7, 251-2		8
2160	Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. 2011 , 136, 696-704		103
2159	Epidemiology and diagnosis of multiple sclerosis. 2011 , 72, M146-51		15
2158	Neuropsychological, medical and rehabilitative management of persons with multiple sclerosis. 2011 , 29, 197-219		64
2157	The long march to surrogates of meaningful clinical outcomes in MS trials: are we there yet?. 2011 , 77, 1658-9		3
2156	Corticospinal output during muscular fatigue differs in multiple sclerosis patients compared to healthy controls. 2012 , 18, 1500-6		19
2155	Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. 2012 , 69, 1026-31		72

2154	Amyotrophic lateral sclerosis and multiple sclerosis overlap: a case report. 2012 , 2012, 324685	9
2153	Value of NMO-IgG determination at the time of presentation as CIS. 2012 , 78, 1608-11	15
2152	Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. 2012 , 13, 11718-52	123
2151	Pediatric multiple sclerosis-a challenging demyelinating disease: case report and brief review of the literature. 2012 , 2012, 684064	2
2150	Neurology and Pregnancy. 2012 ,	
2149	Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. 2012 , 19, 304-8	34
2148	Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. 2012 , 78, 540-4	32
2147	Do not treat from CIS onset: evaluate disease course and prognosis first--no (treat!). 2012 , 18, 394-5	4
2146	Are Mycobacterium avium subsp. paratuberculosis and Epstein-Barr virus triggers of multiple sclerosis in Sardinia?. 2012 , 18, 1181-4	29
2145	Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. 2012 , 18, 587-91	22
2144	Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMPO) of oral teriflunomide in relapsing multiple sclerosis. 2012 , 18, 1625-32	66
2143	Pediatric optic neuritis. 2012 , 52, 29-49, xii	23
2142	Early diagnosis, monitoring, and treatment of optic neuritis. 2012 , 18, 23-31	10
2141	MRI in multiple sclerosis: a review of the current literature. 2012 , 25, 402-9	40
2140	Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. 2012 , 32, 216-20	106
2139	MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. 2011 , 8, 13-21	57
2138	Non-specific alterations of craniocervical venous drainage in multiple sclerosis revealed by cardiac-gated phase-contrast MRI. 2012 , 18, 1000-7	9
2137	Motor fatigue measurement by distance-induced slow down of walking speed in multiple sclerosis. 2012 , 7, e34744	37

2136	No association between chronic cerebrospinal venous insufficiency and pediatric-onset multiple sclerosis. 2012 , 18, 1791-6	18
2135	Very early MS--insights from MRI. 2012 , 18, 1372-6	9
2134	Do not treat from CIS onset: evaluate disease course and prognosis first--yes. 2012 , 18, 391-3	3
2133	CLIPPERS complicating multiple sclerosis causing concerns of CNS lymphoma. 2012 , 79, 715-6	26
2132	Multigate quality Doppler profiles and morphological/hemodynamic alterations in multiple sclerosis patients. 2012 , 9, 120-7	28
2131	Differenzialdiagnose der Multiplen Sklerose (MS) - MS Mimicks. 2012 , 39, 83-99	1
2130	Use of intravenous immunoglobulin in the treatment of immune-mediated demyelinating diseases of the nervous system. 2012 , 18, 4570-82	11
2129	Diseases Involving Myelin. 2012 , 691-704	
2128	Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. 2012 , 79, 708-14	152
2127	Predicting breakdown of the blood-brain barrier in multiple sclerosis without contrast agents. 2012 , 33, 1586-90	21
2126	A touch of MS: therapeutic mislabeling. 2012 , 78, 1981-5	12
2125	Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy. 2012 , 117, 284-92	20
2124	[2012: Update on diagnosis and treatment of multiple sclerosis]. 2012 , 137, 894-9	3
2123	Radiologisch isoliertes Syndrom: Verlauf und Empfehlungen zum klinischen Management. 2012 , 39, S6-S9	
2122	Polyarteritis nodosa with central nervous system involvement mimicking relapsing&emitting multiple sclerosis. 2012 , 1	
2121	FLAIR*: a combined MR contrast technique for visualizing white matter lesions and parenchymal veins. 2012 , 265, 926-32	77
2120	Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. 2012 , 264, 225-33	65
2119	Distribution of brain sodium accumulation correlates with disability in multiple sclerosis: a cross-sectional ²³ Na MR imaging study. 2012 , 264, 859-67	87

2118	Advances in imaging to support the development of novel therapies for multiple sclerosis. 2012 , 91, 621-34	17
2117	Application of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Spanish cohort of patients with clinically isolated syndromes. 2012 , 18, 39-44	33
2116	Magnetic resonance imaging signatures of vascular pathology in multiple sclerosis. 2012 , 34, 780-92	21
2115	Update on multiple sclerosis, its diagnosis and treatments. 2012 , 50, 1203-10	3
2114	Journal club: Intrathecal effects of daclizumab treatment of multiple sclerosis. 2012 , 78, e131-3	1
2113	Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy. 2012 , 33, 1596-601	51
2112	Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis. 2012 , 18, 322-8	26
2111	Truly benign multiple sclerosis is rare: let's stop fooling ourselves--no. 2012 , 18, 11-2	10
2110	Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI. 2012 , 83, 877-82	108
2109	Therapeutisches Drug-Monitoring der Natalizumab-Sättigung von Immunzellen mittels Durchflusszytometrie bei Multipler Sklerose/Flow cytometry and drug monitoring of natalizumab saturation of immune cells in multiple sclerosis. 2012 , 36,	
2108	Zukünftiger Stellenwert von Liquor-Biomarker in der modernen MS-Therapie/Future relevance of CSF biomarkers in modern MS treatment. 2012 , 36,	
2107	Predictors of Conversion to Multiple Sclerosis in Patients with Clinical Isolated Syndrome Using the 2010 Revised McDonald Criteria. 2012 , 2012, 792192	18
2106	Voxelwise analysis of conventional magnetic resonance imaging to predict future disability in early relapsing-remitting multiple sclerosis. 2012 , 18, 1585-91	10
2105	Emerging oral immunomodulating agents - focus on teriflunomide for the treatment of multiple sclerosis. 2012 , 2, 15-28	4
2104	BG-12 and its potential for the prevention of relapse in multiple sclerosis. 2012 , 2, 119-132	1
2103	The impact of osteopontin gene variations on multiple sclerosis development and progression. 2012 , 2012, 212893	25
2102	Activities-specific balance confidence in people with multiple sclerosis. 2012 , 2012, 613925	56
2101	Cortical Pathology in RRMS: Taking a Cue from Four Sisters. 2012 , 2012, 760254	2

2100	Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time: commentary. 2012 , 18, 1533	3
2099	Moyamoya disease can masquerade as multiple sclerosis. 2012 , 18, 398-403	8
2098	A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy. 2012 , 135, 900-11	38
2097	Multiple sclerosis: a comprehensive review for the physician assistant. 2012 , 25, 24-9	6
2096	A case of relapsing-remitting neuroborreliosis? Challenges in the differential diagnosis of recurrent myelitis. 2012 , 4, 47-53	2
2095	Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine. 2012 , 4, 1-14	3
2094	Neuropathologic correlates of magnetic resonance imaging in multiple sclerosis. 2012 , 71, 762-78	18
2093	Teriflunomide for multiple sclerosis. 2012 ,	1
2092	Carnitine for fatigue in multiple sclerosis. 2012 , CD007280	15
2091	Placebo-controlled trials in relapsing&remitting multiple sclerosis: are they still needed?. 2012 , 7, 37-44	
2090	Fluoxetine for multiple sclerosis. 2012 ,	
2089	Unmet medical needs with current standard treatments. 2012 , 6-16	
2088	Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients. 2012 , 12, CD009903	3
2087	Multiple sclerosis-associated uveitis. 2012 , 7, 587-594	3
2086	CD226 Gly307Ser association with neuromyelitis optica in Southern Han Chinese. 2012 , 39, 488-90	11
2085	Cerebrospinal fluid IL-21 levels in Neuromyelitis Optica and multiple sclerosis. 2012 , 39, 813-20	20
2084	Association of neuromyelitis optica with severe and intractable pain. 2012 , 69, 1482-7	65
2083	Multiple sclerosis: symptom management. 2012 , 14, 405-409	1

2082	A perceptually relevant channelized joint observer (PCJO) for the detection-localization of parametric signals. 2012 , 31, 1875-88	8
2081	The clinical overlap of multiple sclerosis and headache. 2012 , 52 Suppl 2, 111-6	7
2080	Measurement and clinical effect of grey matter pathology in multiple sclerosis. 2012 , 11, 1082-92	213
2079	Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. 2012 , 56, 508-13	34
2078	Vitamin D responsive elements within the HLA-DRB1 promoter region in Sardinian multiple sclerosis associated alleles. 2012 , 7, e41678	26
2077	Fingolimod for multiple sclerosis. 2012 , 366, 339-47	238
2076	MS, MRI, and the 2010 McDonald criteria: a Canadian expert commentary. 2012 , 79, S1-15	24
2075	Disease-specific therapy of idiopathic inflammatory demyelinating disorders. 2012 , 12, 1113-24	2
2074	Using magnetic resonance imaging as a means to study chronic cerebral spinal venous insufficiency in multiple sclerosis patients. 2012 , 15, 101-12	22
2073	Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. <i>Annals of Neurology</i> , 2012 , 72, 610-24	9.4 201
2072	Cerebrospinal fluid and lumbar puncture: a practical review. 2012 , 259, 1530-45	108
2071	Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender. 2012 , 259, 2105-10	30
2070	Wheels within wheels: multifocal autoimmune myelitis in a woman with Huntington's disease. 2012 , 259, 1973-5	
2069	Patients with migraine do not have MRI-visible cortical lesions. 2012 , 259, 2695-8	46
2068	Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: A case-control study from Iran. 2012 , 1, 375-380	2
2067	Inflammation high-field magnetic resonance imaging. 2012 , 22, 135-57, ix	21
2066	Development of Guillain-Barré syndrome in a patient with multiple sclerosis during treatment with glatiramer acetate. 2012 , 46, 189-91	2
2065	Immunotherapies in neurologic disorders. 2012 , 96, 497-523, x	7

2064	Classification of individuals based on ex-vivo glatiramer acetate-induced interferon- γ and interleukin-4 response. 2012 , 18, 1484-92	2
2063	WITHDRAWN: Guía para el tratamiento de pacientes con esclerosis múltiple: uso de inmunomoduladores e inmunosupresores. 2012 ,	
2062	Evaluation of the 2010 McDonald multiple sclerosis criteria in children with a clinically isolated syndrome. 2012 , 18, 1768-74	27
2061	Association of SNPs rs6498169 and rs10984447 with multiple sclerosis in Saudi patients: a model of the usefulness of familial aggregates in identifying genetic linkage in a multifactorial disease. 2012 , 18, 1395-400	8
2060	Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies. 2012 , 12, 453-61	9
2059	Management of children with multiple sclerosis. 2012 , 14, 165-77	8
2058	Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus study. 2012 , 2, 48-57	17
2057	Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus study. 2012 , 2, 58-66	9
2056	Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis. 2012 , CD009427	6
2055	Demyelinating optic neuritis presenting as a clinically isolated syndrome. 2012 , 83, 9-18	3
2054	Paediatric multiple sclerosis: examining utility of the McDonald 2010 criteria. 2012 , 18, 679-82	17
2053	Demyelinating Diseases. 2012 , 50-57	
2052	Cerebrospinal fluid β -synuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during relapse. 2012 , 122, 19-23	25
2051	High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis. 2012 , 413, 1813-6	39
2050	Seroprevalence of NMO-IgG among patients with neuromyelitis optica and opticospinal multiple sclerosis. 2012 , 114, 17-20	8
2049	Old findings in multiple sclerosis but a new application. 2012 , 114, 411	
2048	Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. 2012 , 11, 963-72	216
2047	2010 McDonald criteria for diagnosing pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2012 , 72, 211-239.4	94

2046	Robert Whytt, Benjamin Franklin, and the first probable case of multiple sclerosis. <i>Annals of Neurology</i> , 2012 , 72, 307-11	9.4	2
2045	The feasibility of collecting information from people with Multiple Sclerosis for the UK MS Register via a web portal: characterising a cohort of people with MS. 2012 , 12, 73		47
2044	JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients. 2012 , 10, 248		16
2043	Efficacy of vision restoration therapy after optic neuritis (VISION study): study protocol for a randomized controlled trial. 2012 , 13, 94		7
2042	New magnetic resonance imaging biomarkers for the diagnosis of multiple sclerosis. 2012 , 6, 109-20		8
2041	Adherence to MRI protocol consensus guidelines in multiple sclerosis: an Australian multi-centre study. 2012 , 56, 594-8		9
2040	From the Gothenburg cohort to the Swedish multiple sclerosis registry. 2012 , 126, 13-9		23
2039	Incidence and prevalence of multiple sclerosis in Norway. 2012 , 126, 36-42		13
2038	The Norwegian Multiple Sclerosis Registry and Biobank. 2012 , 126, 20-3		13
2037	Diagnosis. 2012 , 77-100		
2036	Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. 2012 , 32, 1007-11		53
2035	Imaging and diagnostic criteria for Multiple Sclerosis: are we there yet?. 2012 , 56, 588-93		4
2034	First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview. 2012 , 72, 1195-211		12
2033	Teriflunomide for multiple sclerosis. 2012 , 12, CD009882		14
2032	MR imaging findings of the corpus callosum region in the differentiation between multiple sclerosis and neuromyelitis optica. 2012 , 81, 3491-5		8
2031	Multi-task functional MRI in multiple sclerosis patients without clinical disability. 2012 , 59, 573-81		24
2030	An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. 2012 , 59, 3774-83		677
2029	The application of Fourier transform infrared microspectroscopy for the study of diseased central nervous system tissue. 2012 , 59, 3624-40		74

2028	Classifying minimally disabled multiple sclerosis patients from resting state functional connectivity. 2012 , 62, 2021-33	75
2027	Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica. 2012 , 226, 510-6	23
2026	Altered frequency of T regulatory cells is associated with disability status in relapsing-remitting multiple sclerosis patients. 2012 , 249, 76-82	23
2025	Decreased serum levels of nucleolin protein fragment, as analyzed by bead-based proteomic technology, in multiple sclerosis patients compared to controls. 2012 , 250, 71-6	15
2024	Multiple sclerosis-linked and interferon-beta-regulated gene expression in plasmacytoid dendritic cells. 2012 , 250, 99-105	10
2023	Clinical and magnetic resonance imaging features of multiple sclerosis with autoreactive antibodies in Ishikawa Prefecture, Japan. 2012 , 250, 111-4	1
2022	Optic neuritis in an ethnically diverse population: higher risk of atypical cases in patients of African or African-Caribbean heritage. 2012 , 312, 21-5	19
2021	Interleukin 17 gene polymorphism is associated with anti-aquaporin 4 antibody-positive neuromyelitis optica in the Southern Han Chinese--a case control study. 2012 , 314, 26-8	39
2020	Olfactory function in patients with multiple sclerosis: a diffusion tensor imaging study. 2012 , 316, 56-60	27
2019	Neuro-imaging: a review for the general ophthalmologist. 2012 , 27, 192-6	1
2018	Clinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques. 2012 , 12, 323-33	11
2017	Multiple sclerosis and pregnancy: maternal considerations. 2012 , 8, 399-414	10
2016	Imaging of neurologic conditions during pregnancy and the perinatal period. 2012 , 30, 791-822	7
2015	[Prevention of multiple sclerosis: a realistic goal?]. 2012 , 168, 836-45	
2014	Multiple sclerosis: new insights in pathogenesis and novel therapeutics. 2012 , 63, 389-404	55
2013	Cerebrospinal fluid myelin basic protein is frequently ordered but has little value: a test utilization study. 2012 , 138, 262-72	18
2012	Benign multiple sclerosis: does it exist?. 2012 , 12, 601-9	24
2011	Riproducibilit� del punteggio EDSS calcolato con un nuovo software dedicato rispetto al metodo tradizionale in uso. 2012 , 31, 26-31	

2010	Sera from neuromyelitis optica patients disrupt the blood-brain barrier. 2012 , 83, 288-97	72
2009	Assessing brain connectivity at rest is clinically relevant in early multiple sclerosis. 2012 , 18, 1251-8	111
2008	Pediatric multiple sclerosis. 2012 , 27, 1378-83	43
2007	"Undiagnosing" multiple sclerosis: the challenge of misdiagnosis in MS. 2012 , 78, 1986-91	92
2006	Mycophenolate mofetil for relapsing-remitting multiple sclerosis. 2012 ,	
2005	When does multiple sclerosis start? Three case reports and a review of the literature. 2012 , 168, 846-51	3
2004	Recommendations for a definition of multiple sclerosis in support of early treatment. 2012 , 168, 328-37	2
2003	Multiple sclerosis: Which MRI findings predict MS development in children?. 2012 , 8, 185-6	0
2002	Automated detection of multiple sclerosis lesions in serial brain MRI. 2012 , 54, 787-807	55
2001	Impact of electroacupuncture on quality of life for patients with Relapsing-Remitting Multiple Sclerosis under treatment with immunomodulators: a randomized study. 2012 , 12, 209	23
2000	Neuropsychiatric Dysfunction in Multiple Sclerosis. 2012 ,	5
1999	Endotoxin- and ATP-neutralizing activity of alkaline phosphatase as a strategy to limit neuroinflammation. 2012 , 9, 266	18
1998	Measles IgG antibody index correlates with T2 lesion load on MRI in patients with early multiple sclerosis. 2012 , 7, e28094	20
1997	Intrathecal, polyspecific antiviral immune response in oligoclonal band negative multiple sclerosis. 2012 , 7, e40431	27
1996	Low serum urate levels are associated to female gender in multiple sclerosis patients. 2012 , 7, e40608	19
1995	A weak leg. 2012 , 344, e2712	
1994	The photopic negative response of the flash electroretinogram in multiple sclerosis. 2012 , 53, 1315-23	46
1993	Multiple Sclerosis and Demyelinating Conditions of the Central Nervous System. 2012 , 2347-2355	

1992	Multiple sclerosis. 2012 , 122, 1180-8	384
1991	Frü den Krankheitsverlauf der MS beeinflussen. 2012 , 13, 67-67	
1990	Multiple Sclerosis. 237-238	
1989	Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients. 2012 ,	2
1988	Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort. 2012 , 70, 774-9	8
1987	Incidental demyelinating inflammatory lesions in asymptomatic patients: a Brazilian cohort with radiologically isolated syndrome and a critical review of current literature. 2012 , 70, 5-11	20
1986	Multiple sclerosis: an overview. 2012 , 14, 335-337	1
1985	Cognitive impairment in patients with clinically isolated syndrome. 2012 , 6, 266-269	5
1984	Multiple Sclerosis and Celiac Disease. 2012 ,	
1983	Multiple sclerosis and sexual dysfunction. 2012 , 14, 530-5	49
1982	Comparison of functional exercise capacity, pulmonary function and respiratory muscle strength in patients with multiple sclerosis with different disability levels and healthy controls. 2012 , 44, 80-6	36
1981	Neuroimaging in Multiple Sclerosis. 2012 ,	2
1980	Shifting imaging targets in multiple sclerosis: from inflammation to neurodegeneration. 2012 , 36, 1-19	41
1979	White matter and deep gray matter hemodynamic changes in multiple sclerosis patients with clinically isolated syndrome. 2012 , 68, 1932-42	29
1978	Multiple sclerosis or multiple possibilities: the continuing problem of misdiagnosis. 2012 , 78, 1904-6	20
1977	Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?. 2012 , 123, 627-38	133
1976	A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. 2012 , 259, 801-16	43
1975	Cluster-tic syndrome as the initial manifestation of multiple sclerosis. 2012 , 13, 425-9	12

1974	New and emerging disease modifying therapies for multiple sclerosis. 2012 , 1247, 117-37	38
1973	Cuprizone-induced demyelination in the rat cerebral cortex and thyroid hormone effects on cortical remyelination. 2012 , 235, 357-67	47
1972	Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. 2012 , 11, 33-41	153
1971	Multiple sclerosis: more pieces of the immunological puzzle. 2012 , 11, 9-10	8
1970	Clinically isolated syndromes. 2012 , 11, 157-69	307
1969	Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. 2012 , 3, 58-73	61
1968	The CD4+ T-cell subset lacking expression of the CD28 costimulatory molecule is expanded and shows a higher activation state in multiple sclerosis. 2012 , 243, 1-11	20
1967	Plasma sCD28, sCTLA-4 levels in neuromyelitis optica and multiple sclerosis during relapse. 2012 , 243, 52-5	7
1966	The association of V249I and T280M fractalkine receptor haplotypes with disease course of multiple sclerosis. 2012 , 245, 87-92	13
1965	From bench to MS bedside: challenges translating biomarker discovery to clinical practice. 2012 , 248, 66-72	7
1964	The diagnostic criteria for multiple sclerosis: From Charcot to McDonald. 2012 , 1, 9-14	22
1963	Focal segmental glomerulosclerosis secondary to subcutaneous interferon β 1a treatment in a patient with multiple sclerosis. 2012 , 1, 148-51	2
1962	Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliaopathy. 2012 , 42, 26-34	77
1961	Corticosteroid therapy in a patient with cerebral amyloid angiopathy-related inflammation. 2013 , 10, 39	16
1960	Increased plasma interleukin-32 expression in patients with neuromyelitis optica. 2013 , 33, 666-70	19
1959	A novel data mining system points out hidden relationships between immunological markers in multiple sclerosis. 2013 , 10, 1	20
1958	Prevalence and significant determinants of post-traumatic stress disorder in a large sample of patients with multiple sclerosis. 2013 , 20, 240-6	20
1957	MRI characteristics of trigeminal nerve involvement in patients with multiple sclerosis. 2013 , 2, 200-3	14

1956	A pilot MRI study of white and grey matter involvement by multiple sclerosis spinal cord lesions. 2013 , 2, 103-8	26
1955	Imaging of the pre-chiasmatic optic nerve. 2013 , 94, 973-84	7
1954	Can we prevent or treat multiple sclerosis by individualised vitamin D supply?. 2013 , 4, 4	37
1953	Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. 2013 , 113, 415-20	6
1952	Correlation between blink reflex abnormalities and magnetic resonance imaging findings in patients with multiple sclerosis. 2013 , 113, 265-9	6
1951	Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. A new entity?. 2013 , 113, 533-4	6
1950	Autonomic dysfunction in multiple sclerosis presenting with postural orthostatic tachycardia. 2013 , 113, 337-9	1
1949	Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks. 2013 , 28, 629-38	12
1948	Glatiramer Acetate Treatment-Related Effects on Visual EPs and P300 Wave in Patients Suffering from Multiple Sclerosis. 2013 , 45, 234-242	
1947	Analysis of "task-positive" and "task-negative" functional networks during the performance of the Symbol Digit Modalities Test in patients at presentation with clinically isolated syndrome suggestive of multiple sclerosis. 2013 , 225, 399-407	13
1946	Axial 3D gradient-echo imaging for improved multiple sclerosis lesion detection in the cervical spinal cord at 3T. 2013 , 55, 431-9	25
1945	Progressive Multiple Sclerosis. 2013 ,	
1944	The role of exercise in modifying outcomes for people with multiple sclerosis: a randomized trial. 2013 , 13, 69	20
1943	Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. 2013 , 13, 60	52
1942	Incidence of multiple sclerosis among European Economic Area populations, 1985-2009: the framework for monitoring. 2013 , 13, 58	20
1941	The clinical potential of blood-proteomics in multiple sclerosis. 2013 , 13, 45	4
1940	Secretory phospholipase A2 activity in serum and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis. 2013 , 262, 125-7	2
1939	Multiple sclerosis and the spinal cord. 2013 , 31, 55-77	7

1938	A Sardinian map for multiple sclerosis. 2013 , 8, 223-32	34
1937	Contribution of magnetic resonance imaging to the diagnosis and monitoring of multiple sclerosis. 2013 , 118, 251-64	15
1936	Brainstem encephalitis: etiologies, treatment, and predictors of outcome. 2013 , 260, 2312-9	33
1935	Longitudinal 7-year follow-up of chronic pain in persons with multiple sclerosis in the community. 2013 , 260, 2005-15	15
1934	Hemolytic uremic syndrome: an unusual complication of interferon- β treatment in a MS patient. 2013 , 260, 1915-6	13
1933	Acute necrotizing encephalopathy (ANE1): rare autosomal-dominant disorder presenting as acute transverse myelitis. 2013 , 260, 1545-53	20
1932	Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study. 2013 , 260, 1583-93	25
1931	Torque teno virus (TTV) in multiple sclerosis patients with different patterns of disease. 2013 , 85, 2176-83	16
1930	Variants in the promoter region of CYP7A1 are associated with neuromyelitis optica but not with multiple sclerosis in the Han Chinese population. 2013 , 29, 525-30	13
1929	Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. 2013 , 34, 2085-93	40
1928	Multiple Sclerosis and Other Demyelinating Disorders. 2013 , 1-8	
1927	Pattern electroretinogram in neuromyelitis optica and multiple sclerosis with or without optic neuritis and its correlation with FD-OCT and perimetry. 2013 , 127, 201-15	18
1926	Metabolomic approach to human brain spectroscopy identifies associations between clinical features and the frontal lobe metabolome in multiple sclerosis. 2013 , 82, 586-94	24
1925	[Interferon- β in multiple sclerosis therapy: more than 20 years clinical experience]. 2013 , 84, 679-704	2
1924	Coexistence of multiple sclerosis and ankylosing spondylitis: report of two cases. 2013 , 70, 149-54	7
1923	Intrathecal oligoclonal IgG synthesis in multiple sclerosis. 2013 , 262, 1-10	91
1922	Therapies for multiple sclerosis: translational achievements and outstanding needs. 2013 , 19, 309-19	68
1921	^1H magnetic resonance spectroscopy in multiple sclerosis and related disorders. 2013 , 23, 459-74	27

1920	[Is MRI monitoring useful in clinical practice in patients with multiple sclerosis? No]. 2013 , 169, 864-8	0
1919	The utility of multimodal evoked potentials in multiple sclerosis prognostication. 2013 , 20, 1576-81	21
1918	[Correlation between demyelinating lesions and executive function decline in a sample of Mexican patients with multiple sclerosis]. 2013 , 28, 394-9	2
1917	Postural control, falls and fear of falling in people with multiple sclerosis without mobility aids. 2013 , 335, 186-90	50
1916	CLIPPERS-like MRI findings in a patient with multiple sclerosis. 2013 , 327, 61-2	29
1915	The B1-cell subpopulation is diminished in patients with relapsing-remitting multiple sclerosis. 2013 , 262, 92-9	20
1914	Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators. 2013 , 258, 77-84	17
1913	Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report. 2013 , 47, 145-51	3
1912	LSN MS guidelines for the management of multiple sclerosis. 2013 , 169, 950-5	1
1911	Myeloproliferative neoplasms in five multiple sclerosis patients. 2013 , 2, 61-3	4
1910	The glutathione S-transferase T1 deletion is associated with susceptibility to multiple sclerosis. 2013 , 334, 6-9	12
1909	Association of serum vitamin D levels in Japanese patients with multiple sclerosis. 2013 , 4, 193-200	10
1908	Pharmacological treatment for memory disorder in multiple sclerosis. 2013 , CD008876	17
1907	Brain reserve and cognitive reserve in multiple sclerosis: what you've got and how you use it. 2013 , 80, 2186-93	112
1906	Feasibility and safety of endovascular treatment for chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. 2013 , 58, 1609-18	15
1905	Personalized Management of Multiple Sclerosis. 2013 ,	
1904	Laquinimod for multiple sclerosis. 2013 , CD010475	1
1903	The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis. 2013 , 264, 100-5	26

1902 Cambios e implicaciones en la aplicaci3n de la revisi3n de criterios de McDonald 2010 en los s3ndromes cl3nicamente aislados. **2013**, 5, 70-77

1901 Rituximab for relapsing-remitting multiple sclerosis. **2013**, CD009130 25

1900 Role of puberty in multiple sclerosis risk and course. **2013**, 149, 192-200 50

1899 Biased Treg/Th17 balance away from regulatory toward inflammatory phenotype in relapsed multiple sclerosis and its correlation with severity of symptoms. **2013**, 262, 106-12 66

1898 Superficial brain stimulation in multiple sclerosis. **2013**, 116, 577-84 2

1897 Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. **2013**, 23, 661-83 149

1896 Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder. **2013**, 260, 3150-7 13

1895 Pediatric multiple sclerosis: what we know and where are we headed?. **2013**, 19, 1-22 16

1894 Multiple Sclerosis Immunology. **2013**, 4

1893 Aquaporin-4 antibody negative recurrent isolated optic neuritis: clinical evidence for disease heterogeneity. **2013**, 331, 72-5 10

1892 Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention. **2013**, 13, 403 61

1891 Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability. **2013**, 37, 819-30 78

1890 [Update on diagnosis and treatment of multiple sclerosis]. **2013**, 34, 628-35 2

1889 Voxel-wise mapping of cervical cord damage in multiple sclerosis patients with different clinical phenotypes. **2013**, 84, 35-41 38

1888 MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients. **2013**, 14, 16087-110 92

1887 Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. **2013**, 3, 65-80 20

1886 Fulminant demyelinating diseases. **2013**, 3, 81-91 37

1885 Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5D. **2013**, 19, 1190-6 22

1884	Multiple Sclerosis. 2013 , 785-801	1
1883	Multiple Sclerosis. 2013 , 329-349	2
1882	Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis. 2013 , 19, 1726-33	39
1881	Epstein-Barr virus neuraxis infection as a trigger for central nervous system demyelinating processes: a case report. 2013 , 19, 380-1	3
1880	International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. 2013 , 19, 1261-7	646
1879	2010 McDonald criteria in a pediatric cohort: is positivity at onset associated with a more aggressive multiple sclerosis course?. 2013 , 19, 1359-62	8
1878	Novel immunomodulatory approaches for the management of multiple sclerosis. 2014 , 95, 32-44	17
1877	Pediatric onset multiple sclerosis: McDonald criteria 2010 and the contribution of spinal cord MRI. 2013 , 19, 1330-5	28
1876	Application of the 2010 revised criteria for the diagnosis of multiple sclerosis to patients with clinically isolated syndromes. 2013 , 20, 1510-6	16
1875	Risk factors for falls in multiple sclerosis: an observational study. 2013 , 19, 1913-22	92
1874	Auditory evoked potentials and vestibular evoked myogenic potentials in evaluation of brainstem lesions in multiple sclerosis. 2013 , 328, 24-7	23
1873	Muscle-specific kinase antibody positive myasthenia gravis and multiple sclerosis co-presentation: a case report and literature review. 2013 , 264, 130-3	6
1872	Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course. 2013 , 19, 411-7	22
1871	Idiopathic acute transverse myelitis: outcome and conversion to multiple sclerosis in a large series. 2013 , 13, 135	28
1870	Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double-blind placebo-controlled trial. 2013 , 14, 272	16
1869	Multiple sclerosis presenting initially with a worsening of migraine symptoms. 2013 , 14, 70	15
1868	Sleep disturbances in patients with multiple sclerosis. 2013 , 34, 1291-6	35
1867	Small internal jugular veins with restricted outflow are associated with severe multiple sclerosis: a sonographer-blinded, case-control ultrasound study. 2013 , 13, 90	8

1866	Balance exercise for persons with multiple sclerosis using Wii games: a randomised, controlled multi-centre study. 2013 , 19, 209-16	107
1865	Increased seroreactivity to HERV-K10 peptides in patients with HTLV myelopathy. 2013 , 10, 360	11
1864	Anti Mycobacterium avium subsp. paratuberculosis heat shock protein 70 antibodies in the sera of Sardinian patients with multiple sclerosis. 2013 , 335, 131-3	20
1863	Multiple sclerosis: Oligoclonal bands--a useful tool to avoid MS misdiagnosis. 2013 , 9, 303-4	5
1862	Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. 2013 , 34, 445-57	20
1861	Quantitative evaluation of CXCL8 and its receptors (CXCR1 and CXCR2) gene expression in Iranian patients with multiple sclerosis. 2013 , 42, 737-48	7
1860	Recent progress in omics-driven analysis of MS to unravel pathological mechanisms. 2013 , 13, 1001-16	4
1859	Analyses of haptoglobin level in the cerebrospinal fluid and serum of patients with neuromyelitis optica and multiple sclerosis. 2013 , 417, 26-30	26
1858	Differences in oligoclonal bands and visual evoked potentials in patients with radiologically and clinically isolated syndrome. 2013 , 113, 13-7	17
1857	Cerebral vein changes in relapsing-remitting multiple sclerosis demonstrated by three-dimensional enhanced T2-weighted angiography at 3.0 T. 2013 , 23, 869-78	5
1856	Validity and reliability of Persian version of Modified Fatigue Impact Scale (MFIS) questionnaire in Iranian patients with multiple sclerosis. 2013 , 35, 1509-12	34
1855	Cell-based reporter gene assay for therapy-induced neutralizing antibodies to interferon-beta in multiple sclerosis. 2013 , 33, 52-7	4
1854	Information Criteria for Dynamic Contrast-Enhanced Magnetic Resonance Imaging. 2013 ,	1
1853	Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. 2013 , 19, 1052-9	128
1852	Lack of Visual Habituation in Multiple Sclerosis: An Electrophysiological Study. 2013 , 37, 7-11	
1851	Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. 2013 , 19, 76-86	94
1850	Evoked potentials are of little use in the diagnosis or monitoring of MS: commentary. 2013 , 19, 1824-5	6
1849	Evoked potentials are of little use in the diagnosis or monitoring of MS: yes. 2013 , 19, 1820-1	5

1848	Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients. 2013 , 19, 1101-5	61
1847	Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations. 2013 , 81, 2073-81	73
1846	An approach to optic neuritis: the initial presentation. 2013 , 8, 539-551	3
1845	Neuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy. 2013 , 10, 111-23	21
1844	Interferon beta and glatiramer acetate therapy. 2013 , 10, 2-18	45
1843	Postural orthostatic tachycardia syndrome associated with multiple sclerosis. 2013 , 173, 65-8	16
1842	Tumefactive demyelination: an approach to diagnosis and management. 2013 , 84, 1047-53	90
1841	Multiple sclerosis: new measures to monitor the disease. 2013 , 12, 12-3	6
1840	Neuromuscular disease: new insights and avenues for therapy. 2013 , 12, 13-5	2
1839	Multiple sclerosis shrinks intralesional, and enlarges extralesional, brain parenchymal veins. 2013 , 80, 145-51	34
1838	Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging. 2013 , 17, 1-18	228
1837	Radiologically isolated syndrome--incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review. 2013 , 19, 271-80	90
1836	Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic. 2013 , 70, 338-44	56
1835	Periventricular venous density in multiple sclerosis is inversely associated with T2 lesion count: a 7 Tesla MRI study. 2013 , 19, 316-25	42
1834	White matter volume is decreased in the brain of patients with neuromyelitis optica. 2013 , 20, 361-7	38
1833	Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate. 2013 , 240, 130-44	35
1832	The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review. 2013 , 19, 844-54	52
1831	Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter. 2013 , 23, 528-40	50

1830	Perception of affective prosody in patients at an early stage of relapsing-remitting multiple sclerosis. 2013 , 7, 91-106	16
1829	[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. 2013 , 88, 1204-12	31
1828	Transcranial direct current stimulation ameliorates tactile sensory deficit in multiple sclerosis. 2013 , 6, 654-9	42
1827	[Gluten-related disorders and demyelinating diseases]. 2013 , 140, 314-9	4
1826	Neurophysiologische Diagnostik und Diagnosekriterien neuroimmunologischer Erkrankungen Multiple Sklerose. 2013 , 35, 1-17	
1825	Quantification of multiple-sclerosis-related brain atrophy in two heterogeneous MRI datasets using mixed-effects modeling. 2013 , 3, 171-9	28
1824	Clinical assessment of orofacial manifestations in 500 patients with multiple sclerosis. 2013 , 71, 290-4	44
1823	Association of HLA-DRB1*1501 tagging rs3135388 gene polymorphism with multiple sclerosis. 2013 , 255, 92-6	15
1822	[Neuropsychiatric manifestations in multiple sclerosis (MS): Might psychotic symptoms signal the onset of the disease?]. 2013 , 42, 1186-95	5
1821	Accurate white matter lesion segmentation by k nearest neighbor classification with tissue type priors (kNN-TTPs). 2013 , 3, 462-9	137
1820	Cerebrospinal fluid light and heavy neurofilaments in neuromyelitis optica. 2013 , 63, 805-8	10
1819	Within-lesion differences in quantitative MRI parameters predict contrast enhancement in multiple sclerosis. 2013 , 38, 1454-61	33
1818	Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis. 2013 , 81, 956-63	25
1817	Multiple sclerosis and fracture. 2013 , 123, 609-16	4
1816	Symptoms and diagnosis of multiple sclerosis. 2013 , 36-48	0
1815	Decreased Ocular Pulse Amplitude and Retinal Nerve Fibre Layer in Multiple Sclerosis. 2013 , 37, 95-99	1
1814	Cognitive impairment and optic nerve axonal loss in patients with clinically isolated syndrome. 2013 , 115, 1032-5	10
1813	Reduced habituation of the retinal ganglion cell response to sustained pattern stimulation in multiple sclerosis patients. 2013 , 124, 1652-8	9

1812	Pragmatic exercise intervention in people with mild to moderate multiple sclerosis: a randomised controlled feasibility study. 2013 , 35, 40-7	29
1811	Seropositive neuromyelitis optica: a pediatric case report and 6-year follow-up. 2013 , 49, 198-202	1
1810	Psychometric properties of a revised Spanish 20-item Toronto Alexithymia Scale adaptation in multiple sclerosis patients. 2013 , 13, 226-234	13
1809	A single lesion-And yet MS?. 2013 , 2, 154-5	
1808	Imagerie des voies optiques pr�chiasmaticques. 2013 , 94, 979-991	
1807	Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. 2013 , 40, 21-7	55
1806	Intra-individual variability in information processing speed reflects white matter microstructure in multiple sclerosis. 2013 , 2, 894-902	21
1805	A long-term follow-up study using IPMSSG criteria in children with CNS demyelination. 2013 , 49, 329-34	23
1804	Correlation between demyelinating lesions and executive function decline in a sample of Mexican patients with multiple sclerosis. 2013 , 28, 394-399	
1803	Neuromielitis �tica: actualizaci�n cl�nica y terap�utica. 2013 , 5, 259-269	
1802	Serum amyloid A level is increased in neuromyelitis optica and atypical multiple sclerosis with smaller T2 lesion volume in brain MRI. 2013 , 259, 92-5	13
1801	Delay in the diagnosis of multiple sclerosis in Croatia. 2013 , 115 Suppl 1, S70-2	13
1800	Comparison of the 2010 and 2005 versions of the McDonald MRI criteria for dissemination-in-time in Taiwanese patients with classic multiple sclerosis. 2013 , 329, 51-4	11
1799	Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis. 2013 , 263, 159-61	14
1798	Determination of �LC and �index in cerebrospinal fluid: a valid alternative to assess intrathecal immunoglobulin synthesis. 2013 , 263, 116-20	51
1797	[Is MRI monitoring useful in clinical practice in patients with multiple sclerosis? Yes]. 2013 , 169, 858-63	2
1796	The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in plasma and CSF. 2013 , 62, 988-97	27
1795	DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis. 2013 , 2, 258-62	26

1794	Treating multiple sclerosis with monoclonal antibodies: a 2013 update. 2013 , 13, 313-35	40
1793	Helicobacter pylori infection in Neuromyelitis Optica and Multiple Sclerosis. 2013 , 20, 107-12	34
1792	IgM to S-nitrosylated protein is found intrathecally in relapsing-remitting multiple sclerosis. 2013 , 256, 77-83	10
1791	A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica). 2013 , 19, 1371-80	5
1790	Mycobacterium avium subsp. paratuberculosis and multiple sclerosis in Sardinian patients: epidemiology and clinical features. 2013 , 19, 1437-42	27
1789	Postinfectious neurologic syndromes: a prospective cohort study. 2013 , 80, 882-9	39
1788	Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. 2013 , 80, 234-41	42
1787	Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. 2013 , 80, 69-75	118
1786	Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. 2013 , 70, 34-43	161
1785	Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course. 2013 , 257, 97-101	49
1784	The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. 2013 , 9, 267-76	144
1783	Central veins in brain lesions visualized with high-field magnetic resonance imaging: a pathologically specific diagnostic biomarker for inflammatory demyelination in the brain. 2013 , 70, 623-8	59
1782	Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. 2013 , 128, 321-7	13
1781	A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden. 2013 , 16, 756-62	5
1780	Movement disorders in multiple sclerosis and other demyelinating diseases. 2013 , 328, 1-8	60
1779	Synthesis and characterization of a novel gadolinium-based contrast agent for magnetic resonance imaging of myelination. 2013 , 56, 1629-40	14
1778	Diagnostic criteria for pediatric multiple sclerosis. 2013 , 13, 354	15
1777	Automated segmentation of MS lesions in brain MR images using localized trimmed-likelihood estimation. 2013 ,	1

1776	Multiple sclerosis: association with the interleukin-1 gene family polymorphisms in the Turkish population. 2013 , 123, 711-8	13
1775	Multiple Sclerosis and Other Demyelinating Diseases. 2013 , 3-18	5
1774	Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. 2013 , 31, 1870-6	51
1773	Mitoxantrone for multiple sclerosis. 2013 , CD002127	46
1772	Idiopathic inflammatory demyelinating diseases of the brainstem. 2013 , 34, 123-30	6
1771	The immune pathogenesis of multiple sclerosis. 2013 , 8, 857-66	56
1770	Standardized magnetic resonance imaging acquisition and reporting in pediatric multiple sclerosis. 2013 , 23, 217-26.e1-7	5
1769	Pediatric multiple sclerosis: pathobiological, clinical, and magnetic resonance imaging features. 2013 , 23, 227-43	14
1768	Consensus guidelines for the diagnosis and treatment of multiple sclerosis. 2013 , 29, 611-21	19
1767	The usefulness of gadolinium-enhanced images on a follow-up magnetic resonance image in suspected multiple sclerosis. 2013 , 64, 358-62	1
1766	Multiple sclerosis and mitochondrial gene variations: a review. 2013 , 330, 10-5	29
1765	Differential effects of genetic susceptibility factors in males and females with multiple sclerosis. 2013 , 149, 170-5	15
1764	Levels of plasma sulfatides C18:0 and C24:1 correlate with disease status in relapsing-remitting multiple sclerosis. 2013 , 127, 600-4	24
1763	Autoantigen induced clonal expansion in immortalized B cells from the peripheral blood of multiple sclerosis patients. 2013 , 261, 98-107	6
1762	Antibody-based profiling of cerebrospinal fluid within multiple sclerosis. 2013 , 13, 2256-67	31
1761	Abnormalities of cerebral blood flow in multiple sclerosis: a pseudocontinuous arterial spin labeling MRI study. 2013 , 31, 990-5	37
1760	Cerebrospinal fluid and plasma oxidative stress biomarkers in different clinical phenotypes of neuroinflammatory acute attacks. Conceptual accession: from fundamental to clinic. 2013 , 33, 767-77	10
1759	No impact of adult attachment and temperament on clinical variability in patients with clinically isolated syndrome and early multiple sclerosis. 2013 , 115, 293-7	8

1758	Multiple sclerosis imaging: recent advances. 2013 , 260, 929-35	14
1757	Therapeutic advances in pediatric multiple sclerosis. 2013 , 163, 631-7	4
1756	Update on therapeutic options for multiple sclerosis. 2013 , 31, 827-45	7
1755	Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. 2013 , 331, 38-42	40
1754	Uhthoff's phenomena in MS--clinical features and pathophysiology. 2013 , 9, 535-40	50
1753	The "central vein sign": is there a place for susceptibility weighted imaging in possible multiple sclerosis?. 2013 , 23, 1956-62	42
1752	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. 2013 , 260, 2286-96	50
1751	Prognostic indicators for long-term disability in multiple sclerosis patients. 2013 , 324, 29-33	36
1750	Assessment of prevalence and pathological response to orthostatic provocation in patients with multiple sclerosis. 2013 , 324, 80-3	21
1749	"Optic neuritis" that is neither. 2013 , 3, 168-170	
1748	Diffusional kurtosis imaging of normal-appearing white matter in multiple sclerosis: preliminary clinical experience. 2013 , 31, 50-5	56
1747	Cross-sectional area variations of internal jugular veins during supine head rotation in multiple sclerosis patients with chronic cerebrospinal venous insufficiency: a prospective diagnostic controlled study with duplex ultrasound investigation. 2013 , 13, 162	7
1746	New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review. 2013 , 32, 271-5	31
1745	Thalamic atrophy is associated with development of clinically definite multiple sclerosis. 2013 , 268, 831-41	119
1744	Clinical impact of early brain atrophy in clinically isolated syndromes. 2013 , 19, 1878-86	71
1743	To tell or not to tell? Revealing the diagnosis in multiple sclerosis. 2013 , 2, 247-51	1
1742	Cognitive impairment in neurological diseases: lessons from apolipoprotein E. 2014 , 38, 1-9	15
1741	Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica. 2013 , 19, 926-31	22

1740	[Clinically isolated syndrome]. 2013 , 84, 1247-59	2
1739	Possible new modifications for the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis. 2013 , 19, 993-4	
1738	In vitro assessment of mesenchymal stem cells immunosuppressive potential in multiple sclerosis patients. 2013 , 149, 9-18	14
1737	Laquinimod for multiple sclerosis. 2013 ,	2
1736	Antibodies target microvessels in neuromyelitis optica and multiple sclerosis patients. 2013 , 35, 922-9	5
1735	Automated extraction of clinical traits of multiple sclerosis in electronic medical records. 2013 , 20, e334-40	40
1734	Anti-neurofascin antibody in patients with combined central and peripheral demyelination. 2013 , 81, 714-22	122
1733	Treatment of pediatric multiple sclerosis. 2013 , 44, 309-13	4
1732	[White matter lesions, young age, female--differential diagnosis of multiple sclerosis and juvenile stroke]. 2013 , 81, 138-44	1
1731	Disease-modifying treatments for relapsing&emitting multiple sclerosis. 2013 , 64-87	
1730	Der ÜhteÜnd der äueä Stellenwert der Evozierten Potenziale in der Diagnose und Prognose der Multiplen Sklerose. 2013 , 44, 187-192	3
1729	Metabolite changes in radiologically isolated syndrome: more pathology than meets the eye?. 2013 , 80, 2084-5	2
1728	Optic nerve head component responses of the multifocal electroretinogram in MS. 2013 , 81, 545-51	10
1727	Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. 2013 , 81, 1215-21	26
1726	Development of a standardized MRI scoring tool for CNS demyelination in children. 2013 , 34, 1271-7	12
1725	Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis. 2013 , 20, 113-8	22
1724	Pediatric multiple sclerosis with primary progressive course--report of a retrospective cohort study in Iran. 2013 , 44, 167-70	1
1723	Rare inflammatory diseases of the white matter and mimics of multiple sclerosis and related disorders. 2013 , 44, 302-8	11

1722	Congenital and acquired abnormalities of the corpus callosum: a pictorial essay. 2013 , 2013, 265619	14
1721	The BDNF Val66Met polymorphism has opposite effects on memory circuits of multiple sclerosis patients and controls. 2013 , 8, e61063	14
1720	Recognition performance differentiates between elderly patients in the long term course of secondary progressive multiple sclerosis and amnesic mild cognitive impairment. 2013 , 19, 799-805	14
1719	Multiple sclerosis: from molecules to treatment. 2013 , 14, 7598-602	
1718	Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72. 2013 , 84, 79-87	46
1717	Education protects against cognitive changes associated with multiple sclerosis. 2013 , 31, 619-31	14
1716	Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. 2013 , 10, e1001500	88
1715	Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. 2013 , 80, 2210-6	83
1714	Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. 2013 , 35, 687-99	55
1713	Abnormal nerve conduction study findings indicating the existence of peripheral neuropathy in multiple sclerosis and neuromyelitis optica. 2013 , 2013, 847670	20
1712	Therapeutic decision making in a new drug era in multiple sclerosis. 2013 , 33, 5-12	3
1711	Validity of the dynamic gait index in people with multiple sclerosis. 2013 , 93, 1369-76	29
1710	Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. 2013 , 19, 567-76	22
1709	Spinal cord tract diffusion tensor imaging reveals disability substrate in demyelinating disease. 2013 , 80, 2201-9	55
1708	Cerebral venous thrombosis in a patient with clinically isolated spinal cord syndrome. 2013 , 2013, 364869	1
1707	Evaluation of an albumin-binding gadolinium contrast agent in multiple sclerosis. 2013 , 81, 206-10	5
1706	Do motor impairments detected on onset of multiple sclerosis suggest an early second attack? A prospective study. 2013 , 33, 423-30	2
1705	Short-term safety of pulse steroid therapy in multiple sclerosis relapses. 2013 , 36, 1-3	12

1704	Optic neuritis and the evaluation of visual impairment in multiple sclerosis. 2013 , 19, 1074-86	6
1703	Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis. 2013 , 45, S3-13	12
1702	Ocular and cervical vestibular evoked myogenic potentials in patients with multiple sclerosis. 2013 , 30, 86-91	25
1701	Multiple sclerosis research: diagnostics, disease-modifying treatments, and emerging therapies. 2013 , 45, S14-23	4
1700	Diagnosis and differential diagnosis of multiple sclerosis. 2013 , 19, 922-43	14
1699	Automated determination of brain parenchymal fraction in multiple sclerosis. 2013 , 34, 498-504	43
1698	Multiple sclerosis in pregnancy. 2013 , 27, 232-41	6
1697	Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system. 2013 , 33, 123-7	77
1696	Four Square Step Test in ambulant persons with multiple sclerosis: validity, reliability, and responsiveness. 2013 , 36, 253-9	31
1695	Cortical imaging in multiple sclerosis: recent findings and 'grand challenges'. 2013 , 26, 345-52	23
1694	Incidence of multiple sclerosis in multiple racial and ethnic groups. 2013 , 80, 1734-9	146
1693	Diagnostic ability of a new method for measuring haemoglobin levels in the optic nerve head in multiple sclerosis patients. 2013 , 97, 1543-8	13
1692	Synaptic plasticity and PDGF signaling defects underlie clinical progression in multiple sclerosis. 2013 , 33, 19112-9	56
1691	Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-aquaporin 4 antibodies. 2013 , 19, 299-307	32
1690	Wallerian and trans-synaptic degeneration contribute to optic radiation damage in multiple sclerosis: a diffusion tensor MRI study. 2013 , 19, 1610-7	49
1689	Tongue somatosensory-evoked potentials: evaluation of the afferent trigeminal pathway in patients with early multiple sclerosis. 2013 , 44, 286-90	6
1688	A proposed modification to the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis. 2013 , 19, 1095-100	22
1687	Cerebrospinal fluid oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: Yes. 2013 , 19, 714-6	9

1686	CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: Commentary. 2013 , 19, 719-20	7
1685	CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: No. 2013 , 19, 717-8	5
1684	Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. 2013 , 19, 1153-60	17
1683	Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders. 2013 , 19, 1060-7	24
1682	No evidence for impairment of venous hemodynamics in children or young adults with pediatric-onset multiple sclerosis. 2013 , 34, 2366-72	3
1681	IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis. 2013 , 123, 247-60	158
1680	Disclosing a misdiagnosis of multiple sclerosis: do no harm?. 2013 , 19, 1087-91	6
1679	Current and new directions in MRI in multiple sclerosis. 2013 , 19, 1058-73	19
1678	Acute disseminated encephalomyelitis, transverse myelitis, and neuromyelitis optica. 2013 , 19, 944-67	12
1677	Imaging new lesions: enhancing our understanding of multiple sclerosis pathogenesis. 2013 , 81, 202-3	1
1676	Risk of multiple sclerosis after a first demyelinating syndrome in an Australian Paediatric cohort: clinical, radiological features and application of the McDonald 2010 MRI criteria. 2013 , 19, 1749-59	29
1675	The retinal nerve fiber layer of patients with neuromyelitis optica and chronic relapsing optic neuritis is more severely damaged than patients with multiple sclerosis. 2013 , 33, 220-4	26
1674	Alpha actinin is specifically recognized by Multiple Sclerosis autoantibodies isolated using an N-glycosylated peptide epitope. 2013 , 12, 277-82	13
1673	Flow cytometry and drug-monitoring of natalizumab saturation of immune cells in multiple sclerosis ¹). 2013 , 36,	
1672	Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotrophic hormone. 2013 , 4, 21	30
1671	Venocentric Lesions: An MRI Marker of MS?. 2013 , 4, 98	13
1670	Multicontrast MR imaging at 7T in multiple sclerosis: highest lesion detection in cortical gray matter with 3D-FLAIR. 2013 , 34, 791-6	52
1669	The afferent visual pathway: designing a structural-functional paradigm of multiple sclerosis. 2013 , 2013, 134858	52

1668	Multiple sclerosis in malaysia: demographics, clinical features, and neuroimaging characteristics. 2013 , 2013, 614716	8
1667	Demyelinating Disease following Anti-TNF α Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature. 2013 , 2013, 671935	40
1666	Pediatric multiple sclerosis: current concepts and consensus definitions. 2013 , 2013, 673947	22
1665	The Contribution of Resting State Networks to the Study of Cortical Reorganization in MS. 2013 , 2013, 857807	19
1664	Quantifying gait impairment using an instrumented treadmill in people with multiple sclerosis. 2013 , 2013, 867575	32
1663	A mechanistic, stochastic model helps understand multiple sclerosis course and pathogenesis. 2013 , 2013, 910321	15
1662	Three-dimensional geometries representing the retinal nerve fiber layer in multiple sclerosis, optic neuritis, and healthy eyes. 2013 , 50, 72-81	3
1661	The evaluation of the retinal nerve fiber layer in multiple sclerosis with special-domain optical coherence tomography. 2013 , 230, 116-20	10
1660	Neuroimaging of the afferent visual system. 2012 , 32, 273-319	2
1659	Difficulties in planning among patients with multiple sclerosis: a relative consequence of deficits in information processing speed. 2013 , 19, 613-20	12
1658	MS cortical lesions on DIR: not quite what they seem?. 2013 , 8, e78879	34
1657	Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. 2013 , 84, 909-14	207
1656	Gray matter damage predicts the accumulation of disability 13 years later in MS. 2013 , 81, 1759-67	133
1655	Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. 2013 , 19, 188-98	148
1654	Anti-neurofascin antibody in combined central and peripheral demyelination. 2013 , 4, 68-75	3
1653	Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. <i>Annals of Neurology</i> , 2013 , 73, 626-36	9.4 69
1652	Structural and metabolic features of two different variants of multiple sclerosis: a PET/MRI study. 2013 , 23, 431-6	26
1651	Increased disease severity in non-Western immigrants with multiple sclerosis in Oslo, Norway. 2013 , 20, 1546-52	16

1650	Are magnetic resonance imaging findings influenced by genetic background in multiple sclerosis patients?. 2013 , 4, 157-158	
1649	Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. 2013 , 136, 2305-17	85
1648	Fully automatic detection of deep white matter T1 hypointense lesions in multiple sclerosis. 2013 , 58, 8323-37	11
1647	International Pediatric MS Study Group Clinical Trials Summit: meeting report. 2013 , 80, 1161-8	49
1646	Olfactory dysfunction in multiple sclerosis: evidence of a decrease in different aspects of olfactory function. 2013 , 69, 166-70	39
1645	Reproductive decision making after the diagnosis of multiple sclerosis (MS). 2013 , 19, 351-8	50
1644	Molecular biomarkers of neurodegeneration. 2013 , 13, 845-61	23
1643	Application of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinean cohort of patients with clinically isolated syndromes. 2013 , 19, 1297-301	24
1642	Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations?. 2013 , 19, 1493-8	20
1641	Risk Prediction of a Multiple Sclerosis Diagnosis. 2013 ,	1
1640	Neuroradiological evaluation of demyelinating disease. 2013 , 6, 249-68	45
1639	Structural brain MR imaging changes associated with obsessive-compulsive disorder in patients with multiple sclerosis. 2013 , 34, 305-9	14
1638	Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. 2013 , 19, 1887-95	119
1637	Evaluation of brainstem involvement in multiple sclerosis. 2013 , 13, 299-311	30
1636	Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis. 2013 , 3, 467-482	
1635	Clinical trials in pediatric multiple sclerosis: overcoming the challenges. 2013 , 3, 49-56	2
1634	Cytokine profile in relapsing-remitting multiple sclerosis patients and the association between progression and activity of the disease. 2013 , 7, 1010-20	71
1633	Intravenous immunoglobulin to prevent relapses during pregnancy and postpartum in multiple sclerosis. 2013 ,	

1632	Cerebrospinal Venous Outflow in Multiple Sclerosis Patients versus Fatigue and/or Depression. 2014 , 2, 193-200	
1631	Seltener Beginn einer Multiplen Sklerose. 2013 , 25, 412-413	1
1630	Future directions in multiple sclerosis. 2013 , 218-225	
1629	Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis. 2013 , 13, 1002-9	16
1628	Treatment optimization in MS: Canadian MS Working Group updated recommendations. 2013 , 40, 307-23	159
1627	The Incidence and Prevalence of Multiple Sclerosis in Nova Scotia, Canada. 2013 , 40, 824-831	44
1626	Multiple sclerosis: managing patients in primary care. 2013 , 38, 24-35; quiz 35-6	8
1625	Vaccines for preventing influenza in multiple sclerosis patients. 2013 ,	1
1624	Central nervous system infectious diseases mimicking multiple sclerosis: recognizing distinguishable features using MRI. 2013 , 71, 738-46	20
1623	Sodium channel blockers for neuroprotection in multiple sclerosis. 2013 ,	1
1622	[NMDA receptor encephalitis in the course of recurrent CNS demyelinating disorders: a case report]. 2013 , 53, 345-50	4
1621	[110th Scientific Meeting of the Japanese Society of Internal Medicine: Educational lecture: 11. Multiple sclerosis (MS) and neuromyelitis optica (NMO)]. 2013 , 102, 2426-32	
1620	Role of oral teriflunomide in the management of multiple sclerosis. 2013 , 9, 539-53	8
1619	Inflammatory, immune-mediated, and systemic disorders. 145-165	
1618	Sporadic Porphyria Cutanea Tarda in a Patient with Multiple Sclerosis Treated with Interferon Beta 1-a Therapy: A Case Report. 2013 , 9, 196-7	1
1617	Attributional style and depression in multiple sclerosis: the learned helplessness model. 2013 , 15, 81-9	4
1616	Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta. 2013 , 9, 1339-49	13
1615	Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. 2013 , 9, 893-914	26

1614	Early respiratory evaluation should be carried out systematically in patients with multiple sclerosis. 2013 , 71, 142-5	8
1613	Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. 2013 , 7, 247-58	27
1612	Delayed Liver Function Impairment Secondary to Interferon β 1a Use in Multiple Sclerosis. 2013 , 5, 130-4	3
1611	Are Periventricular Lesions Specific for Multiple Sclerosis?. 2013 , 4, 150	3
1610	Encephalomyelopathy associated with HTLV-I a primary disease or coexisting with multiple sclerosis?. 2013 , 7, 439-443	4
1609	[Diagnostic value of brain biopsy in a pediatric multiple sclerosis mimicking brain stem glioma]. 2013 , 36, 175-9	
1608	Proresolution lipid mediators in multiple sclerosis - differential, disease severity-dependent synthesis - a clinical pilot trial. 2013 , 8, e55859	67
1607	Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles. 2013 , 8, e58352	36
1606	Serum biomarker gMS-Classifer2: predicting conversion to clinically definite multiple sclerosis. 2013 , 8, e59953	3
1605	Increased concentrations of glutamate and glutamine in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans. 2013 , 8, e61817	53
1604	Autoantibodies and Sjogren's Syndrome in multiple sclerosis, a reappraisal. 2013 , 8, e65385	15
1603	Presence and significant determinants of cognitive impairment in a large sample of patients with multiple sclerosis. 2013 , 8, e69820	36
1602	Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of multiple sclerosis. 2013 , 8, e71145	85
1601	Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders. 2013 , 8, e74773	37
1600	Examination of cognitive fatigue in multiple sclerosis using functional magnetic resonance imaging and diffusion tensor imaging. 2013 , 8, e78811	82
1599	Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. 2013 , 8, e83036	46
1598	Optic nerve diffusion tensor imaging after acute optic neuritis predicts axonal and visual outcomes. 2013 , 8, e83825	34
1597	Mood disorder as the presenting manifestation of demyelination. 2013 , 5, 104-9	2

1596	Regional brain atrophy and functional connectivity changes related to fatigue in multiple sclerosis. 2013 , 8, e77914	50
1595	Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. 2013 , 8, e79185	29
1594	Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. 2013 , 8, e66151	125
1593	Neuromuscular Disease: A Case-Based Approach. 31-33	
1592	Genomic analysis of ERVWE2 locus in patients with multiple sclerosis: absence of genetic association but potential role of human endogenous retrovirus type W elements in molecular mimicry with myelin antigen. 2013 , 4, 172	21
1591	Use of a time-of-flight camera with an Omek Beckonâ€¦framework to analyze, evaluate and correct in real time the verticality of multiple sclerosis patients during exercise. 2013 , 10, 5807-29	6
1590	New Markers of Early Cardiovascular Risk in Multiple Sclerosis Patients: Oxidized-LDL Correlates with Clinical Staging. 2013 , 34, 341-348	48
1589	Cognitive impairment is correlated with reduced quality of life in patients with clinically isolated syndrome. 2013 , 71, 74-7	8
1588	Which immune cells matter? The immunopathogenesis of multiple sclerosis. 2013 , 33, 283-306	32
1587	Concomitant amyotrophic lateral sclerosis and paraclinical laboratory features of multiple sclerosis: coincidence or causal relationship?. 2013 , 2013,	3
1586	Oligodendrocyte Metabolic Stress in Neurodegeneration. 2013 ,	
1585	Multiple sclerosis: offering care tailored to the person's needs. 2013 , 7, 594-599	
1584	Investigation of cerebrospinal fluid. 2014 , 660-672	
1583	Anatomical Findings of Hemiplegia Cruciata in Multiple Sclerosis. 2014 , 16, 39	
1582	Glutathione homeostasis disruption of erythrocytes, but not glutathione peroxidase activity change, is closely accompanied with neurological and radiological scoring of acute CNS inflammation. 2014 , 21, 13-20	12
1581	Pain-related mood influences pain perception differently in fibromyalgia and multiple sclerosis. 2014 , 7, 81-7	10
1580	Investigation of relationship between social capital and quality of life in multiple sclerosis patients. 2014 , 6, 261-72	14
1579	Serum thyroid-stimulating hormone and anti-thyroglobulin antibody are independently associated with lesions in spinal cord in central nervous system demyelinating diseases. 2014 , 9, e100672	22

1578	Quantitative determination of regional lesion volume and distribution in children and adults with relapsing-remitting multiple sclerosis. 2014 , 9, e85741	46
1577	The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis. 2014 , 9, e87398	44
1576	Rapid parametric mapping of the longitudinal relaxation time T1 using two-dimensional variable flip angle magnetic resonance imaging at 1.5 Tesla, 3 Tesla, and 7 Tesla. 2014 , 9, e91318	27
1575	Quantitative detection of epstein-barr virus DNA in cerebrospinal fluid and blood samples of patients with relapsing-remitting multiple sclerosis. 2014 , 9, e94497	22
1574	Soluble CD163 as a marker of macrophage activity in newly diagnosed patients with multiple sclerosis. 2014 , 9, e98588	39
1573	Frequency of autoantibodies and connective tissue diseases in Chinese patients with optic neuritis. 2014 , 9, e99323	11
1572	Altered inter-subregion connectivity of the default mode network in relapsing remitting multiple sclerosis: a functional and structural connectivity study. 2014 , 9, e101198	40
1571	Microstructural changes in the striatum and their impact on motor and neuropsychological performance in patients with multiple sclerosis. 2014 , 9, e101199	26
1570	Detection of olfactory dysfunction using olfactory event related potentials in young patients with multiple sclerosis. 2014 , 9, e103151	23
1569	Abnormal control of orbicularis oculi reflex excitability in multiple sclerosis. 2014 , 9, e103897	10
1568	Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration. 2014 , 9, e103984	27
1567	Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention. 2014 , 9, e109679	53
1566	Ultrasonographic evaluation of cerebral arterial and venous haemodynamics in multiple sclerosis: a case-control study. 2014 , 9, e111486	4
1565	Magnetic resonance imaging in multiple sclerosis--patients' experiences, information interests and responses to an education programme. 2014 , 9, e113252	14
1564	The relationship between specific cognitive domains, fear of falling, and falls in people with multiple sclerosis. 2014 , 2014, 281760	34
1563	Robot-assisted vs. sensory integration training in treating gait and balance dysfunctions in patients with multiple sclerosis: a randomized controlled trial. 2014 , 8, 318	41
1562	Extracellular Vesicles in Multiple Sclerosis: What are They Telling Us?. 2014 , 8, 100	71
1561	Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis. 2014 , 72, 445-50	19

1560	Prevalence of temporomandibular disorders symptoms in patients with multiple sclerosis. 2014 , 72, 422-5	5
1559	ENCOMS: Argentinian survey in cost of illness and unmet needs in multiple sclerosis. 2014 , 72, 337-43	8
1558	Association between smoking and cognitive impairment in multiple sclerosis. 2014 , 10, 1715-9	23
1557	Chronic pain in multiple sclerosis: is there also fibromyalgia? An observational study. 2014 , 20, 758-66	3
1556	Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity?. 2014 , 20, 178-84	11
1555	Chapitre 7. La sclérose en plaques. 2014 , 183	
1554	An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection device. 2014 , 8, 843-51	18
1553	Contingent negative variation is associated with cognitive dysfunction and secondary progressive disease course in multiple sclerosis. 2014 , 10, 296-303	6
1552	Impairment of Visual Cognition in Progressive Multiple Sclerosis. 2014 , 02,	
1551	The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis. 2014 , 72, 712-4	14
1550	Multiparameter Flow Cytometric Assays to Quantify Effector and Regulatory T-Cell Function in Multiple Sclerosis. 2015 , 2,	2
1549	Neurosarcoidosis. 2014 , 1, 51-56	1
1548	Multiple sclerosis. 637-654	
1547	Influenza vaccine-induced CNS demyelination in a 50-year-old male. 2014 , 15, 368-73	2
1546	The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS. 2014 , 7, 910	24
1545	Partial acute transverse myelitis is a predictor of multiple sclerosis in children. 2014 , 20, 1485-93	12
1544	CHARACTERIZATION OF SIGNAL CONDUCTION ALONG DEMYELINATED AXONS BY ACTION-POTENTIAL-ENCODED SECOND HARMONIC GENERATION. 2014 , 07, 1330003	2
1543	Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis. 2014 , 85, 544-51	52

1542	Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome. 2014 , 7, 279-88	9
1541	Multiple Sclerosis: An Overview of Clinical Features, Pathophysiology, Neuroimaging, and Treatment Options. 2014 , 6, 1-117	3
1540	[Prognostic and predictively relevant factors for multiple sclerosis]. 2014 , 85, 1255-62	
1539	A prospective study of patients with brain MRI showing incidental t2 hyperintensities addressed as multiple sclerosis: a lot of work to do before treating. 2014 , 3, 123-32	17
1538	Immune responses in rapidly progressive dementia: a comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer's disease and multiple sclerosis. 2014 , 11, 170	29
1537	Increased levels of sphingosine-1-phosphate in cerebrospinal fluid of patients diagnosed with tick-borne encephalitis. 2014 , 11, 193	11
1536	Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies. 2014 , 11, 188	22
1535	Efficacy and safety of subcutaneous interferon- β 1a in patients with a first demyelinating event and early multiple sclerosis. 2014 , 14, 1207-14	4
1534	K Index in cerebrospinal fluid: a valid tool in multiple sclerosis diagnosis. 2014 , 10, 167-171	1
1533	Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease. 2014 , 9, 49	16
1532	[Future challenges in multiple sclerosis]. 2014 , 143 Suppl 3, 44-7	2
1531	Early pathological alterations of lower lumbar cords detected by ultrahigh-field MRI in a mouse multiple sclerosis model. 2014 , 26, 93-101	22
1530	Biomarkers of treatment response in multiple sclerosis. 2014 , 14, 165-72	8
1529	Efficacy of subcutaneous interferon β 1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. 2014 , 85, 647-53	16
1528	Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica. 2014 , 85, 419-30	40
1527	Categorization of multiple sclerosis relapse subtypes by B cell profiling in the blood. 2014 , 2, 138	10
1526	Multiple sclerosis remission following antiretroviral therapy in an HIV-infected man. 2014 , 20, 640-3	15
1525	Evaluation of McDonald MRI criteria for dissemination in space in Korean patients with clinically isolated syndromes. 2014 , 20, 492-5	12

1524	Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study. 2014 , 20, 174-82	35
1523	The link between resting-state functional connectivity and cognition in MS patients. 2014 , 20, 338-48	56
1522	Characteristics of multiple sclerosis in the Middle East with special reference to the applicability of international guidelines to the region. 2014 , 124, 635-41	9
1521	Stability of intraindividual variability as a marker of neurologic dysfunction in relapsing remitting multiple sclerosis. 2014 , 36, 455-63	14
1520	Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. 2014 , 7, 263-75	68
1519	CB1 receptor affects cortical plasticity and response to physiotherapy in multiple sclerosis. 2014 , 1, e48	13
1518	Variants of autophagy-related gene 5 are associated with neuromyelitis optica in the Southern Han Chinese population. 2014 , 47, 563-6	15
1517	Crohns disease with central nervous system vasculitis causing subarachnoid hemorrhage due to aneurysm and cerebral ischemic stroke. 2014 , 17, 444-7	4
1516	MRI correlates of disability progression in patients with CIS over 48 months. 2014 , 6, 312-9	32
1515	Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. 2014 , 9, e88680	54
1514	Infectious and noninfectious granulomatosis in patient with multiple sclerosis: diagnostic dilemmas and followup. 2014 , 2014, 876525	
1513	Primary central nervous system lymphoma with preceding spontaneous pseudotumoral demyelination in an immunocompetent adult patient: A case report and literature review. 2014 , 7, 1835-1838	13
1512	HLA-G Molecules in Autoimmune Diseases and Infections. 2014 , 5, 592	68
1511	The antibody genetics of multiple sclerosis: comparing next-generation sequencing to sanger sequencing. 2014 , 5, 166	10
1510	Cerebral arterial bolus arrival time is prolonged in multiple sclerosis and associated with disability. 2014 , 34, 34-42	42
1509	Multiple Sclerosis; Diagnosis. 2014 , 148-152	0
1508	Multiple Sclerosis and Other Demyelinating Disorders. 2014 ,	
1507	Mycophenolate mofetil in the treatment of multiple sclerosis: a preliminary report. 2014 , 62, 646-8	4

1506	Preliminary validation study of the Spanish version of the satisfaction with life scale in persons with multiple sclerosis. 2014 , 36, 1001-5	19
1505	Multiple sclerosis in the Levant: a regional consensus statement. 2014 , 124, 377-82	2
1504	Elevated CNS inflammation in patients with preclinical Alzheimer's disease. 2014 , 34, 30-3	62
1503	Pathologies neurologiques. 2014 , 181-213	
1502	Prospective randomized trial of venous angioplasty in MS (PREMiSe). 2014 , 83, 441-9	29
1501	Validity of maximal exercise testing in people with multiple sclerosis and low to moderate levels of disability. 2014 , 94, 1168-75	27
1500	Oral dalfampridine improves standing balance detected at static posturography in multiple sclerosis. 2014 , 2014, 802307	8
1499	Disease Modifying Therapy in Multiple Sclerosis. 2014 , 2014, 307064	5
1498	The role of TPA I/D and PAI-1 4G/5G polymorphisms in multiple sclerosis. 2014 , 2014, 362708	8
1497	Prevalence of Anti-JC Virus Antibody in Multiple Sclerosis Patients in Kuwait. 2014 , 2014, 861091	7
1496	Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment. 2014 , 8, 1123-34	18
1495	Study of association between polymorphisms in the PSMB5 (rs11543947) and PSMA3 (rs2348071) genes and multiple sclerosis in Latvians. 2014 , 30, 305-309	3
1494	Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: relation to brain findings and clinical disability. 2014 , 20, 1860-5	56
1493	Clinically isolated syndromes with no further disease activity suggestive of multiple sclerosis at the age of population life expectancy. 2014 , 20, 496-500	10
1492	Retinal architecture and mfERG: Optic nerve head component response characteristics in MS. 2014 , 82, 1888-96	10
1491	What's new in multiple sclerosis?. 2014 , 64, 612-3	10
1490	Antineutrophil cytoplasmic antibodies in patients with idiopathic inflammatory-demyelinating diseases. 2014 , 21, 297-303	6
1489	In vivo MRI monitoring of inflammatory alterations and cellular dynamics in the central nervous system. 2014 ,	

1488	Multiple Sklerose im Überblick. 2014 , 06, 8-14	
1487	Detecting Optic Atrophy in Multiple Sclerosis Patients Using New Colorimetric Analysis Software: From Idea to Application. 2016 , 31, 459-62	2
1486	[Introduction. Multiple sclerosis]. 2014 , 143 Suppl 3, 1-2	
1485	CNS inflammation other than multiple sclerosis: how likely is diagnosis?. 2014 , 82, 1187-9	5
1484	Successful twin delivery after a radical trachelectomy. 2014 , 34, 87	2
1483	Multiple sclerosis: managing a complex neurological disease. 2014 , 29, 49-58	7
1482	[Optic neuritis]. 2014 , 231, 1073-83	1
1481	Para-dichlorobenzene toxicity - a review of potential neurotoxic manifestations. 2014 , 7, 177-87	14
1480	Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. 2014 , 1, e40	157
1479	Spinal cord MRI should always be performed in clinically isolated syndrome patients: No. 2014 , 20, 1686-7	6
1478	Leptin hormone level in serum of opticospinal, neuromyelitisoptica and multiple sclerosis patients. 2014 , 5, 77-83	3
1477	Defining encephalopathy in acute disseminated encephalomyelitis. 2014 , 29, 751-5	14
1476	A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. 2014 , 83, 1492-9	60
1475	In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses. <i>Annals of Neurology</i> , 2014 , 75, 266-76	9-4 60
1474	Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases. 2014 , 192, 2551-63	69
1473	Dose reduction therapy of fingolimod for Japanese patients with multiple sclerosis: 24-month experience. 2014 , 5, 383-384	5
1472	Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes. 2014 , 20, 458-63	18
1471	What explains gray matter atrophy in long-standing multiple sclerosis?. 2014 , 272, 832-42	57

1470	Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse. 2014 , 23, 546-9	11
1469	Gene expression analysis of histamine receptors in peripheral blood mononuclear cells from individuals with clinically-isolated syndrome and different stages of multiple sclerosis. 2014 , 277, 186-8	6
1468	Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome. 2014 , 3, 712-9	5
1467	The cerebrospinal fluid cytokine signature of multiple sclerosis: a homogenous response that does not conform to the Th1/Th2/Th17 convention. 2014 , 277, 153-9	21
1466	Japanese guidelines for fingolimod in multiple sclerosis: Putting into practice. 2014 , 5, 34-48	4
1465	Vitamin D status and age of onset of demyelinating disease. 2014 , 3, 684-8	13
1464	Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. 2014 , 347, 229-34	8
1463	Apathy in multiple sclerosis: a validation study of the apathy evaluation scale. 2014 , 347, 295-300	30
1462	Evaluation of the humoral response against mycobacterial peptides, homologous to MOG α in multiple sclerosis patients. 2014 , 347, 78-81	8
1461	Month of birth and risk of multiple sclerosis: confounding and adjustments. 2014 , 1, 141-4	22
1460	Increased soluble C5b-9 in CSF of neuromyelitis optica. 2014 , 79, 127-30	24
1459	Usability and potential of geostatistics for spatial discrimination of multiple sclerosis lesion patterns. 2014 , 24, 278-86	3
1458	Longitudinal absolute metabolite quantification of white and gray matter regions in healthy controls using proton MR spectroscopic imaging. 2014 , 27, 304-11	18
1457	Neuroactive steroid levels in plasma and cerebrospinal fluid of male multiple sclerosis patients. 2014 , 130, 591-7	40
1456	[Two new oral disease modifying therapies in relapsing remitting multiple sclerosis]. 2014 , 170, 721-2	
1455	Changes in cognition, arm function and lower body function after slow-release Fampridine treatment. 2014 , 20, 1872-80	41
1454	Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. 2014 , 85, 1109-15	115
1453	Developing Biomarkers for MS. 2015 , 26, 179-94	4

1452	Effective communication at the point of multiple sclerosis diagnosis. 2014 , 20, 397-402	23
1451	The contribution of assessing cognitive impairment in radiologically-isolated syndrome (RIS): a single case report follow-up study. 2014 , 20, 1912-5; discussion 1916-7	6
1450	An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab. 2014 , 14, 139	8
1449	Multiple sclerosis in Germany: data analysis of administrative prevalence and healthcare delivery in the statutory health system. 2014 , 14, 381	30
1448	Demyelinating disease and anti-N-methyl-D-aspartate receptor immunoglobulin G antibodies: a case report. 2014 , 7, 948	8
1447	Environmental exposures and the risk of multiple sclerosis investigated in a Norwegian case-control study. 2014 , 14, 196	39
1446	Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients. 2014 , 14, 218	16
1445	A woman with sensory deficits, paresthesias, and ataxia. 2014 , 27, 34-6, 38	
1444	Etiologic spectrum and prognosis of longitudinally extensive transverse myelopathies. 2014 , 72, 86-94	18
1443	Functional correlates of cognitive dysfunction in multiple sclerosis: A multicenter fMRI Study. 2014 , 35, 5799-814	54
1442	Sleep disorders in multiple sclerosis in China: clinical, polysomnography study, and review of the literature. 2014 , 31, 375-81	24
1441	The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project. 2014 , 20, 374-81	18
1440	Pathologic and imaging correlates of cognitive deficits in multiple sclerosis: changing the paradigm of diagnosis and prognosis. 2014 , 27, 1-7	3
1439	Pragmatic intervention for increasing self-directed exercise behaviour and improving important health outcomes in people with multiple sclerosis: a randomised controlled trial. 2014 , 20, 1112-22	62
1438	Cortical plasticity predicts recovery from relapse in multiple sclerosis. 2014 , 20, 451-7	52
1437	Cerebrospinal fluid transferrin levels are reduced in patients with early multiple sclerosis. 2014 , 20, 1569-77	10
1436	Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. 2014 , 20, 43-50	81
1435	Optimization of magnetization-prepared 3-dimensional fluid attenuated inversion recovery imaging for lesion detection at 7 T. 2014 , 49, 290-8	25

1434	Isolated bilateral horizontal gaze palsy as first manifestation of multiple sclerosis. 2014 , 20, 754-5	9
1433	Multiple sclerosis in pregnancy. 2014 , 20, 42-59	12
1432	Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. 2014 , 49, 685-90	311
1431	Multiple sclerosis, solitary sclerosis or something else?. 2014 , 20, 1819-24	20
1430	Reducing survey burden: feasibility and validity of PROMIS measures in multiple sclerosis. 2014 , 20, 1102-11	46
1429	Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome. 2014 , 20, 35-42	11
1428	Polyarteritis nodosa with central nervous system involvement mimicking relapsing-remitting multiple sclerosis. 2014 , 24, 525-8	6
1427	Inflammatory Demyelinating Diseases. 2014 , 22-38	
1426	Oligoclonal bands in multiple sclerosis reactive against two herpesviruses and association with magnetic resonance imaging findings. 2014 , 20, 27-34	36
1425	Current and future potential of retinal optical coherence tomography in multiple sclerosis with and without optic neuritis. 2014 , 4, 165-76	22
1424	Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. 2014 ,	7
1423	Pseudotumoral forms of multiple sclerosis: report of 14 cases and review of the literature. 2014 , 72, 72-8	13
1422	Evaluation and treatment of autoimmune neurologic disorders in the pediatric intensive care unit. 2014 , 21, 284-90	4
1421	[Current description of multiple sclerosis]. 2014 , 143 Suppl 3, 3-6	6
1420	Investigation of magnetization transfer ratio-derived pial and subpial abnormalities in the multiple sclerosis spinal cord. 2014 , 137, 2456-68	32
1419	Validity of the diagnostic criteria for chronic cerebrospinal venous insufficiency and association with multiple sclerosis. 2014 , 186, E418-26	7
1418	Neurodegeneration and Multiple Sclerosis. 2014 , 227-245	5
1417	Resting State Functional Connectivity Analysis of Multiple Sclerosis and Neuromyelitis Optica Using Graph Theory. 2014 , 206-209	3

1416	Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. 2014 , 71, 1506-13	102
1415	Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. 2014 , 20, 1234-43	12
1414	Evaluating the role of coping style as a moderator of fatigue and risk for future cognitive impairment in multiple sclerosis. 2014 , 20, 751-5	16
1413	Magnetic resonance spectroscopy: a possible in vivo marker of disease progression for multiple sclerosis?. 2014 , 71, 828-30	7
1412	A routine-qualified flow cytometric method for the identification of multiple sclerosis patients with a reduced therapeutic effectiveness of natalizumab. 2014 , 38,	
1411	Overcoming recruitment challenges in patients with multiple sclerosis: Results from an Italian survey. 2014 , 11, 667-72	6
1410	Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. 2014 , 82, 2173-9	39
1409	Increasing Incidence in Relapsing-Remitting MS and High Rates among Young Women in Finland: A Thirty-Year Follow-Up. 2014 , 2014, 186950	8
1408	Multiple sclerosis presents with psychotic symptoms and coexists with hypertrophic cardiomyopathy. 2014 , 2014, 383108	2
1407	Sound Lateralization Test Distinguishes Unimpaired MS Patients from Healthy Controls. 2014 , 2014, 462043	0
1406	The frequency of anti-aquaporin-4 Ig g antibody in neuromyelitis optica and its spectrum disorders at a single tertiary referral center in malaysia. 2014 , 2014, 568254	7
1405	Gray matters in multiple sclerosis: cognitive impairment and structural MRI. 2014 , 2014, 609694	31
1404	Comparisons of Costs between Black Caribbean and White British Patients with Advanced Multiple Sclerosis in the UK. 2014 , 2014, 613701	4
1403	Bedside tested ocular motor disorders in multiple sclerosis patients. 2014 , 2014, 732329	8
1402	Autoimmune disease prevalence in a multiple sclerosis cohort in Argentina. 2014 , 2014, 828162	3
1401	Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. 2014 , 2014, 961863	39
1400	Aquaporin-1 antibody in neuromyelitis optical patients. 2014 , 72, 271-2	11
1399	Subjective cognitive fatigue in multiple sclerosis depends on task length. 2014 , 5, 214	31

1398	Beta-interferon therapy in relapsing and remitting multiple sclerosis - challenges in an emerging country. 2014 , 4, 34	2
1397	Inflammatory Demyelinating Diseases of Childhood: Case Report and Literature Review. 2014 , 51, 74-78	
1396	Clinical and neuroimaging correlation of movement disorders in multiple sclerosis: case series and review of the literature. 2014 , 52, 92-100	5
1395	Routine-tägliche durchflusszytometrische Methode zur Identifikation von Multiple Sklerose PatientInnen mit einer nicht ausreichenden Therapieeffizienz unter einer Natalizumab-Therapie. 2014 , 38,	
1394	Antinuclear antibodies in pediatric acquired demyelinating diseases of the central nervous system. 2014 , 20, 1665-6	
1393	Perceived stress in multiple sclerosis: the potential role of mindfulness in health and well-being. 2014 , 19, 104-11	70
1392	Neuroradiology in women of childbearing age. 2014 , 20, 23-41	9
1391	Inflammatory optic neuropathies. 2014 , 20, 816-37	6
1390	Dual-task assessment in natalizumab-treated multiple sclerosis patients. 2014 , 71, 247-51	16
1389	Multiple sclerosis: current knowledge and future outlook. 2014 , 72, 132-41	169
1388	Demographics and clinical characteristics of multiple sclerosis in Kuwait. 2014 , 72, 181-5	8
1387	Multiple sclerosis. 2014 , 168-189	
1386	Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. 2014 , 6, 248ra106	149
1385	A comparison of sagittal short T1 inversion recovery and T2-weighted FSE sequences for detection of multiple sclerosis spinal cord lesions. 2014 , 129, 198-203	16
1384	The relationship between fear of falling to spatiotemporal gait parameters measured by an instrumented treadmill in people with multiple sclerosis. 2014 , 39, 739-44	33
1383	Demyelination in a patient receiving ustekinumab for refractory Crohn's disease. 2014 , 8, 1138-9	21
1382	A novel stop mutation in the EDNRB gene in a family with Hirschsprung's disease associated with multiple sclerosis. 2014 , 49, 622-5	6
1381	Corticosteroid-responsive torticollis as a presenting symptom of multiple sclerosis. 2014 , 340, 239-40	3

1380	Intramedullary spinal cord metastasis from salivary ductal carcinoma of the parotid gland mimicking transverse myelitis in a patient with radiologically isolated syndrome. 2014 , 336, 265-8	3
1379	Mise au point sur la sclérose en plaques de début tardif: 10 questions portant sur la SEP du sujet âgé. 2014 , 5, 32-38	
1378	Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. 2014 , 3, 147-55	43
1377	The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. 2014 , 48, 111-5	5
1376	Retinal layer segmentation in patients with multiple sclerosis using spectral domain optical coherence tomography. 2014 , 121, 573-9	77
1375	Gait and jogging parameters in people with minimally impaired multiple sclerosis. 2014 , 39, 297-302	17
1374	Disability in patients with multiple sclerosis: influence of insulin resistance, adiposity, and oxidative stress. 2014 , 30, 268-73	58
1373	Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. 2014 , 3, 186-93	80
1372	Recall strategies for the verbal fluency test in patients with multiple sclerosis. 2014 , 29, 139-45	4
1371	Low DPP4 expression and activity in multiple sclerosis. 2014 , 150, 170-83	24
1370	Coexistence of systemic lupus erythematosus and multiple sclerosis: prevalence, clinical characteristics, and natural history. 2014 , 43, 751-8	17
1369	Cortical reorganization in multiple sclerosis after intrathecal baclofen therapy. 2014 , 20, 225-9	2
1368	Interleukin-1 β promotes long-term potentiation in patients with multiple sclerosis. 2014 , 16, 38-51	60
1367	Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. 2014 , 261, 17-26	86
1366	Neurology at the Bedside. 2014 ,	1
1365	Multiple sclerosis during adalimumab treatment in a case with ankylosing spondylitis. 2014 , 34, 141-3	8
1364	The presence of oligoclonal IgG bands in human CSF during the course of neurological diseases. 2014 , 261, 554-60	10
1363	Patient subgroup analyses of the treatment effect of subcutaneous interferon β 1a on development of multiple sclerosis in the randomized controlled REFLEX study. 2014 , 261, 490-9	12

1362	The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. 2014 , 48-49, 134-42	177
1361	Prevalence of human Herpesviridae in cerebrospinal fluid of patients with multiple sclerosis and noninfectious neurological disease in the Netherlands. 2014 , 20, 412-8	5
1360	Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla. 2014 , 24, 841-9	66
1359	Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial. 2014 , 15, 37	14
1358	Home-based system for physical activity monitoring in patients with multiple sclerosis (Pilot study). 2014 , 13, 10	37
1357	Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring. 2014 , 14, 27	5
1356	Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012. 2014 , 261, 759-67	26
1355	Improved characterization of visual evoked potentials in multiple sclerosis by topographic analysis. 2014 , 27, 318-27	11
1354	Differential diagnosis of white matter lesions: Nonvascular causes-Part II. 2014 , 24, 93-110	10
1353	Topography of brain sodium accumulation in progressive multiple sclerosis. 2014 , 27, 53-62	41
1352	Mindfulness based interventions in multiple sclerosis--a systematic review. 2014 , 14, 15	117
1351	Improved MRI quantification of spinal cord atrophy in multiple sclerosis. 2014 , 39, 617-23	64
1350	Mycophenolate mofetil for relapsing-remitting multiple sclerosis. 2014 , CD010242	7
1349	Assessing tissue damage in multiple sclerosis: a biomarker approach. 2014 , 130, 81-9	55
1348	Advances in multiple sclerosis and its variants: conventional and newer imaging techniques. 2014 , 52, 321-36	13
1347	An algorithmic approach to structural imaging in dementia. 2014 , 85, 692-8	71
1346	MRI characteristics of periaqueductal lesions in multiple sclerosis. 2014 , 3, 542-51	10
1345	MRI mimics of multiple sclerosis. 2014 , 122, 291-316	40

1344	Neurodegenerative Diseases. 2014,	2
1343	Multiple Sclerosis. 2014, 735-756	1
1342	Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. 2014,	1
1341	Multiple sclerosis in two patients with coexisting Wilson's disease. 2014, 3, 387-90	4
1340	Validity and reliability of VO ₂ max measurements in persons with multiple sclerosis. 2014, 342, 79-87	39
1339	Ten years of proteomics in multiple sclerosis. 2014, 14, 467-80	27
1338	Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells. 2014, 270, 75-85	18
1337	The incidence of clinically isolated syndrome in a multi-ethnic cohort. 2014, 261, 1349-55	20
1336	Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization. 2014, 339, 196-206	21
1335	Analysis of CD4+ CD8+ double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions. 2014, 177, 404-11	18
1334	Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. 2014, 82, 1776-83	124
1333	Early predictors of multiple sclerosis after a typical clinically isolated syndrome. 2014, 20, 1721-6	28
1332	Recall strategies for the verbal fluency test in patients with multiple sclerosis. 2014, 29, 139-145	1
1331	Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. 2014, 270, 98-9	39
1330	Activation-induced cell death in T lymphocytes from multiple sclerosis patients. 2014, 272, 51-5	8
1329	ILAE official report: a practical clinical definition of epilepsy. 2014, 55, 475-82	2408
1328	Long-term endurance exercise improves aerobic capacity in patients with relapsing-remitting multiple sclerosis: impact of baseline fatigue. 2014, 336, 29-35	23
1327	Oligoclonal bands and age at onset correlate with genetic risk score in multiple sclerosis. 2014, 20, 660-8	35

1326	Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis. 2014 , 8, 185-94	66
1325	Hemodynamic evidence linking cognitive deficits in clinically isolated syndrome to regional brain inflammation. 2014 , 21, 499-505	12
1324	Relapses in multiple sclerosis: effects of high-dose steroids on cortical excitability. 2014 , 21, 630-6	25
1323	Plasmacytoid dendritic cell deficit of early response to toll-like receptor 7 agonist stimulation in multiple sclerosis patients. 2014 , 153, 211-9	7
1322	Best Practices in Neurological Care. 2014 ,	
1321	Dimethyl fumarate for multiple sclerosis. 2014 ,	3
1320	Outcomes after microvascular decompression for patients with trigeminal neuralgia and suspected multiple sclerosis. 2014 , 81, 599-603	35
1319	The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. 2014 , 20, 695-704	56
1318	Differential Diagnosis: "What Is the Lesion?" 2014 , 137-269	
1317	Optic neuritis. 2014 , 13, 83-99	329
1316	Understanding the pharmacology of stroke and multiple sclerosis through imaging. 2014 , 14, 34-41	1
1315	The progress of cognitive decline in newly diagnosed MS patients. 2014 , 129, 184-91	20
1314	Neuroimaging of multiple sclerosis, acute disseminated encephalomyelitis, and other demyelinating diseases. 2014 , 49, 76-85	18
1313	Limited utility of current MRI criteria for distinguishing multiple sclerosis from common mimickers: primary and secondary CNS vasculitis, lupus and Sjogren's syndrome. 2014 , 20, 57-63	30
1312	Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study. 2014 , 383, 138-45	70
1311	Multiple sclerosis: basic knowledge and new insights in perioperative management. 2014 , 28, 267-78	31
1310	Revised diagnostic criteria of multiple sclerosis. 2014 , 13, 518-24	192
1309	Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI. 2014 , 21, 583-6	19

1308	Prediction of MS disability by multimodal evoked potentials: investigation during relapse or in the relapse-free interval?. 2014 , 125, 1889-92		16
1307	A pattern approach to focal white matter hyperintensities on magnetic resonance imaging. 2014 , 52, 241-61		16
1306	Clinical and magnetic resonance imaging (MRI) distinctions between tumefactive demyelination and brain tumors in children. 2014 , 29, 654-65		12
1305	Body fluid biomarkers in multiple sclerosis. 2014 , 13, 113-26		157
1304	Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. 2014 , 20, 295-303		97
1303	High prevalence and no latitude gradient of multiple sclerosis in Norway. 2014 , 20, 1780-2		37
1302	High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis. 2014 , 276, 175-9		45
1301	Low familial risks for multiple sclerosis in Buenos Aires, Argentina. 2014 , 346, 268-70		8
1300	Identification of a point mutation impairing the binding between aquaporin-4 and neuromyelitis optica autoantibodies. 2014 , 289, 30578-30589		23
1299	Higher incidence of Epstein-Barr virus-induced lymphocyte transformation in multiple sclerosis. 2014 , 130, 90-6		14
1298	Spinal cord normalization in multiple sclerosis. 2014 , 24, 577-584		25
1297	Prevalence of multiple sclerosis in Csongrđ County, Hungary. 2014 , 130, 277-82		15
1296	Spinal cord gray matter atrophy correlates with multiple sclerosis disability. <i>Annals of Neurology</i> , 2014 , 76, 568-80	9.4	131
1295	Fatigue, emotional functioning, and executive dysfunction in pediatric multiple sclerosis. 2014 , 20, 71-85		30
1294	Dĕcision kinšithfapique : Suzette B. Scłfose en plaques. 2014 , 14, 10-17		
1293	Mechanisms and pharmacology of neuropathic pain in multiple sclerosis. 2014 , 20, 75-97		11
1292	Affinity proteomic profiling of plasma, cerebrospinal fluid, and brain tissue within multiple sclerosis. 2014 , 13, 4607-19		36
1291	Neue Therapieoptionen. 2014 , 156, 69-76		2

1290	Serum iron metabolism markers including hepcidin in multiple sclerosis patients. 2014 , 8, 226-230	4
1289	Coin rotation task: a valid test for manual dexterity in multiple sclerosis. 2014 , 94, 1644-51	16
1288	Brain temperature in multiple sclerosis. 2014 , 20, 894-6	2
1287	Comment on: 'Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients'. 2014 , 20, 897-8	
1286	CD8+ MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis. 2014 , 44, 3119-28	104
1285	Emerging spectra of silent brain infarction. 2014 , 45, 3461-71	67
1284	Added value of double inversion recovery magnetic resonance sequence in detection of cortical and white matter brain lesions in multiple sclerosis. 2014 , 45, 1193-1199	3
1283	Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MS. 2014 , 83, 1500-7	40
1282	Differential effects of fingolimod on B-cell populations in multiple sclerosis. 2014 , 20, 1371-80	45
1281	Multiple sclerosis: changes in microarchitecture of white matter tracts after training with a video game balance board. 2014 , 273, 529-38	68
1280	Multiple sclerosis and the cerebellum. 2014 , 32, 957-77	11
1279	Bilateral congenital cataract with suspected lens-induced granulomatous uveitis. 2014 , 18, 492-4	3
1278	Eight-and-a-half syndrome as presenting sign of childhood multiple sclerosis. 2014 , 18, 490-2	15
1277	Antibodies to neural and non-neural autoantigens in Japanese patients with CNS demyelinating disorders. 2014 , 274, 155-60	3
1276	Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. 2014 , 85, 279-83	21
1275	ALCAM and CD6--multiple sclerosis risk factors. 2014 , 276, 98-103	21
1274	MRI outcomes in the diagnosis and disease course of multiple sclerosis. 2014 , 122, 405-25	14
1273	Active and progressive: a new duality of MS classification. 2014 , 83, 206-7	5

1272	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. 2014 , CD009333	16
1271	Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency in people with multiple sclerosis: a summary of a Cochrane systematic review. 2014 , 85, 405-10	7
1270	An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. 2014 , 20, 1381-90	24
1269	Gray matter involvement in multiple sclerosis and neuromyelitis optica. 2014 , 5, 69-76	1
1268	Phase white matter signal abnormalities in patients with clinically isolated syndrome and other neurologic disorders. 2014 , 35, 1916-23	9
1267	[Physiotherapy and neurogenic lower urinary tract dysfunction in multiple sclerosis patients: a randomized controlled trial]. 2014 , 24, 697-707	12
1266	Diffusion-weighted imaging thermometry in multiple sclerosis. 2014 , 40, 649-54	13
1265	Lymphocytic hypophysitis associated with pediatric multiple sclerosis. 2014 , 51, 580-2	3
1264	Tumor necrosis factor beta Nco1 polymorphism is associated with inflammatory and metabolic markers in multiple sclerosis patients. 2014 , 346, 156-63	10
1263	Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. 2014 , 20, 304-12	89
1262	Multiple Sclerosis and Inflammatory Diseases. 2014 , 162-171	
1261	Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial. 2014 , 20, 382-90	143
1260	Subcortical deep gray matter pathology in patients with multiple sclerosis is associated with white matter lesion burden and atrophy but not with cortical atrophy: a diffusion tensor MRI study. 2014 , 35, 912-9	32
1259	Accuracy of postcontrast 3D turbo spin-echo MR sequence for the detection of enhanced inflammatory lesions in patients with multiple sclerosis. 2014 , 35, 519-23	11
1258	Use of the 2010 McDonald criteria can facilitate early diagnosis of pediatric multiple sclerosis in a predominantly black cohort. 2014 , 51, 826-30	7
1257	Association of cognitive impairment and lesion volumes in multiple sclerosis--a MRI study. 2014 , 127, 54-8	14
1256	Early prognosis of multiple sclerosis. 2014 , 122, 371-91	12
1255	New multiple sclerosis phenotypic classification. 2014 , 72 Suppl 1, 1-5	165

1254	HHV-6-positivity in diseases with demyelination. 2014 , 61, 216-9	11
1253	Clinical features and sera anti-aquaporin 4 antibody positivity in patients with demyelinating disorders of the central nervous system from Tianjin, China. 2014 , 20, 32-9	25
1252	Clinically isolated syndromes and the relationship to multiple sclerosis. 2014 , 21, 2065-71	47
1251	Diagnosis and trials of clinically isolated syndrome. 2014 , 13, 962-3	3
1250	Relapsing multiple sclerosis patients treated with disease modifying therapy exhibit highly variable disease progression: a predictive model. 2014 , 127, 86-92	11
1249	Revised McDonald criteria for multiple sclerosis diagnostics in central Russia: sensitivity and specificity. 2014 , 20, 1896-9	13
1248	MRI in Diagnosis and Disease Monitoring. 2014 , 29-44	
1247	Neurological Disorders in the Arab World. 2014 ,	3
1246	Alemtuzumab for multiple sclerosis. 2014 ,	1
1245	Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis. 2014 , 20, 1699-703	44
1244	Insights from magnetic resonance imaging. 2014 , 122, 115-49	18
1243	Sex-specific extent and severity of white matter damage in multiple sclerosis: implications for cognitive decline. 2014 , 35, 2348-58	49
1242	Disease-modifying agents in multiple sclerosis. 2014 , 122, 465-501	9
1241	Application of the 2012 revised diagnostic definitions for paediatric multiple sclerosis and immune-mediated central nervous system demyelination disorders. 2014 , 85, 790-4	7
1240	Development of a cell-based assay for the detection of anti-aquaporin 1 antibodies in neuromyelitis optica spectrum disorders. 2014 , 273, 103-10	19
1239	Pain in multiple sclerosis: a systematic review of neuroimaging studies. 2014 , 5, 322-31	34
1238	A changing treatment landscape for multiple sclerosis: challenges and opportunities. 2014 , 275, 364-81	46
1237	A 3meter Timed Tandem Walk is an early marker of motor and cerebellar impairment in fully ambulatory MS patients. 2014 , 346, 99-106	10

1236	Increasing prevalence and incidence rates of multiple sclerosis in Kuwait. 2014 , 20, 543-7	81
1235	Cerebrospinal fluid analysis. 2014 , 122, 681-702	24
1234	Elevated antibody reactivity to measles virus NCORE protein among patients with multiple sclerosis and their healthy siblings with intrathecal oligoclonal immunoglobulin G production. 2014 , 61, 107-12	5
1233	Magnetic resonance imaging of intramedullary spinal cord lesions: a pictorial review. 2014 , 58, 569-81	9
1232	Evaluation of visual structural and functional factors that predict the development of multiple sclerosis in clinically isolated syndrome patients. 2014 , 55, 6127-31	24
1231	Non-parametric analysis of seasonality in birth and multiple sclerosis risk in second generation of migrants in Kuwait. 2014 , 14, 170	3
1230	Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?. 2014 , 2, 97	38
1229	The clinical course of multiple sclerosis. 2014 , 122, 343-69	96
1228	Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. 2014 , 13, 936-48	102
1227	Biomarkers for neurology: Guides and lines. 2014 , 83, 1130-1	6
1226	Diagnosis of multiple sclerosis. 2014 , 122, 317-42	6
1225	Decreased level of sRAGE in the cerebrospinal fluid of multiple sclerosis patients at clinical onset. 2014 , 21, 226-33	19
1224	Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. 2014 , 20, 1471-7	22
1223	[New aspects in the therapy of multiple sclerosis and optic neuritis]. 2014 , 111, 709-14	
1222	Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. 2014 , 261, 1735-44	38
1221	The gender-specific association of CXCL16 A181V gene polymorphism with susceptibility to multiple sclerosis, and its effects on PBMC mRNA and plasma soluble CXCL16 levels: preliminary findings. 2014 , 261, 1544-51	7
1220	Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. 2014 , 15, 1019-27	13
1219	Site-specific chemokine expression regulates central nervous system inflammation and determines clinical phenotype in autoimmune encephalomyelitis. 2014 , 193, 564-70	40

1218	Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. 2014 , 13, 795-806	68
1217	Growth factors and synaptic plasticity in relapsing-remitting multiple sclerosis. 2014 , 16, 490-8	16
1216	Tumor necrosis factor beta (TNF- β) NcoI polymorphism is associated with multiple sclerosis in Caucasian patients from Southern Brazil independently from HLA-DRB1. 2014 , 53, 211-21	3
1215	The importance of nitric oxide and arginase in the pathogenesis of acute neuroinflammation: are those contra players with the same direction?. 2014 , 26, 392-9	15
1214	Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis. 2014 , 114, 273-8	14
1213	Interferon beta-associated recurrence of painful trigeminal neuropathy attributed to a multiple sclerosis plaque. 2014 , 15, 21	3
1212	Comparison of diffusion-weighted imaging and contrast-enhanced T1-weighted imaging on a single baseline MRI for demonstrating dissemination in time in multiple sclerosis. 2014 , 14, 100	15
1211	Social participation in patients with multiple sclerosis: correlations between disability and economic burden. 2014 , 14, 115	25
1210	Quantification of relevance of quality of life assessment for patients with cognitive impairment: the suitability indices. 2014 , 14, 78	11
1209	Characterization of the spectrum of Korean inflammatory demyelinating diseases according to the diagnostic criteria and AQP4-Ab status. 2014 , 14, 93	13
1208	Using perceptive computing in multiple sclerosis - the Short Maximum Speed Walk test. 2014 , 11, 89	39
1207	Prevalence of radiologically isolated syndrome and white matter signal abnormalities in healthy relatives of patients with multiple sclerosis. 2014 , 35, 106-12	37
1206	Arguments for the sake of endophenotypes: examining common misconceptions about the use of endophenotypes in psychiatric genetics. 2014 , 165B, 122-30	113
1205	Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general. 2014 , 274, 174-9	6
1204	Multiple sclerosis: a review of the disease and treatment options. 2014 , 29, 469-79	14
1203	Vitamin D supplementation could limit T helper-17 response in multiple sclerosis. 2014 , 5, 336-339	
1202	Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy. 2014 , 274, 149-54	42
1201	Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. 2014 , 122, 269-90	53

1200 Diagnostic Process. **2014**, 18-28

1199	The epidemiology of multiple sclerosis: insights to disease pathogenesis. 2014 , 122, 231-66	99
1198	Is it time for a new global classification of multiple sclerosis?. 2014 , 344, 171-81	57
1197	Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. 2014 , 13, 977-86	208
1196	Uhthoff's phenomena and brain MRI suggesting demyelinating lesions: RIS or CIS? A case report. 2014 , 345, 262-4	0
1195	Clinically isolated syndrome in pregnancy. 2014 , 34, 86	
1194	Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis. 2014 , 35, 831-2	10
1193	New regulatory CD19(+)CD25(+) B-cell subset in clinically isolated syndrome and multiple sclerosis relapse. Changes after glucocorticoids. 2014 , 270, 37-44	42
1192	Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. 2014 , 268, 95-8	41
1191	Magnetic resonance imaging in neuromyelitis optica. 2014 , 20, 1153-64	48
1190	Defining the clinical course of multiple sclerosis: the 2013 revisions. 2014 , 83, 278-86	1632
1189	Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod. 2014 , 20, 1714-20	20
1188	Plantarflexor weakness negatively impacts walking in persons with multiple sclerosis more than plantarflexor spasticity. 2014 , 95, 1358-65	40
1187	Association of vitamin D deficiency with RNFL thickness in MS individuals without history of optic neuritis. 2014 , 3, 489-93	5
1186	Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1. 2014 , 272, 56-61	22
1185	The risk of Bipolar Disorders in Multiple Sclerosis. 2014 , 155, 255-60	54
1184	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. 2014 , 13, 257-67	156
1183	Prevalence of epilepsy in a cohort of patients with multiple sclerosis. 2014 , 23, 81-3	31

1182	Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis. 2014 , 6, 475-87	25
1181	Effect of seasonal fluctuation of ambient temperature on fatigue in multiple sclerosis patients living in Attica, Greece. 2014 , 21, 1188-91	7
1180	Emergency Department visits before the diagnosis of MS. 2014 , 3, 350-4	8
1179	Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod. 2014 , 3, 408-12	4
1178	Age independently affects myelin integrity as detected by magnetization transfer magnetic resonance imaging in multiple sclerosis. 2014 , 4, 641-8	17
1177	Erythrocytes' antioxidative capacity as a potential marker of oxidative stress intensity in neuroinflammation. 2014 , 337, 8-13	21
1176	Increased deep gray matter iron is present in clinically isolated syndromes. 2014 , 3, 194-202	15
1175	Impaired recognition of emotional facial expressions in patients with multiple sclerosis. 2014 , 3, 482-8	26
1174	Are Hsp70 protein expression and genetic polymorphism implicated in multiple sclerosis inflammation?. 2014 , 268, 84-8	19
1173	POLG mutations associated with remitting/relapsing neurological events. 2014 , 21, 186-8	5
1172	Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait. 2014 , 119, 17-20	10
1171	Magnetic resonance spectroscopy findings as related to fatigue and cognitive performance in multiple sclerosis patients with mild disability. 2014 , 339, 35-40	15
1170	A case of mental nerve paresthesia due to dynamic compression of alveolar inferior nerve along an elongated styloid process. 2014 , 72, 1267.e1-7	3
1169	Elevated levels of autoantibodies targeting the M1 muscarinic acetylcholine receptor and neurofilament medium in sera from subgroups of patients with schizophrenia. 2014 , 269, 68-75	12
1168	B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients. 2014 , 272, 86-90	10
1167	Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis peptides are cross recognized by anti-myelin basic protein antibodies in multiple sclerosis patients. 2014 , 270, 51-5	42
1166	Cortical thickness at the time of the initial attack in two patients with paediatric relapsing-remitting multiple sclerosis. 2014 , 18, 295-300	2
1165	Autophagy-related gene 16L2, a potential serum biomarker of multiple sclerosis evaluated by bead-based proteomic technology. 2014 , 562, 34-8	22

1164	CCL2 induction by 1,25(OH)2D3 in dendritic cells from healthy donors and multiple sclerosis patients. 2014 , 144 Pt A, 102-5	10
1163	Suppression of IL-10 production by calcitriol in patients with multiple sclerosis. 2014 , 270, 86-94	17
1162	Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin-4 antibodies in cerebral spinal fluid. 2014 , 269, 62-7	17
1161	The role of imaging in diagnosing neuromyelitis optica spectrum disorder. 2014 , 3, 284-93	11
1160	Relationship between quality of life and dysarthria in patients with multiple sclerosis. 2014 , 95, 2047-54	25
1159	Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. 2014 , 89, 225-40	283
1158	Body temperature is elevated and linked to fatigue in relapsing-remitting multiple sclerosis, even without heat exposure. 2014 , 95, 1298-302	30
1157	Identification of a B cell-dependent subpopulation of multiple sclerosis by measurements of brain-reactive B cells in the blood. 2014 , 152, 20-4	17
1156	Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. 2014 , 338, 128-34	16
1155	Genetic variants of homocysteine metabolism and multiple sclerosis: a case-control study. 2014 , 562, 75-8	10
1154	Comparison of brain 3.0-T with 1.5-T MRI in patients with multiple sclerosis: a 6-month follow-up study. 2014 , 121, 55-8	2
1153	[Paroxysmal dystonia and multiple sclerosis]. 2014 , 170, 119-23	6
1152	Relapsing optic neuritis: a multicentre study of 62 patients. 2014 , 20, 848-53	23
1151	Relationship between damage to the cerebellar peduncles and clinical disability in multiple sclerosis. 2014 , 271, 822-30	38
1150	Atypical hereditary spastic paraplegia mimicking multiple sclerosis associated with a novel SPG11 mutation. 2014 , 21, e14-5	18
1149	The squares test as a measure of hand function in multiple sclerosis. 2014 , 123, 55-60	4
1148	Childhood CNS inflammatory demyelinating diseases. 2014 , 24, 439-446	1
1147	Predictive markers of disease evolution after a CIS in everyday practice. 2014 , 343, 8-14	4

1146	Place of perineal electrophysiologic testing in multiple sclerosis patients. 2014 , 57, 288-296	2
1145	Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?. 2014 , 343, 110-4	15
1144	Increased thalamic intrinsic oscillation amplitude in relapsing-remitting multiple sclerosis associated with the slowed cognitive processing. 2014 , 38, 605-10	13
1143	Increased autotaxin activity in multiple sclerosis. 2014 , 273, 120-3	23
1142	Working memory performance of early MS patients correlates inversely with modularity increases in resting state functional connectivity networks. 2014 , 94, 385-395	82
1141	Multiple sclerosis and bipolar disorders: the burden of comorbidity and its consequences on quality of life. 2014 , 167, 192-7	32
1140	Understanding disease processes in multiple sclerosis through magnetic resonance imaging studies in animal models. 2014 , 4, 743-56	32
1139	Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. 2014 , 102, 116-22	34
1138	Conventional and advanced imaging in neuromyelitis optica. 2014 , 35, 1458-66	41
1137	Hereditary diffuse leukoencephalopathy with spheroids characterized by spastic hemiplegia preceding mental impairment. 2014 , 53, 1377-80	6
1136	Cognitive and affective assessments of multiple sclerosis (MS) and neuromyelitis optica (NMO) patients utilizing computerized touch panel-type screening tests. 2014 , 53, 2281-90	13
1135	Validity of Oxygen Uptake Efficiency Slope in patients with multiple sclerosis. 2014 , 46, 656-61	15
1134	Cluster headache as a first manifestation of multiple sclerosis: case report and literature review. 2014 , 10, 2269-74	15
1133	Radiologically isolated syndrome: 5-year risk for an initial clinical event. 2014 , 9, e90509	190
1132	Conventional brain imaging of white matter lesions. 117-128	
1131	Juvenile myoclonic epilepsy with multiple sclerosis: is there a dual role for valproate?. 2014 , 2014,	1
1130	The Multiple Sclerosis Performance Test (MSPT): an iPad-based disability assessment tool. 2014 , e51318	51
1129	Magnetic resonance techniques for investigation of multiple sclerosis. 2014 ,	2

1128	Elevated levels of carbonyl proteins in cerebrospinal fluid of patients with neurodegenerative diseases. 2014 , 234, 313-7	12
1127	Neurological Disease of Metabolism. 2014 , 534-555	
1126	Accumulation and therapeutic modulation of 6-sulfo LacNAc(+) dendritic cells in multiple sclerosis. 2014 , 1, e33	25
1125	Monitoring increased iron levels in multiple sclerosis using MRI. 2014 , 9, 387-391	1
1124	You're the flight surgeon: atrial tachycardia. 2014 , 85, 586-9	
1123	You're the flight surgeon: multiple sclerosis. 2014 , 85, 585-6	
1122	4th International Congress on Neurology and Epidemiology. Kuala Lumpur, Malaysia, November 6-8, 2014: Abstracts. 2014 , 43, 71-113	2
1121	A history of multiple sclerosis investigations in Canada between 1850 and 1950. 2014 , 41, 320-32	3
1120	Evaluation of brainstem involvement in multiple sclerosis. 2014 , 41, 346-9	15
1119	Information provision for people with multiple sclerosis. 2014 , CD008757	28
1118	Amyloid PET imaging in multiple sclerosis: an (18)F-florbetaben study. 2015 , 15, 243	46
1117	Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes. 2015 , 12, 119	53
1116	The association of HLA-DRB1 and HLA-DQB1 alleles with genetic susceptibility to multiple sclerosis in the Slovak population. 2015 , 37, 1060-7	9
1115	[Relevance of Magnet Resonance Tomography in the Diagnosis and Assessment of Course of Disease in Patients with Multiple Sclerosis]. 2015 , 83, 522-32; quiz 533-4	0
1114	Cholinesterase inhibitors for rarer dementias associated with neurological conditions. 2015 , CD009444	29
1113	Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. 2015 , CD011381	97
1112	Optimizing multiple sclerosis diagnosis: gene expression and genomic association. 2015 , 2, 271-7	5
1111	Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis. 2015 , 2, 445-55	36

1110	Tablet-based screening improves continence management in multiple sclerosis. 2015 , 2, 679-87	6
1109	Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. 2015 , 2, 960-71	113
1108	Pioglitazone regulates myelin phagocytosis and multiple sclerosis monocytes. 2015 , 2, 1071-84	25
1107	An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. 2015 , 5, e00362	106
1106	The Norwegian Multiple Sclerosis Registry and Biobank. 2015 , 132, 24-8	21
1105	Association of multiple sclerosis with lateral olfactory tract usher substance (LOTUS), a possible endogenous inhibitor of axonal degeneration. 2015 , 6, 64-69	
1104	Comments on the review article 'Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades'. 2015 , 132, 364-7	2
1103	Anodal transcranial direct current stimulation of motor cortex does not ameliorate spasticity in multiple sclerosis. 2015 , 33, 487-92	27
1102	The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients. 2015 , 5, 14265	9
1101	You're the Flight Surgeon: lateral epicondylitis. 2015 , 86, 1077-80	
1100	T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis. 2015 , 129, 291-303	33
1099	Results of sustained long-term use of interferon beta-1a in a community-based cohort of patients with relapsing multiple sclerosis. 2015 , 4, 1-6	2
1098	Using mental visual imagery to improve autobiographical memory and episodic future thinking in relapsing-remitting multiple sclerosis patients: A randomised-controlled trial study. 2015 , 33, 621-38	22
1097	Cognitive rehabilitation of working memory in juvenile multiple sclerosis-effects on cognitive functioning, functional MRI and network related connectivity. 2015 , 33, 713-25	20
1096	[A case of multiple sclerosis with bilateral intermediate uveitis]. 2015 , 55, 716-21	
1095	Tumefactive Demyelinating Lesion Differentiated from a Brain Tumor Using a Combination of Magnetic Resonance Imaging and (11)C-methionine Positron Emission Tomography. 2015 , 54, 1411-4	9
1094	Introducing a new method to assess vision: Computer-adaptive contrast-sensitivity testing predicts visual functioning better than charts in multiple sclerosis patients. 2015 , 1, 2055217315596184	13
1093	Investigation of neurodegenerative diseases from body fluid samples using Fourier transform infrared spectroscopy. 2015 , 4, 341-357	9

- 1092 Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial. **2015**, 2, e147 6
- 1091 Neue Studien zu Multipler Sklerose und Neuromyelitis optica. **2015**, 16, 18-19
- 1090 JC Virus Replication at the First Symptoms of Multiple Sclerosis: A Case Report. **2015**, 58, 278-82 3
- 1089 Eine Therapie sollte frühzeitig erfolgen. **2015**, 27, 26-33
- 1088 Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis. **2015**, 12, 196 21
- 1087 Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation. **2015**, 12, 245 23
- 1086 Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses. **2015**, 15, 206 9
- 1085 Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis. **2015**, 15, 240 5
- 1084 Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease management. **2015**, 6, 16 27
- 1083 Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study. *Annals of Neurology*, **2015**, 78, 801-13 9.4 226
- 1082 Using MRI to make informed clinical decisions in multiple sclerosis care. **2015**, 28, 244-9 13
- 1081 Increasing prevalence of multiple sclerosis in Västerbotten County of Sweden. **2015**, 132, 389-94 16
- 1080 Human immunoglobulin G suppresses the production of matrix metalloproteinase-9 in peripheral blood mononuclear cells of patients with multiple sclerosis. **2015**, 6, 281-288 1
- 1079 Assessing clinical correlates of self-rated disability in patients with multiple sclerosis. **2015**, 1, 2055217315592425
- 1078 Free kappa light chains in cerebrospinal fluid as a biomarker to assess risk conversion to multiple sclerosis. **2015**, 1, 2055217315620935 8
- 1077 Remote cognitive assessments for patients with multiple sclerosis: a feasibility study. **2015**, 21, 1072-9 19
- 1076 Stress and multiple sclerosis: A systematic review considering potential moderating and mediating factors and methods of assessing stress. **2015**, 2, 2055102915612271 24
- 1075 A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. **2015**, 15, 204 28

1074	Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. 2015 , 15, 232		9
1073	The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis. 2015 , 12, 12		35
1072	The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort. 2015 , 12, 27		25
1071	Participant recruitment into a randomised controlled trial of exercise therapy for people with multiple sclerosis. 2015 , 16, 468		12
1070	Rhythmic cued motor imagery and walking in people with multiple sclerosis: a randomised controlled feasibility study. 2015 , 1, 25		12
1069	Exercise therapy for fatigue in multiple sclerosis. 2015 , CD009956		114
1068	Periventricular lesions correlate with cortical thinning in multiple sclerosis. <i>Annals of Neurology</i> , 2015 , 78, 530-9	9.4	24
1067	Multiple sclerosis increases the risk of venous thromboembolism: a nationwide cohort analysis. 2015 , 45, 1228-33		6
1066	Optic Neuritis and the Visual Pathway: Evaluation of Neuromyelitis Optica Spectrum by Resting-State fMRI and Diffusion Tensor MRI. 2015 , 25, 807-12		13
1065	MS lesions are better detected with 3D T1 gradient-echo than with 2D T1 spin-echo gadolinium-enhanced imaging at 3T. 2015 , 36, 501-7		23
1064	Development and validation of an ELISA for quantification of soluble IFN- γ receptor: assessment in multiple sclerosis. 2015 , 7, 2869-80		5
1063	In vivo quantitative whole-brain T1 rho MRI of multiple sclerosis. 2015 , 42, 1623-30		16
1062	A 15-year-old girl with a rapidly progressing tumor-like lesion. 2015 , 35, 497-501		
1061	Effect of interferon- β on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients. 2015 , 182, 162-72		6
1060	The relationship between alexithymia, empathy and moral judgment in patients with multiple sclerosis. 2015 , 22, 1295-303		34
1059	Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis. <i>Annals of Neurology</i> , 2015 , 78, 3-20	9.4	85
1058	Progressive multiple sclerosis. 2015 , 28, 237-43		46
1057	Sodium channel blockers for neuroprotection in multiple sclerosis. 2015 , CD010422		7

1056 You're the Flight Surgeon: white matter hyperintensities. **2015**, 86, 1075-7

1055 Melanoma cell adhesion molecule-positive CD8 T lymphocytes mediate central nervous system inflammation. *Annals of Neurology*, **2015**, 78, 39-53 9.4 43

1054 Validation of the Japanese version of the Modified Fatigue Impact Scale and assessment of the effect of pain on scale responses in patients with multiple sclerosis. **2015**, 6, 409-412 4

1053 Jugular Venous Flow Abnormalities in Multiple Sclerosis Patients Compared to Normal Controls. **2015**, 25, 600-7 20

1052 Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations. **2015**, 1, 2055217315589775 4

1051 Oligoclonal bands predict multiple sclerosis in children with optic neuritis. *Annals of Neurology*, **2015**, 77, 1076-82 9.4 45

1050 Detection of aquaporin-4 antibody status of Thai patients with neuromyelitis optica spectrum disorders using a recombinant Escherichia coli aquaporin-4 enzyme-linked immunosorbent assay. **2015**, 6, 57-66

1049 A woman with difficulty walking and multiple falls. **2015**, 28, 54-6

1048 Prevalence of autonomic dysfunction in patients with multiple sclerosis. **2015**, 28, 51-5 10

1047 Why this is not multiple sclerosis: a case based approach. **2015**, 73, 985-92 1

1046 Diplopia as first symptom of multiple sclerosis. **2015**, 74, 73-75

1045 Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research. **2015**, 16, 14850-65 13

1044 Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod. **2015**, 16, 21832-45 7

1043 The Etiological Spectrum of Acute Sensory Myelitis. **2015**, 11, 227-33 1

1042 The profile of patients followed at the Neuroimmunology Clinic at UNIFESP: 20 years analysis. **2015**, 73, 304-8 7

1041 Sleep disorders in patients with multiple sclerosis. **2015**, 11, 553-7 29

1040 Skewness of Fractional Anisotropy Detects Decreased White Matter Integrity Resulting From Acute Optic Neuritis. **2015**, 56, 7597-603 2

1039 Clinical and epidemiological profile of patients diagnosed with multiple sclerosis in João Pessoa, Paraíba, Brazil. **2015**, 73, 741-5 5

1038	A Case Control Study: Vitamin D Status and Sun Exposure in Multiple Sclerosis. 2015 , 02,	
1037	Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis. 2015 , 17, 231-5	9
1036	[Multiple sclerosis with stroke-like symptoms: a diagnostic challenge. Case report]. 2015 , 156, 1514-8	
1035	Polymorphism of the osteopontin gene and clinical course of multiple sclerosis in the Polish population. 2015 , 53, 343-6	2
1034	Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study. 2015 , 7, 3424-35	3
1033	Physiological Dynamics in Demyelinating Diseases: Unraveling Complex Relationships through Computer Modeling. 2015 , 16, 21215-36	11
1032	Early and Degressive Putamen Atrophy in Multiple Sclerosis. 2015 , 16, 23195-209	19
1031	Meningeal Infiltration of the Spinal Cord by Non-Classically Activated B Cells is Associated with Chronic Disease Course in a Spontaneous B Cell-Dependent Model of CNS Autoimmune Disease. 2015 , 6, 470	23
1030	Modulation of TLR3/TLR4 inflammatory signaling by the GABAB receptor agonist baclofen in glia and immune cells: relevance to therapeutic effects in multiple sclerosis. 2015 , 9, 284	33
1029	Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis. 2015 , 6, 97	17
1028	Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence. 2015 , 9, 265-74	10
1027	Genome-wide DNA methylation profiles indicate CD8+ T cell hypermethylation in multiple sclerosis. 2015 , 10, e0117403	71
1026	Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis. 2015 , 10, e0121488	37
1025	Markedly increased IP-10 production by blood-brain barrier in neuromyelitis optica. 2015 , 10, e0122000	22
1024	CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes. 2015 , 10, e0122045	10
1023	Decoding diffusivity in multiple sclerosis: analysis of optic radiation lesional and non-lesional white matter. 2015 , 10, e0122114	42
1022	Intrinsic functional plasticity of the sensorimotor network in relapsing-remitting multiple sclerosis: evidence from a centrality analysis. 2015 , 10, e0130524	10
1021	Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study. 2015 , 10, e0127757	27

1020	Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration. 2015 , 10, e0128386	14
1019	Plasma biomarkers discriminate clinical forms of multiple sclerosis. 2015 , 10, e0128952	30
1018	Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing. 2015 , 10, e0132139	16
1017	Multiple Sclerosis Risk Allele in CLEC16A Acts as an Expression Quantitative Trait Locus for CLEC16A and SOCS1 in CD4+ T Cells. 2015 , 10, e0132957	11
1016	Circulating CCR7+ICOS+ Memory T Follicular Helper Cells in Patients with Multiple Sclerosis. 2015 , 10, e0134523	32
1015	A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity. 2015 , 10, e0135974	28
1014	Neurophysiological Evidence of Compensatory Brain Mechanisms in Early-Stage Multiple Sclerosis. 2015 , 10, e0136786	21
1013	The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study. 2015 , 10, e0139659	11
1012	Diagnostic and Prognostic Value of the Cerebrospinal Fluid Concentration of Immunoglobulin Free Light Chains in Clinically Isolated Syndrome with Conversion to Multiple Sclerosis. 2015 , 10, e0143375	27
1011	Development of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies Detection. 2015 , 10, e0143679	4
1010	T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients. 2015 , 10, e0144693	24
1009	Increased multiple sclerosis relapses related to lower prevalence of pain. 2015 , 73, 593-600	2
1008	Induction and escalation therapies in multiple sclerosis. 2015 , 14, 26-34	16
1007	Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?. 2015 , 3, 545-55	115
1006	Adipsin Is Associated with Multiple Sclerosis: A Follow-Up Study of Adipokines. 2015 , 2015, 371734	11
1005	Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment. 2015 , 2015, 901312	8
1004	Functional and Structural Brain Plasticity Enhanced by Motor and Cognitive Rehabilitation in Multiple Sclerosis. 2015 , 2015, 481574	61
1003	Italian validation of the 12-item multiple sclerosis walking scale. 2015 , 2015, 540828	10

1002	Evaluation of Retinal Nerve Fiber Layer and Ganglion Cell Complex in Patients with Optic Neuritis or Neuromyelitis Optica Spectrum Disorders Using Optical Coherence Tomography in a Chinese Cohort. 2015 , 2015, 832784	12
1001	Applying an Open-Source Segmentation Algorithm to Different OCT Devices in Multiple Sclerosis Patients and Healthy Controls: Implications for Clinical Trials. 2015 , 2015, 136295	29
1000	Rapid Exercise-Induced Mobilization of Dendritic Cells Is Potentially Mediated by a Flt3L- and MMP-9-Dependent Process in Multiple Sclerosis. 2015 , 2015, 158956	4
999	CCL27: Novel Cytokine with Potential Role in Pathogenesis of Multiple Sclerosis. 2015 , 2015, 189638	16
998	The Therapeutic Potential of the Ketogenic Diet in Treating Progressive Multiple Sclerosis. 2015 , 2015, 681289	31
997	Relapsing remitting multiple sclerosis in x-linked charcot-marie-tooth disease with central nervous system involvement. 2015 , 2015, 841897	3
996	Depression and Anxiety among Patients with Epilepsy and Multiple Sclerosis: UAE Comparative Study. 2015 , 2015, 196373	9
995	Impact of depression, fatigue, and global measure of cortical volume on cognitive impairment in multiple sclerosis. 2015 , 2015, 519785	29
994	The Diagnosis and Treatment of Optic Neuritis. 2015 , 112, 616-25; quiz 626	48
993	Prevalence of Depression and Anxiety among Patients with Multiple Sclerosis Attending the MS Clinic at Sheikh Khalifa Medical City, UAE: Cross-Sectional Study. 2015 , 2015, 487159	16
992	The Communication of Multiple Sclerosis Diagnosis: The Patients' Perspective. 2015 , 2015, 353828	5
991	Managing Neuropsychological Impairment in Multiple Sclerosis: Pilot Study on a Standardized Metacognitive Intervention. 2015 , 17, 130-7	21
990	Sociocultural and Demographic Risk Factors for the Development of Multiple Sclerosis in Kuwait: A Case - Control Study. 2015 , 10, e0132106	13
989	Effects of Eight-week Resistance Training Program in Men With Multiple Sclerosis. 2015 , 6, e22838	24
988	Why brain banking should be regarded as a special type of biobanking: ethical, practical, and data-management challenges. 2015 , 3	2
987	Multiplesclerose in de huisartsenpraktijk. 2015 , 58, 258-263	
986	Fatigue at time of CIS is an independent predictor of a subsequent diagnosis of multiple sclerosis. 2015 , 86, 543-6	39
985	Circadian cortisol and fatigue severity in relapsing-remitting multiple sclerosis. 2015 , 56, 120-31	29

984	TLR2 stimulation regulates the balance between regulatory T cell and Th17 function: a novel mechanism of reduced regulatory T cell function in multiple sclerosis. 2015 , 194, 5761-74	53
983	MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression. 2015 , 13, 148	29
982	Guidelines on Cerebrospinal Fluid Analysis. 2015 , 407-428	
981	Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. 2015 , 72, 81-7	162
980	Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry. 2015 , 4, 264-72	7
979	High doses of biotin in chronic progressive multiple sclerosis: a pilot study. 2015 , 4, 159-69	153
978	Relation between plasmatic and cerebrospinal fluid oxidative stress biomarkers and intrathecal Ig synthesis in Multiple Sclerosis patients. 2015 , 283, 39-42	5
977	Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS). 2015 , 31, 1349-61	23
976	Home-based training to improve manual dexterity in patients with multiple sclerosis: A randomized controlled trial. 2015 , 21, 1546-56	22
975	The effect of executive function on stress, depression, anxiety, and quality of life in multiple sclerosis. 2015 , 37, 549-62	14
974	Cervical cord lesion load is associated with disability independently from atrophy in MS. 2015 , 84, 367-73	81
973	Balanced oxidative stress index in spite of decreased uric acid levels in multiple sclerosis patients. 2015 , 9, 153-158	1
972	Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. 2015 , 72, 897-904	63
971	Acute abdominal pain as the only symptom of a thoracic demyelinating lesion in multiple sclerosis. 2015 , 37, 983-7	1
970	FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients. 2015 , 6, e1741	18
969	Redefining epilepsy. 2015 , 28, 130-5	48
968	A longitudinal MRI study of cervical cord atrophy in multiple sclerosis. 2015 , 262, 1622-8	18
967	Besonderheiten der multiplen Sklerose im Kindes- und Jugendalter. 2015 , 50, 74-77	

966 Demyelinating Diseases. **2015**, 895-905

- 965 Rotation-invariant multi-contrast non-local means for MS lesion segmentation. **2015**, 8, 376-89 48
- 964 EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. **2015**, 1, e000022 150
- 963 Classification, diagnosis, and differential diagnosis of multiple sclerosis. **2015**, 28, 193-205 122
- 962 Protocol for a multicentre randomised controlled TRial of IntraVENous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). **2015**, 5, e008312 14
- 961 Multiple deep white matter lesions mimicking multiple sclerosis as an unusual complication of a left atrial myxoma. **2015**, 21, 111-2
- 960 Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. **2015**, 21, 1802-10 2
- 959 High sensitivity C-reactive protein and cerebral white matter hyperintensities on magnetic resonance imaging in migraine patients. **2015**, 16, 9 26
- 958 Decision-making under explicit risk is impaired in multiple sclerosis: relationships with ventricular width and disease disability. **2015**, 15, 61 9
- 957 Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. **2015**, 16, 184 24
- 956 Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS. **2015**, 85, 29-39 91
- 955 Chronic Pain in Multiple Sclerosis Patients: Utility of Sensory Quantitative Testing in Patients with Fibromyalgia Comorbidity. **2015**, 73, 257-63 6
- 954 Association of cerebrospinal fluid levels of lateral olfactory tract usher substance (LOTUS) with disease activity in multiple sclerosis. **2015**, 72, 176-9 13
- 953 Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review. **2015**, 44, 199-214 79
- 952 Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate. **2015**, 64, 1112-21 21
- 951 Serum anti-Müllerian hormone levels in reproductive-age women with relapsing-remitting multiple sclerosis. **2015**, 21, 41-7 46
- 950 Incidence and prevalence of pediatric onset multiple sclerosis in Kuwait: 1994-2013. **2015**, 353, 107-10 26
- 949 Spinal cord MRI in multiple sclerosis--diagnostic, prognostic and clinical value. **2015**, 11, 327-38 131

948	Neuroinflammation and demyelination from the point of nitrosative stress as a new target for neuroprotection. 2015 , 26, 49-73	11
947	ACTH gel in the treatment of multiple sclerosis exacerbation: a case study. 2015 , 8, 23-7	1
946	Cross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil. 2015 , 29, 836-46	37
945	Locally adaptive MR intensity models and MRF-based segmentation of multiple sclerosis lesions. 2015 ,	1
944	Overview of magnetic resonance imaging for management of relapsing-remitting multiple sclerosis in everyday practice. 2015 , 22 Suppl 2, 22-7	12
943	Quantified CSF antibody reactivity against myelin in multiple sclerosis. 2015 , 2, 1116-23	5
942	Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. 2015 , 132, 29-36	44
941	Human autoimmune diseases: a comprehensive update. 2015 , 278, 369-95	331
940	Significance of gray matter brain lesions in multiple sclerosis and neuromyelitis optica. 2015 , 35, 481-6	9
939	Expanding spectrum of neurologic manifestations in patients with NLRP3 low-penetrance mutations. 2015 , 2, e109	34
938	Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis. 2015 , 138, 2571-83	56
937	LOTUS, a possible endogenous inhibitor of axonal degeneration, as a new biomarker for multiple sclerosis. 2015 , 5, 469-72	3
936	Transcranial brain photoplethysmography to study the venules of cerebral cortex in patients with multiple sclerosis. 2015 , 30, 119-26	2
935	Development and validation of an administrative data algorithm to estimate the disease burden and epidemiology of multiple sclerosis in Ontario, Canada. 2015 , 21, 1045-54	58
934	A single-nucleotide polymorphism in serine-threonine kinase 11, the gene encoding liver kinase B1, is a risk factor for multiple sclerosis. 2015 , 7,	8
933	Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. 2015 , 12, 146	19
932	Krankenversicherungsdaten bestätigen hohe Prävalenz der Multiplen Sklerose. 2015 , 42, 191-196	5
931	Biomechanical analysis of spasticity treatment in patients with multiple sclerosis. 2015 , 8, 203-11	4

930	Immunologic and MRI markers of the therapeutic effect of IFN- β 1a in relapsing-remitting MS. 2015 , 2, e176	11
929	Increase in the iron content of the substantia nigra and red nucleus in multiple sclerosis and clinically isolated syndrome: a 7 Tesla MRI study. 2015 , 41, 1065-70	28
928	Myelin Disorders: Multiple Sclerosis. 2015 , 139-151	
927	THE ROLE OF ANTICIPATORY POSTURAL ADJUSTMENTS AND COMPENSATORY CONTROL OF POSTURE IN BALANCE CONTROL OF PATIENTS WITH MULTIPLE SCLEROSIS. 2015 , 15, 1550087	3
926	Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology. 2015 , 2, e175	63
925	Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis. 2015 , 12, 132	15
924	Paraoxonase 1 activity and polymorphisms in multiple sclerosis patients. 2015 , 70, 1672-1676	2
923	Serum complement factor H and Tyr402 His gene polymorphism among Egyptians with multiple sclerosis. 2015 , 37, 845-52	4
922	Solitary sclerosis: Progressive neurological deficit from a spatially isolated demyelinating lesion: A further report. 2015 , 38, 551-5	6
921	Prevalence and risk factors of low bone mineral density in patients with multiple sclerosis. 2015 , 70, 188-92	11
920	Treadmill-virtual reality combined training program to improve gait in multiple sclerosis individuals. 2015 ,	2
919	[Is it always useful to perform lumbar puncture for the diagnosis of multiple sclerosis? Yes]. 2015 , 171, 605-6	
918	Randomized trial of erhuangfang for relapsing multiple sclerosis. 2015 , 37, 633-7	12
917	Short-term effect of high-dose vitamin D on the level of interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. 2015 , 22, 400-4	35
916	Chemokine receptor V β 2 deletion in multiple sclerosis patients in Csongr�d County in Hungary and the North-B�ska region in Serbia. 2015 , 76, 59-64	2
915	Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis. 2015 , 180, 243-9	41
914	The role of cerebellar abnormalities in neuromyelitis optica--a comparison with multiple sclerosis and healthy controls. 2015 , 21, 757-66	6
913	Acute idiopathic transverse myelitis in children: early predictors of relapse and disability. 2015 , 84, 341-9	46

912	Diagnostic value of 3D fluid attenuated inversion recovery sequence in multiple sclerosis. 2015 , 56, 622-7	24
911	Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis. 2015 , 21, 1414-22	17
910	Integrity of hypothalamic fibers and cognitive fatigue in multiple sclerosis. 2015 , 4, 39-46	19
909	Decreased serum vitamin D levels in Japanese patients with multiple sclerosis. 2015 , 279, 40-5	27
908	OFSEP, a nationwide cohort of people with multiple sclerosis: Consensus minimal MRI protocol. 2015 , 42, 133-40	42
907	Clinical and radiological characteristics of 17 Chinese patients with pathology confirmed tumefactive demyelinating diseases: follow-up study. 2015 , 348, 153-9	6
906	Role of interferon-beta in Mycobacterium avium subspecies paratuberculosis antibody response in Sardinian MS patients. 2015 , 349, 249-50	10
905	Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future. 2015 , 11, 69-91	39
904	Subclinical central inflammation is risk for RIS and CIS conversion to MS. 2015 , 21, 1443-52	39
903	Place of birth, age of immigration, and disability in Hispanics with multiple sclerosis. 2015 , 4, 25-30	17
902	Altered basal ganglia functional connectivity in multiple sclerosis patients with fatigue. 2015 , 21, 925-34	109
901	Latitude and HLA-DRB1 alleles independently affect the emergence of cerebrospinal fluid IgG abnormality in multiple sclerosis. 2015 , 21, 1112-20	10
900	Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. 2015 , 84, 776-83	123
899	Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapy. 2015 , 262, 771-3	12
898	Neuromyelitis optica spectrum disorders associated with other autoimmune diseases. 2015 , 35, 243-53	23
897	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. 2015 , 21, 1013-24	181
896	Analysis of normal-appearing white matter of multiple sclerosis by tensor-based two-compartment model of water diffusion. 2015 , 25, 1701-7	8
895	Optic radiation damage in multiple sclerosis is associated with visual dysfunction and retinal thinning--an ultrahigh-field MR pilot study. 2015 , 25, 122-31	67

894	Cerebrospinal Fluid in Clinical Neurology. 2015,	13
893	Neurological outcome and predictive factors of idiopathic optic neuritis in China. 2015, 349, 94-8	7
892	Predicting outcome in clinically isolated syndrome using machine learning. 2015, 7, 281-7	40
891	The relationship between regional microstructural abnormalities of the corpus callosum and physical and cognitive disability in relapsing-remitting multiple sclerosis. 2015, 7, 28-33	22
890	Predictors of institutionalization for people with multiple sclerosis. 2015, 8, 271-7	7
889	Capillary isoelectric focusing immunoassay as a new nanoscale approach for the detection of oligoclonal bands. 2015, 36, 355-62	8
888	Criteria improving multiple sclerosis diagnosis at the first MRI. 2015, 262, 979-87	11
887	Treatment of pediatric multiple sclerosis. 2015, 17, 336	23
886	Extensive acute axonal damage in pediatric multiple sclerosis lesions. <i>Annals of Neurology,</i> 2015, 77, 655-67	54
885	The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients. 2015, 294, 9-12	22
884	The +190 G/A (rs1799864) polymorphism in the C-C chemokine receptor 2 (CCR2) gene is associated with susceptibility to multiple sclerosis in HLA-DRB1*15:01-negative individuals. 2015, 349, 138-42	4
883	Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. 2015, 138, 517-39	32
882	Blood-brain barrier breakdown in the aging human hippocampus. 2015, 85, 296-302	1023
881	Double inversion recovery sequence of the cervical spinal cord in multiple sclerosis and related inflammatory diseases. 2015, 36, 219-25	30
880	Outcomes after early administration of plasma exchange in pediatric central nervous system inflammatory demyelination. 2015, 30, 874-80	36
879	New mutations in the Notch3 gene in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL). 2015, 349, 196-201	14
878	Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab. 2015, 73, 57-65	18
877	Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis. 2015, 21, 1521-32	18

876	Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis. 2015 , 36, 1796-807	47
875	Inflammation of the Spinal Cord. 2015 , 315-367	
874	Brain atrophy in radiologically isolated syndromes. 2015 , 25, 68-71	39
873	Imaging phenotypes in multiple sclerosis. 2015 , 25, 83-96	6
872	Genomewide admixture study in Mexican Mestizos with multiple sclerosis. 2015 , 130, 55-60	17
871	The need for a disease-specific prospective pregnancy registry for multiple sclerosis (MS). 2015 , 4, 6-17	16
870	Progression rates and sample size estimates for PPMS based on the CLIMB study population. 2015 , 21, 180-8	9
869	Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs. 2015 , 16, 659-73	16
868	Longitudinal assessment of clinically isolated syndrome with diffusion tensor imaging and volumetric MRI. 2015 , 39, 207-12	6
867	A Model of Population and Subject (MOPS) Intensities With Application to Multiple Sclerosis Lesion Segmentation. 2015 , 34, 1349-61	44
866	We can compare the relative efficacy of multiple sclerosis medications by examining the results of independent clinical trials: yes. 2015 , 21, 35-6	1
865	The role of fractalkine (CX3CL1) in regulation of CD4(+) cell migration to the central nervous system in patients with relapsing-remitting multiple sclerosis. 2015 , 157, 121-32	18
864	No association between multiple sclerosis and periodontitis after adjusting for smoking habits. 2015 , 22, 588-90	6
863	Therapeutic uses of anti- α -integrin (anti-VLA-4) antibodies in multiple sclerosis. 2015 , 27, 47-53	37
862	Multiple sclerosis in children and adolescents. An important differential diagnosis of acute neurological disease. 2015 , 19, 211-7	5
861	Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. 2015 , 21, 1431-42	18
860	The role of the cerebellum in multiple sclerosis. 2015 , 14, 364-74	34
859	Identifying individuals with multiple sclerosis in an electronic medical record. 2015 , 21, 217-24	28

858	Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study. 2015 , 262, 961-7	23
857	Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. 2015 , 21, 1251-61	88
856	Decreased concentration of Klotho in the cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis. 2015 , 281, 5-8	31
855	Serum NSE level and disability progression in multiple sclerosis. 2015 , 350, 46-50	12
854	Predictive value of different conventional and non-conventional MRI-parameters for specific domains of cognitive function in multiple sclerosis. 2015 , 7, 715-20	22
853	MS risk allele rs1883832T is associated with decreased mRNA expression of CD40. 2015 , 56, 540-5	11
852	Assessment of visual and auditory evoked potentials in multiple sclerosis patients with and without fatigue. 2015 , 36, 235-42	10
851	The Role of Matrix Metalloproteinase 3 and 9 in the Pathogenesis of Acute Neuroinflammation. Implications for Disease Modifying Therapy. 2015 , 56, 840-847	12
850	The expression of IL-7RA in Egyptian patients with multiple sclerosis. 2015 , 24, 1223-1230	
849	GM-CSF production by CD4+ T cells in MS patients: regulation by regulatory T cells and vitamin D. 2015 , 280, 36-42	12
848	The aetiology of acute neurological decline in multiple sclerosis: experience from an open-access clinic. 2015 , 21, 67-75	12
847	Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. 2015 , 21, 1713-22	20
846	Electrophysiological Evaluation of Dysphagia in the Mild or Moderate Patients with Multiple Sclerosis: A Concept of Subclinical Dysphagia. 2015 , 30, 296-303	23
845	A rapid method for preparation of the cerebrospinal fluid proteome. 2015 , 15, 10-5	6
844	Processing speed and working memory training in multiple sclerosis: a double-blind randomized controlled pilot study. 2015 , 37, 113-27	39
843	Acute disseminated encephalomyelitis: current controversies in diagnosis and outcome. 2015 , 262, 2013-24	53
842	An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis. 2015 , 11, 1563-72	57
841	Infection risk in patients on multiple sclerosis therapeutics. 2015 , 29, 229-44	40

840	Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients. 2015 , 14, 903-13	41
839	The intelligent use and clinical benefits of electronic medical records in multiple sclerosis. 2015 , 11, 205-11	6
838	Clinical and radiological features of recurrent demyelination following acute disseminated encephalomyelitis (ADEM). 2015 , 4, 451-456	6
837	Biomarkers for Phase Switches in Multiple Sclerosis. 2015 , 1053-1080	
836	Identifying employed multiple sclerosis patients at-risk for job loss: When do negative work events pose a threat?. 2015 , 4, 409-413	22
835	A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway. 2016 , 87, 100-5	33
834	Lack of association between mitochondrial DNA G15257A and G15812A variations and multiple sclerosis. 2015 , 356, 102-6	8
833	Neuroanesthesia and Cerebrospinal Protection. 2015 ,	3
832	A toolbox for multiple sclerosis lesion segmentation. 2015 , 57, 1031-43	58
831	A new method for quantifying mfVEP signal intensity in multiple sclerosis. 2015 , 22, 119-125	3
830	Ligation of metabotropic glutamate receptor 3 (Grm3) ameliorates lupus-like disease by reducing B cells. 2015 , 160, 142-54	16
829	Evaluation of retinal nerve fiber layer thickness measured by optical coherence tomography in Moroccan patients with multiple sclerosis. 2015 , 38, 497-503	5
828	Impaired sleep-associated modulation of post-exercise corticomotor depression in multiple sclerosis. 2015 , 354, 91-6	7
827	Trigeminal root entry zone involvement in neuromyelitis optica and multiple sclerosis. 2015 , 355, 147-9	10
826	Brain functional plasticity at rest and during action in multiple sclerosis patients. 2015 , 22, 1438-43	8
825	Th Cell Diversity in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. 2015 , 195, 2552-9	47
824	InMS: Chronic insomnia disorder in multiple sclerosis - a Portuguese multicentre study on prevalence, subtypes, associated factors and impact on quality of life. 2015 , 4, 477-483	12
823	Síndrome radiológico aislado: ¿esclerosis múltiple preclínica o asintomática?. 2015 , 7, 105-111	

822	Walking improvements with nabiximols in patients with multiple sclerosis. 2015 , 262, 2472-7	32
821	MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing. 2015 , 572, 191-7	15
820	Recovery From Central Nervous System Acute Demyelination in Children. 2015 , 136, e115-23	33
819	Biomarkers in multiple sclerosis. 2015 , 161, 51-8	105
818	Injury to white matter tracts in relapsing-remitting multiple sclerosis: A possible therapeutic window within the first 5 years from onset using diffusion-tensor imaging tract-based spatial statistics. 2015 , 8, 261-6	11
817	Mitochondrial DNA sequence variation in multiple sclerosis. 2015 , 85, 325-30	46
816	Clinical and cognitive implications of cerebrospinal fluid oligoclonal bands in multiple sclerosis patients. 2015 , 36, 2053-60	11
815	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. 2015 , 11, 471-82	272
814	Quantitative oxygen extraction fraction from 7-Tesla MRI phase: reproducibility and application in multiple sclerosis. 2015 , 35, 131-9	33
813	A Clinical Approach to the Differential Diagnosis of Multiple Sclerosis. 2015 , 15, 57	22
812	Neuromyelitis optica with linear enhancement of corpus callosum in brain magnetic resonance imaging with contrast: a case report. 2015 , 9, 137	3
811	Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. 2015 , 10, e0119681	46
810	Multimodal Quantitative MR Imaging of the Thalamus in Multiple Sclerosis and Neuromyelitis Optica. 2015 , 277, 784-92	30
809	Information processing speed and attention in multiple sclerosis: Reconsidering the Attention Network Test (ANT). 2015 , 37, 518-29	17
808	Incidental learning during rapid information processing on the symbol-digit modalities test. 2015 , 30, 322-8	9
807	Increased circulating levels of vitamin D binding protein in MS patients. 2015 , 7, 129-37	28
806	Differential upregulation of the hypothetical transmembrane protein 66 () in multiple sclerosis patients with potential inflammatory response. 2015 , 3, 98-104	7
805	Dynamics of brain iron levels in multiple sclerosis: A longitudinal 3T MRI study. 2015 , 84, 2396-402	46

804	MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a. 2015 , 278, 185-9	46
803	A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis. 2015 , 24, 5619-27	28
802	Memory impairment in multiple sclerosis: Relevance of hippocampal activation and hippocampal connectivity. 2015 , 21, 1705-12	47
801	Vitamin D supplementation up-regulates IL-6 and IL-17A gene expression in multiple sclerosis patients. 2015 , 28, 414-9	30
800	Natalizumab modulates the humoral response against HERV-Wenv73-88 in a follow-up study of Multiple Sclerosis patients. 2015 , 357, 106-8	10
799	Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis. 2015 , 85, 248-55	31
798	GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. 2015 , 4, 370-6	40
797	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. 2015 , 21, 967-8	8
796	Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis. 2015 , 283, 64-9	28
795	Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. 2015 , 285, 125-8	35
794	An ImmunoChip study of multiple sclerosis risk in African Americans. 2015 , 138, 1518-30	44
793	Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes. 2015 , 355, 84-9	16
792	Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. 2015 , 15, 273-9	118
791	The Framingham cardiovascular risk score in multiple sclerosis. 2015 , 22, 1176-83	39
790	Speedy eye movements in multiple sclerosis: association with performance on visual and nonvisual cognitive tests. 2015 , 37, 1-15	6
789	Smoking worsens multiple sclerosis prognosis: two different pathways are involved. 2015 , 281, 23-34	38
788	Evaluating response to disease-modifying therapy in relapsing multiple sclerosis. 2015 , 15, 407-23	4
787	Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β 1a. 2015 , 22, 1113-23	22

786	Protocolo diagnóstico del paciente con sospecha de enfermedad desmielinizante. 2015 , 11, 4648-4650		
785	There is still a role for the blink reflex in the diagnosis and follow-up of multiple sclerosis. 2015 , 126, 743-7		6
784	Cardiovascular autonomic dysfunction in multiple sclerosis: a meta-analysis. 2015 , 4, 104-11		28
783	Abnormally high levels of anti-collagen type IV IgG antibodies in the serum of patients with a clinically isolated syndrome correlate with an increased risk of conversion to MS. 2015 , 133, 30-3		3
782	Mujer joven con dolor y visión borrosa en el ojo derecho de 5 días de evolución. 2015 , 11, 4666.e1-4666.e5		
781	Diagnostic value of aquaporin 4 antibody in assessing idiopathic inflammatory demyelinating central nervous system diseases in Egyptian patients. 2015 , 22, 670-5		1
780	Epitopes of HERV-Wenv induce antigen-specific humoral immunity in multiple sclerosis patients. 2015 , 280, 66-8		19
779	Dynamics of retinal injury after acute optic neuritis. <i>Annals of Neurology</i> , 2015 , 77, 517-28	9-4	107
778	Most Scottish neurologists do not apply the 2010 McDonald criteria when diagnosing multiple sclerosis. 2015 , 45, 23-6		5
777	Perceived cognitive difficulties and cognitive test performance as predictors of employment outcomes in people with multiple sclerosis. 2015 , 21, 156-68		63
776	Dimethyl fumarate for multiple sclerosis. 2015 , CD011076		43
775	Natalizumab in spinal multiple sclerosis in a daily clinical setting. 2015 , 15, 633-40		
774	Investigating the phenomenon of "cognitive-motor interference" in multiple sclerosis by means of dual-task posturography. 2015 , 41, 780-5		24
773	Association of copeptin and cortisol in newly diagnosed multiple sclerosis patients. 2015 , 282, 21-4		10
772	Targeted clinical audits immediately following the establishment of clinical practice guidelines for multiple sclerosis in 17 neurology departments: A pragmatic and collaborative study. 2015 , 171, 407-14		1
771	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. 2015 , 138, 1863-74		302
770	Increased natural killer cell chemotaxis to CXCL12 in patients with multiple sclerosis. 2015 , 282, 39-44		10
769	Esclerosis múltiple. 2015 , 11, 4610-4621		4

768	Pharmacogenomics of interferon- β in multiple sclerosis: what has been accomplished and how can we ensure future progress?. 2015 , 26, 249-61	7
767	Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: A multicenter study. 2015 , 36, 2809-25	55
766	Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. 2015 , 85, 18-28	178
765	(11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. 2015 , 42, 1081-92	69
764	Fecundity in women with multiple sclerosis: an observational mono-centric study. 2015 , 262, 957-60	34
763	Psychometric properties of the Hamilton Depression Rating Scale in multiple sclerosis. 2015 , 24, 1973-80	32
762	IT Infrastructure to support the secondary use of routinely acquired clinical imaging data for research. 2015 , 13, 65-81	7
761	Dominant and Protective Role of the CYTH4 Primate-Specific GTTT-Repeat Longer Alleles Against Neurodegeneration. 2015 , 56, 593-6	11
760	Multiple sclerosis and HIV-1 infection: case report of a HIV controller. 2015 , 21, 464-7	17
759	Multiple Sclerosis in the Elderly: Considerations in the Geriatric Population for Diagnosis and Management. 2015 , 4, 131-141	
758	Reassessment of Lhermitte's sign in multiple sclerosis. 2015 , 115, 605-8	7
757	Progressive multiple sclerosis and mood disorders. 2015 , 36, 1625-31	11
756	Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study. 2015 , 55, 1131-6	19
755	Spinal segmental myoclonus as an unusual presentation of multiple sclerosis. 2015 , 15, 15	11
754	A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohort. 2015 , 15, 21	17
753	Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. 2015 , 12, 46	112
752	Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial. 2015 , 16, 106	19
751	Status migrainosus as an initial presentation of multiple sclerosis. 2015 , 4, 28	7

750	Relapse in multiple sclerosis. 2015 , 350, h1765	32
749	Mitochondrial DNA T4216C and A4917G variations in multiple sclerosis. 2015 , 356, 55-60	18
748	Severe cognitive impairment associated with intrathecal antibodies to the NR1 subunit of the N-methyl-D-aspartate receptor in a patient with multiple sclerosis. 2015 , 72, 96-9	19
747	Identification of cortical lesions using DIR and FLAIR in early stages of multiple sclerosis. 2015 , 262, 1473-82	18
746	Putaminal alteration in multiple sclerosis patients with spinal cord lesions. 2015 , 122, 1465-73	3
745	Rates of white matter hyperintensities compatible with the radiological profile of multiple sclerosis within self-referred synesthete populations. 2015 , 21, 322-30	6
744	Identification of ncRNAs as potential therapeutic targets in multiple sclerosis through differential ncRNA - mRNA network analysis. 2015 , 16, 250	14
743	Walking function in clinical monitoring of multiple sclerosis by telemedicine. 2015 , 262, 1706-13	12
742	The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. 2015 , 127-128, 1-22	90
741	Puberty in females enhances the risk of an outcome of multiple sclerosis in children and the development of central nervous system autoimmunity in mice. 2015 , 21, 735-48	39
740	Therapeutic management of severe relapses in multiple sclerosis. 2015 , 17, 345	19
739	Accuracy and reproducibility of a quantitative magnetic resonance imaging method for concurrent measurements of tissue relaxation times and proton density. 2015 , 33, 584-91	49
738	Aerobic capacity in persons with multiple sclerosis: a systematic review and meta-analysis. 2015 , 45, 905-23	77
737	Memory and selective attention in multiple sclerosis: cross-sectional computer-based assessment in a large outpatient sample. 2015 , 265, 439-43	15
736	A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis. 2015 , 8, 59-70	4
735	MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. 2015 , 14, 443-54	81
734	Statin treatment in multiple sclerosis: a systematic review and meta-analysis. 2015 , 29, 277-91	65
733	Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring. 2015 , 42, 159-67	14

732	Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study. 2015 , 262, 1637-45	19
731	Disease-modifying therapy for multiple sclerosis. 2015 , 10, 253-279	
730	Novel diagnostic tools and solutions for multiple sclerosis treatment: a patent review (2009 - 2014). 2015 , 25, 873-84	4
729	Multi-Output Decision Trees for Lesion Segmentation in Multiple Sclerosis. 2015 , 9413,	6
728	Inflammatory Disorders in the Brain and CNS. 2015 , 913-916	
727	Brain Inflammation, Degeneration, and Plasticity in Multiple Sclerosis. 2015 , 917-927	1
726	Association between perceived fatigue and gait parameters measured by an instrumented treadmill in people with multiple sclerosis: a cross-sectional study. 2015 , 12, 34	24
725	A patient care program for adjusting the autoinjector needle depth according to subcutaneous tissue thickness in patients with multiple sclerosis receiving subcutaneous injections of glatiramer acetate. 2015 , 47, E22-30	3
724	Multiple sclerosis: From new concepts to updates on management. 2015 , 44, e101-2	
723	Advanced imaging tools to investigate multiple sclerosis pathology. 2015 , 44, e159-67	13
722	Update on clinically isolated syndrome. 2015 , 44, e121-36	7
721	Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly. 2015 , 281, 44-50	1
720	Epstein-Barr virus genetic variants are associated with multiple sclerosis. 2015 , 84, 1362-8	29
719	Retinal damage and vision loss in African American multiple sclerosis patients. <i>Annals of Neurology</i> , 2015 , 77, 228-36	9-4 35
718	Treatment of multiple sclerosis in children and its challenges. 2015 , 44, e153-8	6
717	Human leukocyte antigen association with neuromyelitis optica in a south Indian population. 2015 , 21, 1217-8	14
716	Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis. 2015 , 73, 220-229	11
715	MRI in Clinical Management of Multiple Sclerosis. 2015 , 907-912	

714	Association of circulating follicular helper T cells with disease course of NMO spectrum disorders. 2015 , 278, 239-46	32
713	Neuromyelitis optica spectrum disorders: beyond longitudinally extensive transverse myelitis. 2015 , 70, 630-7	8
712	Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?. 2015 , 2, e62	201
711	A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis. 2015 , 21, 1781-93	41
710	Association between anemia and multiple sclerosis. 2015 , 73, 233-237	10
709	The "butterfly diagram": A gait marker for neurological and cerebellar impairment in people with multiple sclerosis. 2015 , 358, 92-100	24
708	Anesthesia for Patients with Neuromuscular Disease. 2015 , 481-490	
707	Validation of MRI radiological reports in pediatric MS according to the McDonald 2017 criteria: A Danish nationwide multicenter cohort study.. 2021 , 57, 103443	
706	Central Nervous System Systemic Lupus Erythematosus: Pathophysiologic, Clinical, and Imaging Features.. 2022 , 42, 212-232	3
705	Validation of an automatic tool for the rapid measurement of brain atrophy and white matter hyperintensity: QyScore [®] .. 2022 , 1	2
704	Diagnosis of multiple sclerosis: Progress or confusion?. 2022 , 57, 103528	0
703	Mental Health Status of People with Multiple Sclerosis during the COVID-19 Pandemic.. 2022 , 11,	
702	Neuromyelitis Optica Spectrum Disorders and Glial Fibrillary Acidic Protein Autoimmunity. 2022 , 315-341	
701	From Diagnosis to Satisfaction in Multiple Sclerosis: A Swiss Patient Survey Highlighting the Importance of the First Diagnostic Consultation. 2022 , 6, 4	
700	Central Vein Sign Profile of Newly Developing Lesions in Multiple Sclerosis: A 3-Year Longitudinal Study.. 2022 , 9,	1
699	Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPRiMS Score.. 2021 , 12, 766956	0
698	Successful treatment with dimethyl fumarate in a child with relapsing-remitting multiple sclerosis.. 2022 ,	1
697	Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM.. 2022 ,	51

696	Constructing a Multiple Sclerosis Diagnosis Model Based on Microarray.. 2021 , 12, 721788	
695	Automatic segmentation of white matter hyperintensities: validation and comparison with state-of-the-art methods on both Multiple Sclerosis and elderly subjects.. 2022 , 33, 102940	0
694	A Multisite and Multimodal Comparative Study of Cerebellar Connectome Between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.	
693	Long-Term Suppression of Circulating Proinflammatory Cytokines in Multiple Sclerosis Patients Following Autologous Haematopoietic Stem Cell Transplantation.. 2021 , 12, 782935	
692	Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome.. 2022 , e2494	1
691	Reflex Locomotion Therapy for Balance, Gait, and Fatigue Rehabilitation in Subjects with Multiple Sclerosis.. 2022 , 11,	0
690	Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression.. 2022 , 59, 103561	1
689	Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis.. 2022 , 1	3
688	Anti-aquaporin-4 immunoglobulin G colorimetric detection by silver nanoparticles.. 2022 , 102531	0
687	Characterization of Antigen-Induced CD4+ T-Cell Senescence in Multiple Sclerosis.. 2022 , 13, 790884	2
686	Transcriptional effects of fingolimod treatment on peripheral T cells in relapsing remitting multiple sclerosis patients.. 2022 ,	
685	Sustained immunotolerance in multiple sclerosis after stem cell transplant.. 2022 ,	1
684	The aerobic capacity - fatigue relationship in persons with Multiple Sclerosis is not reproducible in a pooled analysis of two randomized controlled trials.. 2021 , 58, 103476	0
683	Alterations of host-gut microbiome interactions in multiple sclerosis.. 2022 , 76, 103798	4
682	The impact of lifetime coffee and tea loads on Multiple Sclerosis severity.. 2022 , 47, 199-205	
681	Neuroinflammation as potential precursor of leukoencephalopathy in early-stage breast cancer patients: A cross-sectional PET-MRI study.. 2022 , 62, 61-68	0
680	Impact of rituximab in Mexican patients with Multiple Sclerosis-A single-center retrospective study.. 2022 , 58, 103485	1
679	Administration of Maresin-1 ameliorates the physiopathology of experimental autoimmune encephalomyelitis.. 2022 , 19, 27	2

678	Consistency of the "central vein sign" in chronic multiple sclerosis lesions.. 2022 , 58, 103530	0
677	Using myelin water imaging to link underlying pathology to clinical function in multiple sclerosis: A scoping review.. 2022 , 59, 103646	0
676	Two-dimensional measurements with cut-off values are useful for assessing brain volume, physical disability, and processing speed in multiple sclerosis.. 2022 , 59, 103543	2
675	Lifetime physical activity is associated with gut bacteria and brain health in people with multiple sclerosis: Focus on physical activity intensity.. 2022 , 59, 103639	
674	Elevated levels of IL-32 in cerebrospinal fluid of neuro-Behcet disease: Correlation with NLRP3 inflammasome.. 2022 , 365, 577820	1
673	Successful long-term management of spasticity in people with multiple sclerosis using a software application: Results from a randomized, controlled, multicenter study.. 2022 ,	
672	CNS endothelial derived extracellular vesicles are biomarkers of active disease in multiple sclerosis.. 2022 , 19, 13	2
671	Managing neuropsychological impairment in multiple sclerosis - Controlled study on a standardized metacognitive intervention (MaTiMS).. 2022 , 59, 103687	0
670	Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study.. 2022 , 1	0
669	Next-generation sequencing of the whole mitochondrial genome identifies functionally deleterious mutations in patients with multiple sclerosis.. 2022 , 17, e0263606	2
668	Epstein-Barr Virus Load Correlates with Multiple Sclerosis-Associated Retrovirus Envelope Expression.. 2022 , 10,	0
667	La moelle se traite-elle comme le cerveau?. 2022 , 13, 71-71	
666	Effectiveness of Anti-Cluster of Differentiation 20 as a Disease-Modifying Therapy in Multiple Sclerosis Across Its Different Phenotypes at the University Hospital of Caen.. 2022 , 14, e22120	
665	Postural Control in Relapsing-Remitting Multiple Sclerosis.	
664	The role of wisdom and self-management skills for coping with fear of progression among patients with multiple sclerosis with moderate disability: Results from a cross-sectional study. 2022 , 8, 100311	
663	Choroid plexus volume predicts expansion of chronic lesions and brain atrophy.	0
662	Serum metabolic profiles and metal levels of patients with multiple sclerosis and patients with neuromyelitis optica spectrum disorders - NMR spectroscopy and ICP-MS studies.. 2022 , 60, 103672	
661	Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis.. 2022 , 1352458521106915	

- 660 No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis.. **2022**, 11, 471 0
- 659 Comparing natural history of early and late onset pediatric multiple sclerosis.. *Annals of Neurology*, **2022**, 9:4 2
- 658 The BDNF Val66Met Polymorphism (rs6265) Modulates Inflammation and Neurodegeneration in the Early Phases of Multiple Sclerosis.. **2022**, 13, 0
- 657 Lesion Volume in Relapsing Multiple Sclerosis is Associated with Perivascular Space Enlargement at the Level of the Basal Ganglia.. **2022**, 43, 238-244 1
- 656 Ozanimod for relapsing remitting multiple sclerosis and how Brexit changed the journey. **2022**, 4, 64-71
- 655 Multimodal Evoked Potentials as Potential Biomarkers of Disease Activity in Patients With Clinically Isolated Syndrome.. **2021**, 12, 678035 1
- 654 Effects of actual and imagined music-cued gait training on motor functioning and brain activity in people with multiple sclerosis: protocol of a randomised parallel multicentre trial.. **2022**, 12, e056666
- 653 Not all roads lead to the immune system: The Genetic Basis of Multiple Sclerosis Severity Implicates Central Nervous System and Mitochondrial Involvement. 0
- 652 Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.. **2022**, 59, 103669 1
- 651 A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab.. **2022**, 59, 103670 0
- 650 Distribution and relation of two arm function tests, Box and Blocks test and Nine Hole Peg test, across disease severity levels and types of multiple sclerosis.. **2022**, 59, 103683 1
- 649 The expansion and severity of chronic MS lesions follows a periventricular gradient. 0
- 648 Autonomic Nervous System Function in Newly Diagnosed Multiple Sclerosis: Association With Lipid Levels and Insulin Resistance. **2021**, 70,
- 647 Assessment of fingolimod versus dimethyl fumarate for the treatment of multiple sclerosis; a 24-month follow-up study. **2021**, 10, 86-92
- 646 Advanced Diffusion MR Imaging for Multiple Sclerosis in the Brain and Spinal Cord.. **2022**, 21, 0
- 645 Olfactory Dysfunction Reflects Disease Progression in Japanese Patients with Multiple Sclerosis.. **2022**,
- 644 Current and future applications of artificial intelligence in multiple sclerosis. **2022**, 107-144 1
- 643 Relationship between optical coherence tomography angiography and visual evoked potential in patients with multiple sclerosis.. **2022**, 70, 873-878 0

642	Multiple Sclerosis Lesion Analysis in Brain Magnetic Resonance Images: Techniques and Clinical Applications.. 2022 , PP,	2
641	A systematic review of self-concept change in multiple sclerosis.. 2022 , 1-40	1
640	Val66Met Polymorphism Is Associated With Motor Recovery After Rehabilitation in Progressive Multiple Sclerosis Patients.. 2022 , 13, 790360	1
639	Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis.. 2022 , 13, 820256	2
638	Coupling of brain activity and structural network in multiple sclerosis: A graph frequency analysis study.. 2022 ,	
637	Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review.. 2022 ,	1
636	A Quantitative Synthesis of Eight Decades of Global Multiple Sclerosis Research Using Bibliometrics.. 2022 , 13, 845539	3
635	Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.. 2022 , 1	0
634	Twin study reveals non-heritable immune perturbations in multiple sclerosis.. 2022 ,	3
633	Coexistence of restless legs syndrome and multiple sclerosis aggravates anxiety and depression.. 2022 ,	
632	Visual Search in Naturalistic Scenes Reveals Impaired Cognitive Processing Speed in Multiple Sclerosis.. 2022 , 13, 838178	
631	Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.. 2022 , 9,	1
630	Relaxation-Compensated Chemical Exchange Saturation Transfer MRI in the Brain at 7T: Application in Relapsing-Remitting Multiple Sclerosis.. 2022 , 13, 764690	
629	Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.. 2022 , 39, 1810	0
628	Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis.. 2022 , 9,	2
627	Comparison of Machine Learning Methods Using Spectralis OCT for Diagnosis and Disability Progression Prognosis in Multiple Sclerosis.. 2022 ,	1
626	Predicting relapse in demyelinating diseases in children. 2022 , 20, 57-62	
625	Multiple Sclerosis Relapses Following Cessation of Fingolimod.. 2022 , 42, 355	1

624	The Pediatric Optic Neuritis Prospective Outcomes Study - Two-Year Results.. 2022,	1
623	Do Hungarian multiple sclerosis care units fulfil international criteria?. 2022, 17, e0264328	0
622	Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab.. 2022, 13, 819911	0
621	Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.. 2022, 1	3
620	"Dry oral and ocular manifestations and autoantibodies characteristic of primary Sjögren's syndrome in multiple sclerosis".. 2022, 62, 103783	0
619	The Application of Diffusion Kurtosis Imaging on the Heterogeneous White Matter in Relapsing-Remitting Multiple Sclerosis.. 2022, 16, 849425	0
618	Contrast-enhanced double inversion recovery sequence for patients with multiple sclerosis: feasibility of subtraction images between pre- and post-contrast images.. 2022, 2841851221080831	
617	Magnetic Resonance Imaging of Autoimmune Demyelinating Diseases as a Diagnostic Challenge for Radiologists: Report of Two Cases and Literature Review.. 2022, 12,	
616	Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis.. 2022, 12, 4411	2
615	Multi-lesion radiomics model for discrimination of relapsing-remitting multiple sclerosis and neuropsychiatric systemic lupus erythematosus.. 2022, 1	1
614	Association between dietary inflammatory index and risk of demyelinating autoimmune diseases.. 2022,	0
613	Incidence and Prevalence of Multiple Sclerosis in MalmöSouthern Sweden.. 2022, 2022, 5464370	
612	Stratification of multiple sclerosis patients using unsupervised machine learning: a single-visit MRI-driven approach.. 2022, 1	0
611	Decreased Intrathecal Concentrations of Free Light Chains Kappa in Multiple Sclerosis Patients Taking Very High Effective Disease-Modifying Treatment.. 2022, 12,	0
610	Hormone therapy and disease activity in Danish women with multiple sclerosis - a population-based cohort study.. 2022,	1
609	Classification of multiple sclerosis patients based on structural disconnection: A robust feature selection approach.. 2022,	1
608	Cross-Country Adaptation of a Psychological Flexibility Measure: The Comprehensive Assessment of Acceptance and Commitment Therapy Processes.. 2022, 19,	0
607	Antibodies to blood coagulation components are implicated in patients with multiple sclerosis.. 2022, 62, 103775	1

606	Olfactory threshold predicts treatment response in relapsing multiple sclerosis.. 2022 , 13524585221079744	1
605	Cross-sectional and longitudinal correlations between the Arm Function in Multiple Sclerosis Questionnaire (AMSQ) and other outcome measures in multiple sclerosis.. 2022 , 61, 103725	
604	KeepStep: Accommodating user diversity through individualized, projection-mapping based exergames for rehabilitation in people with multiple sclerosis. 1	
603	Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients : Review.. 2022 , 1	1
602	Sexual Dysfunction in Women with Neuromyelitis Optica Spectrum Disorders and Multiple Sclerosis. 1	0
601	Botanically-Derived Δ^9 Tetrahydrocannabinol and Cannabidiol, and Their 1:1 Combination, Modulate Toll-like Receptor 3 and 4 Signalling in Immune Cells from People with Multiple Sclerosis.. 2022 , 27,	1
600	MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions.. 2022 , 1	2
599	The Complex Interplay Between Trait Fatigue and Cognition in Multiple Sclerosis.. 2022 , 62, 108-122	1
598	KIRCD8 T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19.. 2022 , 376, eabi9591	15
597	Seasonal Variations in the Concentration of Particulate Matter in the Air of Cracow Affect the Magnitude of CD4+ T Cell Subsets Cytokine Production in Patients with Inflammatory and Autoimmune Disorders. 2022 , 13, 529	0
596	Brain grey matter perfusion in primary progressive multiple sclerosis: Mild decrease over years and regional associations with cognition and hand function.. 2022 ,	0
595	The effect of lesion filling on brain network analysis in multiple sclerosis using structural magnetic resonance imaging.. 2022 , 13, 63	
594	The expansion and severity of chronic MS lesions follows a periventricular gradient.. 2022 , 13524585221080667	
593	Evaluation of peripapillary and subfoveal choroidal vascularity index in patients with multiple sclerosis.. 2022 , 102810	0
592	Misdiagnosis of HIV With Toxoplasmosis Encephalopathy With Progressive Memory Loss as the Initial Symptom: A Case Report.. 2022 , 13, 809811	1
591	Magnetic resonance imaging criteria at onset to differentiate pediatric multiple sclerosis from acute disseminated encephalomyelitis: A nationwide cohort study.. 2022 , 62, 103738	0
590	Long-term Effect of Permanent Demyelination on Axonal Survival in Multiple Sclerosis.. 2022 , 9,	1
589	Incidence of Developmental Venous Anomalies in Patients With Multiple Sclerosis: A 3 Tesla MRI Study.. 2022 , 13, 824347	

588	SWI as an Alternative to Contrast-Enhanced Imaging to Detect Acute MS Lesions.. 2022,	
587	Effects of a 6-Min Treadmill Walking Test on Dual-Task Gait Performance and Prefrontal Hemodynamics in People With Multiple Sclerosis.. 2022, 13, 822952	1
586	Effective Connectivity within the Papez Circuit in the Multiple Sclerosis Patients: A Comparative Study Using Resting-State fMRI.. 2022, 12, 149-160	1
585	Evolution of acute "black hole" lesions in patients with relapsing-remitting multiple sclerosis.. 2022, 1	
584	Upper cervical cord atrophy is independent of cervical cord lesion volume in early multiple sclerosis: A two-year longitudinal study.. 2022, 60, 103713	0
583	Central stress processing, T-cell responsivity to stress hormones and disease severity in multiple sclerosis.. 2022, 4, fcac086	1
582	Inter-joint coordination during gait in people with multiple sclerosis: A focus on the effect of disability.. 2022, 60, 103741	0
581	Relation of sensorimotor and cognitive cerebellum functional connectivity with brain structural damage in patients with multiple sclerosis and no disability.. 2022,	
580	Personalized Disease Monitoring in Pediatric Onset Multiple Sclerosis Using the Saliva Free Light Chain Test.. 2022, 13, 821499	1
579	Transcription Factor c-Maf Promotes Immunoregulation of Programmed Cell Death 1-Expressed CD8 T Cells in Multiple Sclerosis.. 2022, 9,	0
578	The expression pattern of VISTA in the PBMCs of relapsing-remitting multiple sclerosis patients: A single-cell RNA sequencing-based study.. 2022, 148, 112725	0
577	Structural visual metrics associate with moderate to vigorous physical activity in youth with pediatric onset neuroinflammatory disorders.. 2022, 60, 103745	
576	Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis.. 2022, 1	
575	Mechanisms of central brain atrophy in multiple sclerosis.	
574	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.. 2022, 13524585221084577	0
573	Genome-wide DNA methylation profiling identifies epigenetic changes in CD4+ and CD14+ cells of multiple sclerosis patients.. 2022, 60, 103714	0
572	Quantitative assessment of myelin density using [C]MeDAS PET in patients with multiple sclerosis: a first-in-human study.. 2022, 1	1
571	Priming of postural training with cerebellar anodal transcranial direct current stimulation for its effects on postural balance and fear of falling in patients with multiple sclerosis: A randomized, double-blind, sham-controlled study.. 2022, 99, 294-301	0

570	A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial.. 2022 , 61, 103747	0
569	Microstructural white matter abnormalities in multiple sclerosis and neuromyelitis optica spectrum disorders: Evaluation by advanced diffusion imaging.. 2022 , 436, 120205	0
568	Real-life evidence of treatment with alemtuzumab in patients diagnosed with relapsing-remitting multiple sclerosis in Colombia.. 2022 , 61, 103780	0
567	Lnc-HNF1A-AS1 and its target gene ATG5 is dysregulated in HLA-DRB1*15:01-negative female patients with multiple sclerosis. 2022 , 27, 101599	
566	Analysis of choroidal vascularity index in multiple sclerosis patients without optic neuritis attack.. 2022 , 38, 102823	0
565	Risk of Multiple Sclerosis: Analysis of Interactions between Variants of Nuclear and Mitochondrial Genomes. 2021 , 55, 839-846	
564	Iron Rims in Patients With Multiple Sclerosis as Neurodegenerative Marker? A 7-Tesla Magnetic Resonance Study.. 2021 , 12, 632749	1
563	A Three-Arm Parallel-Group Exploratory Trial documents balance improvement without much evidence of white matter integrity changes in people with multiple sclerosis following two months ambulatory neuroproprioceptive "facilitation and inhibition" physical therapy. 2021 ,	1
562	Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia.. 2021 , 18,	0
561	Human KIR CD8 T cells target pathogenic T cells in Celiac disease and are active in autoimmune diseases and COVID-19.. 2021 ,	0
560	Dynamic Functional Connectivity Better Predicts Disability Than Structural and Static Functional Connectivity in People With Multiple Sclerosis.. 2021 , 15, 763966	1
559	Early Diagnosis of Multiple Sclerosis Using Swept-Source Optical Coherence Tomography and Convolutional Neural Networks Trained with Data Augmentation.. 2021 , 22,	1
558	Role of lipoic acid in multiple sclerosis.. 2021 ,	3
557	Anatomical and functional visual network patterns in progressive multiple sclerosis.. 2021 ,	2
556	Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment.. 2021 , 12, 778204	0
555	Factors Associated with Depression and Anxiety Severity in Multiple Sclerosis Patients. 2021 , 1, 69-74	
554	Assessing Cognitive Function in Multiple Sclerosis With Digital Tools: Observational Study.. 2021 , 23, e25748	0
553	Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.. 2021 , 12,	1

- 552 The reliability and validity of the Turkish version of the apraxia screen of TULIA in multiple sclerosis patients.. **2021**, 1-6
- 551 Autonomic Nervous System Function in Newly Diagnosed Multiple Sclerosis: Association With Lipid Levels and Insulin Resistance. **2021**, 875-882
- 550 Targeted cognitive game training enhances cognitive performance in multiple sclerosis patients treated with interferon beta 1-a.. **2021**, 18, 175 1
- 549 Diffusely abnormal white matter converts to T2 lesion volume in the absence of MRI-detectable acute inflammation.. **2021**, 2
- 548 Whole gut virome analysis of 476 Japanese revealed a link between phage and autoimmune disease. **2021**, 3
- 547 Superoxide Dismutase-1 Intracellular Content in T Lymphocytes Associates with Increased Regulatory T Cell Level in Multiple Sclerosis Subjects Undergoing Immune-Modulating Treatment.. **2021**, 10, 1
- 546 The frequency and characteristics of multiple sclerosis misdiagnosis in Latin America: A referral center study in Buenos Aires, Argentina.. **2021**, 13524585211067521 2
- 545 Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability.. **2021**, 4
- 544 Patch individual filter layers in CNNs to harness the spatial homogeneity of neuroimaging data.. **2021**, 11, 24447 0
- 543 Afeto pseudobulbar e ideaõ suicida: hãrelaõ?. **2020**, 10, 6-15
- 542 Multiple Sclerosis Disease Diagnosis and Prognosis in 3D FLAIR MRI Using Deep Learning Network.
- 541 Coping Style Moderates the Effect of Pain on Depression Symptoms in Multiple Sclerosis.. **2022**,
- 540 Comparison of follicular T helper cells, monocytes, and T cells priming between newly diagnosed and rituximab-treated MS patients and healthy controls.. **2022**, 17, 315-323
- 539 Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?. **2022**, 13, 844873 0
- 538 Multiple sclerosis and its impact on dental care. **2022**, 9, 36-42
- 537 A more unstable resting-state functional network in cognitively declining multiple sclerosis. 0
- 536 Home treatment against fatigue in multiple sclerosis by a personalized, bilateral whole-body somatosensory cortex stimulation. **2022**, 103813 1
- 535 Periventricular magnetisation transfer abnormalities in early multiple sclerosis.. **2022**, 34, 103012

534 Intellectual Structure and Emerging Trends of White Matter Hyperintensity Studies: A Bibliometric Analysis From 2012 to 2021.. **2022**, 16, 866312

533 Sleep-Related Breathing Disorders in Multiple Sclerosis: Prevalence, Features and Associated Factors.. **2022**, 14, 741-750

o

532 Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis.. **2022**, 62, 103793

o

531 Rehabilitation of dementia. 509-534

530 Disease-modifying therapy for multiple sclerosis in clinical practice. 583-603

529 Data_Sheet_1.docx. **2018**,

528 Table_1.DOCX. **2019**,

527 Table_2.DOCX. **2019**,

526 Table_3.DOCX. **2019**,

525 Presentation_1.PDF. **2020**,

524 Table_1.DOCX. **2019**,

523 Table_2.DOCX. **2019**,

522 Table_3.DOCX. **2019**,

521 Data_Sheet_1.docx. **2020**,

520 Data_Sheet_1.xlsx. **2020**,

519 Data_Sheet_2.xlsx. **2020**,

518 Data_Sheet_3.xlsx. **2020**,

517 Data_Sheet_4.pdf. **2020**,

516 Image_1.JPEG. 2020,

515 Image_2.JPEG. 2020,

514 Image_1.tif. 2019,

513 Image_2.tif. 2019,

512 DataSheet_1.docx. 2020,

511 data_sheet_1.doc. 2018,

510 Data_Sheet_1.pdf. 2018,

509 Image_1.PDF. 2018,

508 Data_Sheet_1.PDF. 2018,

507 image_1.tif. 2018,

506 image_2.tif. 2018,

505 image_3.tif. 2018,

504 image_4.tif. 2018,

503 table_1.PDF. 2018,

502 Data_Sheet_1.docx. 2020,

501 Image_1.TIF. 2019,

500 Image_2.TIF. 2019,

499 Data_Sheet_1.docx. 2019,

498 data_sheet_1.PDF. **2018,**

497 data_sheet_2.PDF. **2018,**

496 data_sheet_3.PDF. **2018,**

495 table_1.PDF. **2018,**

494 Image_1.tif. **2020,**

493 Image_2.tif. **2020,**

492 Image_3.tif. **2020,**

491 Image_4.tif. **2020,**

490 Image_5.tif. **2020,**

489 Image_6.tiff. **2020,**

488 Presentation_1.pdf. **2020,**

487 Video_1.mp4. **2020,**

486 Presentation_1.pdf. **2020,**

485 Data_Sheet_1.docx. **2018,**

484 Data_Sheet_2.xlsx. **2018,**

483 Data_Sheet_3.xlsx. **2018,**

482 Data_Sheet_4.xlsx. **2018,**

481 Data_Sheet_5.xlsx. **2018,**

480 Data_Sheet_6.xlsx. 2018,

479 Data_Sheet_1.PDF. 2019,

478 Presentation_1.PDF. 2018,

477 Table_1.PDF. 2018,

476 Table_2.PDF. 2018,

475 Table_3.PDF. 2018,

474 image_1.PDF. 2018,

473 table_1.docx. 2018,

472 table_2.docx. 2018,

471 Data_Sheet_1.pdf. 2019,

470 presentation_1.PDF. 2018,

469 Data_Sheet_1.PDF. 2020,

468 Data_Sheet_1.docx. 2019,

467 Table_1.docx. 2019,

466 Table_1.XLSX. 2019,

465 Data_Sheet_1.XLSX. 2018,

464 Table_1.docx. 2021,

463 Table_1.DOCX. 2019,

462 Data_Sheet_1.doc. **2018,**

461 Presentation_1.PDF. **2018,**

460 Data_Sheet_1.docx. **2018,**

459 Data_Sheet_1.PDF. **2019,**

458 Data_Sheet_1.docx. **2018,**

457 Table_1.DOCX. **2018,**

456 Table_1.DOCX. **2018,**

455 Table_2.DOCX. **2018,**

454 Table_3.docx. **2018,**

453 Table_4.docx. **2018,**

452 Table_1.DOCX. **2020,**

451 DataSheet_1.xlsx. **2020,**

450 Image_1.pdf. **2020,**

449 Data_Sheet_1.docx. **2020,**

448 Image_1.pdf. **2018,**

447 Image_2.tif. **2018,**

446 Image_3.tif. **2018,**

445 Table_1.DOC. **2018,**

444 Data_Sheet_1.docx. **2020**,

443 Table_1.DOCX. **2019**,

442 Table_1.DOCX. **2020**,

441 Presentation_1.PDF. **2020**,

440 Data_Sheet_1.docx. **2020**,

439 Data_Sheet_1.PDF. **2019**,

438 Data_Sheet_1.PDF. **2020**,

437 Image_1.JPEG. **2019**,

436 Data_Sheet_1.docx. **2019**,

435 Table_1.DOCX. **2018**,

434 Table_2.DOCX. **2018**,

433 Table_3.DOCX. **2018**,

432 Table_4.DOCX. **2018**,

431 Data_Sheet_1.PDF. **2019**,

430 Data_Sheet_2.PDF. **2019**,

429 Table_1.DOCX. **2019**,

428 Table_1.DOCX. **2020**,

427 Data_Sheet_1.docx. **2019**,

426 Table_1.docx. **2020**,

425 Table_2.docx. **2020**,

424 Table_3.docx. **2020**,

423 Table_1.docx. **2018**,

422 Data_Sheet_1.docx. **2019**,

421 Table_1.docx. **2020**,

420 Natalizumab therapy in patients with pediatric-onset multiple sclerosis in Greece: clinical and immunological insights of time-long administration and future directions-a single-center retrospective observational study.. **2022**, 1 0

419 Slowing processing speed is associated with cognitive fatigue in newly diagnosed multiple sclerosis patients.. **2022**, 1-7 0

418 Relationship between subjective report and objective assessment of neurocognitive functioning in persons with multiple sclerosis.. **2022**, 1-8 0

417 The Association of EBV and HHV-6 Viral Load with Different NK and CD8 T Cell Subsets in The Acute Phase of Relapsing-Remitting Multiple Sclerosis.. **2021**, 23, 626-632

416 Silent stroke in patients with atrial fibrillation: Prevalence and predictive factors.. **2021**, 99, 416-422

415 Diffusion magnetic resonance imaging of normal-appearing white matter in multiple sclerosis: correlation with brain volume and clinical disability.. **2022**, 14, 11795735221098147

414 Oligoclonal bands: An immunological and clinical approach. **2022**,

413 Episodic Past, Future, and counterfactual thinking in Relapsing-Remitting Multiple sclerosis.. **2022**, 34, 103033 1

412 Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis.. **2022**, 15, 17562864211070449

411 Systematic Review and Meta-Analysis Comparing the Safety of Natalizumab, Ocrelizumab, and Alemtuzumab in Treating Relapsing-Remitting, Primary Progressive, and Secondary Progressive Multiple Sclerosis. **2022**, 13, 14-23

410 Single-cell and spatial RNA sequencing identify perturbators of microglial functions with aging. 1

409 Low Contrast Visual Evoked Potentials for Early Detection of Optic Neuritis.. **2022**, 13, 804395

- 408 A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHlgM22 in subjects with multiple sclerosis immediately following a relapse.. **2022**, 8, 20552173221091475
- 407 A translational MRI approach to validate acute axonal damage detection in multiple sclerosis.
- 406 Updates on Pediatric Demyelinating Disorders. **2022**, 231-259
- 405 Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator.. **2022**, 17, e0267504
- 404 Clinical Characteristics and Outcomes of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder With Brainstem Lesions as Heraldng Prodrome. **2022**, 13, 0
- 403 miR-150-5p and let-7b-5p in Blood Myeloid Extracellular Vesicles Track Cognitive Symptoms in Patients with Multiple Sclerosis.. **2022**, 11, 0
- 402 Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients.. **2022**, 0
- 401 A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.. **2022**, 1 0
- 400 Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping.. **2022**, 1 0
- 399 Validity and sensitivity of Canadian normative data for the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) battery.. **2022**, 63, 103865
- 398 Validity and Reliability of The 3-Meter Backward Walk Test in Patients with Multiple Sclerosis. **2022**, 103842 0
- 397 Third wave cognitive behavioural therapies for people with multiple sclerosis: a scoping review.. **2022**, 1-16 5
- 396 Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the Attikon Lupus Cohort. **2022**, 13, 1
- 395 Impact of the covid-19 pandemic on the psychological status and cortisol level of multiple sclerosis patients.. **2022**, 1-24
- 394 A group resilience training program for people with multiple sclerosis: Study protocol of a multi-centre cluster-randomized controlled trial (multi-READY for MS).. **2022**, 17, e0267245 2
- 393 Voxel-wise lesion mapping of restless legs syndrome in multiple sclerosis.. **2022**,
- 392 Multifocal Electroretinogram Photopic Negative Response: A Reliable Paradigm to Detect Localized Retinal Ganglion Cells Impairment in Retrobulbar Optic Neuritis Due to Multiple Sclerosis as a Model of Retinal Neurodegeneration. **2022**, 12, 1156 0
- 391 Reproducibility of Lesion Count in Various Subregions on MRI Scans in Multiple Sclerosis. **2022**, 13, 0

- 390 Effects of Disease-Modifying Treatments discontinuation in patients with Relapsing-Remitting Multiple Sclerosis: A 5 Year Prospective Cohort Study. **2022**, 103857 ○
- 389 Instrumented Assessment of Motor Performance Fatigability During the 6-Min Walk Test in Mildly Affected People With Multiple Sclerosis. **2022**, 13, 1
- 388 The prevalence of internuclear ophthalmoparesis in a population-based cohort of individuals with multiple sclerosis.. **2022**, 63, 103824 ○
- 387 Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot study.. **2022**, 63, 103846
- 386 Brain-derived neurotrophic factor and neurofilament light chain in cerebrospinal fluid are inversely correlated with cognition in Multiple Sclerosis at the time of diagnosis.. **2022**, 63, 103822 ○
- 385 Prognostic value of intrathecal IgM synthesis determined by various laboratory methods in patients with early multiple sclerosis - a prospective observational study.. **2022**, 63, 103847 ○
- 384 Skeletonized mean diffusivity and neuropsychological performance in relapsing-remitting multiple sclerosis.. **2022**, e2591
- 383 White matter disease: Imaging findings and differential diagnosis. 5-17
- 382 Rare co-occurrence of multiple sclerosis and Wilson's disease - case report.. **2022**, 22, 178
- 381 The analysis of dynamic gene expression patterns in peripheral blood of multiple sclerosis patients indicates possible diagnostic and prognostic biomarkers. **2022**, 147, 147-156 1
- 380 Ocrelizumab for multiple sclerosis.. **2022**, 5, CD013247 ○
- 379 Altered grey matter integrity and network vulnerability relate to epilepsy occurrence in patients with multiple sclerosis.. **2022**, ○
- 378 Confirmed disability progression as a marker of permanent disability in multiple sclerosis.. **2022**,
- 377 Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia.. **2022**, ○
- 376 Long-term trajectories of employment status, workhours and disability support pension status, after a first episode of CNS demyelination.. **2022**, 13524585221089900
- 375 Role of Chitinase 3-like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis.. **2022**, 9, 1
- 374 Choroidal Thickness in Multiple Sclerosis: An Optical Coherence Tomography Study.. **2022**, 18, 334-342 ○
- 373 Molecular biomarkers in multiple sclerosis. **2022**, 72, 127-148

- 372 Optical coherence tomography assessment of axonal and neuronal damage of the retina in patients with familial and sporadic multiple sclerosis.
- 371 Effects of Vascular Comorbidity on Cognition in Multiple Sclerosis Are Partially Mediated by Changes in Brain Structure. **2022**, 13, 1
- 370 Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis. **2022**, 103906
- 369 Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis. 135245852210942 1
- 368 Traitements de fond de la sclérose en plaques. État des lieux et perspectives. **2022**,
- 367 Quantitative susceptibility mapping of both ring and non-ring white matter lesions in relapsing remitting multiple sclerosis. **2022**, 91, 45-51
- 366 Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies. **2022**, 103927 1
- 365 Les formes atypiques de sclérose en plaques et formes frontales. **2022**,
- 364 Expression analysis of mTOR-associated lncRNAs in multiple sclerosis. 0
- 363 Predictive Value of the Third Ventricle Width for Neurological Status in Multiple Sclerosis. **2022**, 11, 2841
- 362 Cognitive assessment of Brazilian patients with multiple sclerosis: weighing the impact of disability and depressive symptoms.
- 361 Making Every Step Count: Minute-by-Minute Characterization of Step Counts Augments Remote Activity Monitoring in People With Multiple Sclerosis. 13, 0
- 360 Statistical methodology for highly variable compounds: A novel design approach for the Ofatumumab Phase 2 bioequivalence study. 0
- 359 Exploring Retinal Blood Vessel Diameters as Biomarkers in Multiple Sclerosis. **2022**, 11, 3109 1
- 358 The Reliability and Validity of the Turkish Version of the Dual-Task Questionnaire in Patients with Multiple Sclerosis. **2022**, 103942
- 357 Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression. 0
- 356 Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. 135245852210972
- 355 Incidencia y prevalencia de la esclerosis múltiple en España. Una revisión sistemática. **2022**,

- 354 Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis. **2022**, 63, 103891 ○
- 353 History and prospects of multiple sclerosis treatment. **2022**,
- 352 Myelitis and Myelopathies. **2022**, 419-430
- 351 Peripartum disease activity in moderately and severely disabled women with multiple sclerosis. **2022**, 8, 205521732211049
- 350 The 3-m backward walk test: reliability and validity in ambulant people with multiple sclerosis. Publish Ahead of Print, ○
- 349 Prefrontal-amygdala emotion regulation and depression in multiple sclerosis. **2022**, 4, ○
- 348 Diagnostic value of three-dimensional cube fluid attenuated inversion recovery imaging and its axial MIP reconstruction in multiple sclerosis. **2022**, 53,
- 347 Nonlesional Sources of Contrast Enhancement on Postgadolinium α -Black-Blood β T1-SPACE Images in Patients with Multiple Sclerosis. **2022**, 43, 872-880 ○
- 346 Neural distinctiveness of fatigue and low sleep quality in multiple sclerosis. ○
- 345 Blood-based untargeted metabolomics in relapsing-remitting multiple sclerosis revealed the testable therapeutic target. **2022**, 119, 4
- 344 Applying multilayer analysis to morphological, structural and functional brain networks to identify relevant dysfunction patterns. 1-42 ○
- 343 Role of Helical Structure in MBP Immunodominant Peptides for Efficient IgM Antibody Recognition in Multiple Sclerosis. 10,
- 342 Feasibility trial of a telehealth support group intervention to reduce anxiety in multiple sclerosis. 026921552211070
- 341 Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. 135245852210975 ○
- 340 Brain disconnectome mapping derived from white matter lesions and serum neurofilament light levels in multiple sclerosis: A longitudinal multicenter study. **2022**, 103099 ○
- 339 Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis. **2022**, 9, e200004 3
- 338 Does latent Toxoplasma infection have a protective effect against developing multiple sclerosis? Evidence from an updated meta-analysis. ○
- 337 Clinically relevant profiles of myelin content changes in patients with multiple sclerosis: A multimodal and multicompartiment imaging study. 135245852210969 ○

- 336 Magnetisation transfer, diffusion and g-ratio measures of demyelination and neurodegeneration in early relapsing-remitting multiple sclerosis: a longitudinal microstructural MRI study.
- 335 COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients. 0
- 334 Impact on quality of life in multiple sclerosis patients: Which urinary symptoms are to blame?. **2022**, 0
- 333 "Can I exercise? Would it help? Would it not?" exploring the experiences of people with relapsing remitting multiple sclerosis engaging with physical activity during a relapse: a qualitative study. 1-12 0
- 332 Evaluation of liver injury in multiple sclerosis patients receiving pulsed steroid therapy. **2022**, 103968 0
- 331 Altered functional brain states predict cognitive decline 5 years after a clinically isolated syndrome. 135245852211014
- 330 Spatial distribution of multiple sclerosis iron rim lesions and their impact on disability. **2022**, 64, 103967 1
- 329 The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a. **2022**, 28, 100409 2
- 328 Educational Case: Multiple sclerosis. **2022**, 9, 100036
- 327 Multiple Sclerosis Prevalence and Subtypes in a State-Wide Study of Rhode Island, USA.
- 326 A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?. 135245852211031 0
- 325 Early use of fingolimod is associated with better clinical outcomes in relapsing&emitting multiple sclerosis patients.
- 324 Diffusion-derived parameters in lesions, peri-lesion, and normal-appearing white matter in multiple sclerosis using tensor, kurtosis, and fixel-based analysis. 0271678X2211079
- 323 Real-world data on the effectiveness and safety of teriflunomide in patients with relapsing&emitting multiple sclerosis: The EFFECT study. **2022**,
- 322 Cerebral perfusion and its association with serum endothelin-1 in multiple sclerosis. **2022**, 9, 296-307
- 321 Two years&effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis. 135245852211040 0
- 320 FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis. **2022**, 12, e058506 0
- 319 Peripheral Hemolysis in Relation to Iron Rim Presence and Brain Volume in Multiple Sclerosis. 13, 2

- 318 OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany. 13, ○
- 317 Lesion size and shape in central vein sign assessment for multiple sclerosis diagnosis: An in vivo and postmortem MRI study. 135245852210975
- 316 Grey matter atrophy in patients with benign multiple sclerosis. ○
- 315 Analysis of the entire mitochondrial genome reveals Leber's hereditary optic neuropathy mitochondrial DNA mutations in an Arab cohort with multiple sclerosis. 2022, 12,
- 314 Logistic Regression-Based Model Is More Efficient Than U-Net Model for Reliable Whole Brain Magnetic Resonance Imaging Segmentation. 2022, 31, 31-39 ○
- 313 Avoidant Coping Is Associated with Quality of Life in Persons with Multiple Sclerosis with High Cognitive Reserve. ○
- 312 Quantitative proteomics reveals protein dysregulation during T cell activation in multiple sclerosis patients compared to healthy controls. 2022, 19, ○
- 311 Predictors of progression from first demyelinating event to clinically definite multiple sclerosis. ○
- 310 Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece. ○
- 309 Innate immune cells and myelin profile in multiple sclerosis: a multi-tracer PET/MR study.
- 308 The role of specialist nurses in detecting spasticity and related symptoms in multiple sclerosis.
- 307 Comparison of dimethyl fumarate and interferon outcomes in an MS cohort. 2022, 22,
- 306 Self-employment, sickness absence, and disability pension in multiple sclerosis.
- 305 NMOSD Diagnostic Dilemmas Leading towards Final Diagnosis. 2022, 12, 885 ○
- 304 Rationale for off-label treatments use in primary progressive multiple sclerosis: A review of the literature. 2022,
- 303 Assessing clinical utility of machine learning and artificial intelligence approaches to analyze speech recordings in multiple sclerosis: A pilot study. 2022, 105853 1
- 302 Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE) systematic review protocol. 2022, 11,
- 301 Comparison of Two Different Canine Anti-IgG Antibodies for Assessment of Oligoclonal Bands in Cerebrospinal Fluid and Serum of Dogs via Isoelectric Focusing Followed by an Immunoblot. 9,

- 300 Cyclograms Reveal Alteration of Inter-Joint Coordination during Gait in People with Multiple Sclerosis Minimally Disabled. **2022**, 2, 331-341 ○
- 299 The Diagnostic Challenges and Clinical and Serological Outcome in Patients Hospitalized for Suspected Lyme Neuroborreliosis. **2022**, 10, 1392 ○
- 298 Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. **2022**, 21, 693-703 ○
- 297 Impact of post-contrast MRI in the definition of active multiple sclerosis. **2022**, 440, 120338 ○
- 296 Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif®) using B cell receptor repertoire analysis. **2022**, 370, 577932
- 295 Effects of immersive virtual reality on upper limb function in subjects with multiple sclerosis: A cross-over study. **2022**, 65, 104004 ○
- 294 Oligoclonal bands, age 11-17 years, occipital lesion, and female sex differentiate pediatric multiple sclerosis from acute disseminated encephalomyelitis: A nationwide cohort study. **2022**, 66, 104008
- 293 Progressive Weakness, Cognitive Dysfunction and Seizures. **2016**, 45, 330-331 ○
- 292 The effect of nurse practitioner (NP-led) care on health-related quality of life in people with multiple sclerosis: a randomized trial. **2022**, 22, ○
- 291 Impact of Multiple Sclerosis Risk Polymorphism rs7665090 on MANBA Activity, Lysosomal Endocytosis, and Lymphocyte Activation. **2022**, 23, 8116
- 290 Unraveling the Influence of HHEX Risk Polymorphism rs7923837 on Multiple Sclerosis Pathogenesis. **2022**, 23, 7956
- 289 Alzheimer's Disease Risk Variant rs3865444 in the CD33 Gene: A Possible Role in Susceptibility to Multiple Sclerosis. **2022**, 12, 1094
- 288 Clinical and diagnostic spectrum of optic neuritis: A single-center retrospective study of disorders associated with multiple sclerosis, anti-aquaporin-4 and anti-myelin oligodendrocyte glycoprotein antibodies. **2022**, 221, 107381
- 287 Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study. **2022**, 8, 205521732211150
- 286 The relationship between cognition, education, and employment in multiple sclerosis patients. **2022**, 8, 205521732211183
- 285 Overall and patient-level comparative effectiveness of dimethyl fumarate and fingolimod: A precision medicine application to the Observatoire Français de la Sclérose en Plaques registry. **2022**, 8, 205521732211165
- 284 Mechanisms of central brain atrophy in multiple sclerosis. 135245852211116
- 283 Domestic violence experienced by women with multiple sclerosis: a study from the North-East of Iran. **2022**, 22,

- 282 An Update on the Epidemiology of Uveitis in an Urban Setting in Northern Madrid, Spain. 1-6
- 281 Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions. 135245852211105
- 280 Quality of Life and Cognitive Emotion Regulation Strategies in Multiple Sclerosis Patients.
- 279 Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis. 135245852211147 3
- 278 Evaluation of physical and biomechanical changes of common carotid artery and internal jugular vein in patients with multiple sclerosis.
- 277 Transcriptional Response of Blood Mononuclear Cells from Patients with Inflammatory and Autoimmune Disorders Exposed to Krakow Smog 2022, 11, 2586
- 276 Relation between retina, cognition and brain volumes in MS: a consequence of asymptomatic optic nerve lesions.
- 275 Practice effects in performance outcome measures in patients living with neurologic disorders a systematic review. 2022, e10259 0
- 274 Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. 2022, 387, 704-714 1
- 273 The comorbidity and cognition in multiple sclerosis (CCOMS) neuroimaging protocol: Study rationale, MRI acquisition, and minimal image processing pipelines. 1,
- 272 Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis. 13, 0
- 271 Fragmentation, circadian amplitude, and fractal pattern of daily-living physical activity in people with multiple sclerosis: is there relevant information beyond the total amount of physical activity?. 2022, 104108
- 270 Variant rs4149584 (R92Q) of the TNFRSF1A gene in patients with familial multiple sclerosis. 2022, 0
- 269 Advanced diffusion MRI and image texture analysis detect widespread brain structural differences between relapsing-remitting and secondary progressive multiple sclerosis. 16,
- 268 Routine clinical measurements effective for the evaluation of the impact of multiple sclerosis on vision-related quality of life early in the disease course?.
- 267 Comparing evolvement of visual field defect in neuromyelitis optica spectrum disorder-optic neuritis and idiopathic optic neuritis: a prospective study. 2022, 22,
- 266 Diagnosis of Multiple Sclerosis. 2022, 28, 1006-1024
- 265 Peripheral Myeloid-Derived Suppressor Cells are good biomarkers of the efficacy of Fingolimod in Multiple Sclerosis.

- 264 Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis. **2022**,
- 263 Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis.
- 262 Expression of T cell-related lncRNAs in multiple sclerosis. 13, 0
- 261 Resting state functional connectivity in relapsing remitting multiple sclerosis with mild disability â data driven, whole brain multi-voxel pattern analysis study.
- 260 Neurosyphilis presenting as autoimmune limbic encephalitis: A case report and literature review. **2022**, 101, e30062 1
- 259 The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica. **2022**, 21, 103170
- 258 Menopausal symptoms and hormone therapy in women with multiple sclerosis: A baseline-controlled study. **2022**, 67, 104098
- 257 The figure-of-eight walk test is a reliable and valid test for assessing walking skill in people with multiple sclerosis. **2022**, 67, 104099
- 256 The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades. **2022**, 68, 104103 1
- 255 Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis. **2022**, 68, 104138
- 254 MRI pattern in acute optic neuritis: Comparing multiple sclerosis, NMO and MOGAD. 197140092211243 0
- 253 Validity and reliability characteristics of the Silhouettes Fatigue Scale in measuring multiple sclerosis-related fatigue in Turkish-speaking adults. 0
- 252 Improvement in the multiple sclerosis functional composite score by multi-function swing suspension training program. **2022**, 67, 104174 0
- 251 Symbol digit modalities test predicts decline of off-road driving ability in Japanese patients with multiple sclerosis. **2022**, 68, 104150 0
- 250 Cut-off evaluation of intrathecal oligoclonal bands of IgM in relapsing-remitting multiple sclerosis; a retrospective study. **2022**, 68, 104188 0
- 249 Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis. **2022**, 68, 104167 2
- 248 The sequential natalizumab â alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial â Part I: Rationale and objectives. **2022**, 14, 117957352211239 0
- 247 Amino Acid Levels as Potential Biomarkers of Multiple Sclerosis in Elderly Patients: Preliminary Report. **2022**, 18, 529 0

246 Work difficulties in people with multiple sclerosis: The role of anxiety, depression and coping. **2022**, 8, 205521732211162 ○

245 Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool. **2022**, 8, 205521732211240 ○

244 Brain volume loss and physical and cognitive impairment in naive multiple sclerosis patients treated with fingolimod: prospective cohort study in Buenos Aires, Argentina. **2022**, 80, 699-705 ○

243 The use of functional near infrared spectroscopy and gait analysis to characterize cognitive and motor processing in early-stage patients with multiple sclerosis. 13, ○

242 Multiple sclerosis. **2022**, 81, 173-183 ○

241 RNA-sequencing and mass-spectrometry proteomic time-series analysis of T-cell differentiation identified multiple splice variants models that predicted validated protein biomarkers in inflammatory diseases. 9, ○

240 Towards Effective Telerehabilitation: Assessing Effects of Applying Augmented Reality in Remote Rehabilitation of Patients Suffering from Multiple Sclerosis. 1

239 Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis. **2022**, 23, 9769 1

238 Validation of the French version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire 15 Tools which help nurse for assessing the effect of perceived multiple sclerosis symptoms on sexual activity and satisfaction. ○

237 A Scoping Review on Body Fluid Biomarkers for Prognosis and Disease Activity in Patients with Multiple Sclerosis. **2022**, 12, 1430 ○

236 Evaluation of CSF kappa free light chains for the diagnosis of multiple sclerosis (MS): a comparison with oligoclonal bands (OCB) detection via isoelectric focusing (IEF) coupled with immunoblotting. [jclinpath-2022-20835](#) ○

235 Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study. **2022**, 36, 977-993 ○

234 Efecto de un programa de rehabilitaci3n neuropsicol3gica de funciones ejecutivas en un caso de esclerosis mltiple. **2022**, 15, 97-114 ○

233 Polymorphisms in ARNTL/BMAL1 and CLOCK Are Not Associated with Multiple Sclerosis in Spanish Population. **2022**, 11, 1417 ○

232 An algorithm to determine the date when the McDonald criteria are met for the diagnosis of relapsing-remitting multiple sclerosis. **2022**, ○

231 miR-181a-5p is a potential candidate epigenetic biomarker in Multiple Sclerosis. ○

230 Torso based balance weighting versus tailored physical therapy program in postural control in patients with multiple sclerosis. **2022**, 22, 142-147 ○

229 EVIDENCE FOR NOVEL CELL DEFENCE MECHANISMS SUSTAINED BY DIMETHYL FUMARATE IN MULTIPLE SCLEROSIS PATIENTS: THE HuR/SOD2 CASCADE. **2022**, 104197 ○

- 228 Association of cerebrospinal inflammatory profile with radiological features in newly diagnosed treatment-naïve patients with multiple sclerosis. 13, ○
- 227 Sleep in multiple sclerosis: a systematic review and meta-analysis of polysomnographic findings. ○
- 226 Case report: IgG4-related intracranial lesions mimicking multiple sclerosis in a 14-year-old girl. 13, ○
- 225 Effects of anti-inflammatory-antioxidant-rich diet and co-supplemented synbiotics intervention in patients with progressive forms of multiple sclerosis: a single-center, single-blind randomized clinical trial. 1-12 ○
- 224 Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study. **2022**, 11, 5226 ○
- 223 Evaluation of Disability Progression in Multiple Sclerosis via Magnetic-Resonance-Based Deep Learning Techniques. **2022**, 23, 10651 ○
- 222 Optical coherence tomography assessment of axonal and neuronal damage of the retina in patients with familial and sporadic multiple sclerosis. 13, ○
- 221 Does Gadolinium Deposition Lead to Metabolite Alteration in the Dentate Nucleus? An MRS Study in Patients with MS. **2022**, 43, 1403-1410 ○
- 220 Sensorimotor network dynamics predict decline in upper and lower limb function in people with multiple sclerosis. 135245852211253 ○
- 219 Characteristics of Optic Neuritis in South Korean Children and Adolescents: A Retrospective Multicenter Study. **2022**, 2022, 1-8 ○
- 218 Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study. 13, ○
- 217 Lesion-Specific Metabolic Alterations in Relapsing-Remitting Multiple Sclerosis Via 7 T Magnetic Resonance Spectroscopic Imaging. Publish Ahead of Print, ○
- 216 Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice. ○
- 215 Tekrarlayan ve dđzelen multipl sklerozda mizađve karakter: klinik faktđler ve psikiyatrik bozukluklarla iliđisi. **2022**, 47, 1339-1349 ○
- 214 Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis. **2022**, 17, e0274565 ○
- 213 CLMP Promotes Leukocyte Migration Across Brain Barriers in Multiple Sclerosis. **2022**, 9, e200022 1
- 212 Choroid plexus volume in multiple sclerosis predicts expansion of chronic lesions and brain atrophy. **2022**, 9, 1528-1537 1
- 211 An exposure-response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis. ○

- 210 Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry. *jnp-2022-329713*
- 209 MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls.
- 208 Dramatic changes in multiple sclerosis incidence in Iran may be related to the "Will Rogers phenomenon" **2022**, 104217
- 207 A new look at cognitive functioning in pediatric MS. 135245852211239
- 206 What are the trends in the treatment of multiple sclerosis in recent studies? A bibliometric analysis with global productivity during 1980-2021. **2022**, 68, 104185
- 205 Longitudinal microstructural MRI markers of demyelination and neurodegeneration in early relapsing-remitting multiple sclerosis: Magnetisation transfer, water diffusion and g-ratio. **2022**, 36, 103228
- 204 Sleep disorders in multiple sclerosis: a case-control study using the S3 Paulo Epidemiologic sleep study (Episono) database. **2022**, 80, 822-830
- 203 Structure-function correlates of vision loss in neuromyelitis optica spectrum disorders. **2022**, 12,
- 202 Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome. **2023**, 10, e200044
- 201 The Use of Kappa Free Light Chains to Diagnose Multiple Sclerosis. **2022**, 58, 1512
- 200 Body Composition in Multiple Sclerosis Patients and Its Relationship to the Disability Level, Disease Duration and Glucocorticoid Therapy. **2022**, 14, 4249
- 199 Investigating the role of common and rare variants in multiplex multiple sclerosis families reveals an increased burden of common risk variation. **2022**, 12,
- 198 Patient's perspective in clinical practice to assess and predict disability in multiple sclerosis. **2022**, 12,
- 197 Correlation between the Neutrophil-to-Lymphocyte Ratio and Multiple Sclerosis: Recent Understanding and Potential Application Perspectives. **2022**, 2022, 1-10
- 196 Topological reorganization of brain network might contribute to the resilience of cognitive functioning in mildly disabled relapsing remitting multiple sclerosis.
- 195 Clinical correlates of R1 relaxometry and magnetic susceptibility changes in multiple sclerosis: a multi-parameter quantitative MRI study of brain iron and myelin.
- 194 Quantifying lower extremity inter-segmental coordination variability during walking in people with multiple sclerosis with high and low fear of falling. **2022**, 104258
- 193 Trends in the environmental risks associated with earlier onset in multiple sclerosis. **2022**, 104250

- 192 Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. jnnp-2022-330104 ○
- 191 Tau seeding in cases of multiple sclerosis. **2022**, 10, ○
- 190 Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis. **2022**, 9, e200030 ○
- 189 Trans-Synaptic Degeneration Following Acute Optic Neuritis in Multiple Sclerosis. ○
- 188 Genetic Markers for Thrombophilia and Cardiovascular Disease Associated with Multiple Sclerosis. **2022**, 10, 2665 ○
- 187 The Interpretation of Mirror Pattern Bands During Oligoclonal Immunoglobulin Isoelectric Focusing Electrophoresis: A Retrospective Study. ○
- 186 Kessler Foundation Strategy-Based Training to Enhance Memory (KF-STEMâ) Study protocol for a single site double-blind randomized, clinical trial in Multiple Sclerosis. **2022**, 101026 ○
- 185 The Effectiveness of anodal tDCS and cognitive training on cognitive functions in Multiple Sclerosis; A randomized, double-blind, parallel-group study. **2022**, 104392 ○
- 184 Contemporary study of multiple sclerosis disability in South East Wales. jnnp-2022-330013 ○
- 183 Can fatigue predict the worsening of multiple sclerosis one year later? An explorative study with participants referred to assess their ability to work. **2022**, 104393 ○
- 182 Early spinal cord pseudoatrophy in interferon-beta treated multiple sclerosis. ○
- 181 Subjective Report, Objective Neurocognitive Performance, and âInvisible Symptomsâ in Multiple Sclerosis. ○
- 180 OCT and VEP correlate to disability in secondary progressive multiple sclerosis. **2022**, 68, 104255 ○
- 179 Serum 3-phenyllactic acid level is reduced in benign multiple sclerosis and is associated with effector B cell ratios. **2022**, 68, 104239 ○
- 178 Restless legs syndrome in multiple sclerosis is related to retinal thinning. **2022**, 40, 103169 ○
- 177 Exploring (peri-) lesional and structural connectivity tissue damage through T1/T2-weighted ratio in iron rim multiple sclerosis lesions. **2023**, 95, 12-18 ○
- 176 Tracking the impact of multiple sclerosis on employment status: the development of a questionnaire. **2022**, 80, 929-934 ○
- 175 Changes in Brain Volumes Are Relevant during Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: Lessons from a Case Report. **2022**, 23, 13642 ○

- 174 Optical coherence tomography as a prognostic tool for disability progression in MS: a systematic review. ○
- 173 Spatiotemporal gait changes in people with multiple sclerosis with different disease progression subtypes. **2022**, 105818 ○
- 172 Choroid plexus enlargement in paediatric multiple sclerosis: clinical relevance and effect of sex. *jnp-2022-330343*
- 171 Additive interaction between dietary inflammatory index and some key risk factors of multiple sclerosis: a population-based incident case-control study. 1-8 ○
- 170 The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series. **2022**, 9, 1698 ○
- 169 Machine learning-optimized Combinatorial MRI scale (COMRISv2) correlates highly with cognitive and physical disability scales in Multiple Sclerosis patients. 2, ○
- 168 From kitchen to clinic: Pharmacotherapeutic potential of common spices in Indian cooking in age-related neurological disorders. 13, ○
- 167 Analysis of herpesvirus infection and genome single nucleotide polymorphism risk factors in multiple sclerosis, Volga federal district, Russia. 13, ○
- 166 The relation between the symbol digit modalities test, fatigue, depression, and anxiety symptoms in a Belgian MS cohort. ○
- 165 Gait quality and function after Fampridine treatment in patients with multiple sclerosis - A prospective cohort study. **2022**, 105826 ○
- 164 Nontraumatic Spinal Cord Injury: Epidemiology, Etiology and Management. **2022**, 12, 1872 ○
- 163 Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study. **2022**, 4, e000334 ○
- 162 Multistage classification identifies altered cortical phase- and amplitude-coupling in Multiple Sclerosis. **2022**, 119752 ○
- 161 Negative and positive personification of multiple sclerosis: Role in psychological adaptation. **2022**, 111078 ○
- 160 Chasing Shadows: Cytologically detected Shadow Cells in the Cerebrospinal Fluid of Patients with Multiple Sclerosis. **2022**, 104420 ○
- 159 HLA-DRB1*1501 influences long-term disability progression and tissue damage on MRI in relapse-onset multiple sclerosis. 135245852211309 1
- 158 Multimodal-neuroimaging machine-learning analysis of motor disability in multiple sclerosis. ○
- 157 Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. ○

- 156 Comparing pre- and post-diagnosis presentations of multiple sclerosis and other inflammatory diseases in primary care: an agnostic study of French and British health records.. ○
- 155 Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis. **2022**, 19, ○
- 154 Age-related blood transcriptional regulators affect disease progression in pediatric multiple sclerosis. **2023**, 176, 105953 ○
- 153 Pharmacotherapeutic potential of walnut (*Juglans* spp.) in age-related neurological disorders. **2023**, 14, 1-20 ○
- 152 Esclerosis múltiple en pacientes pediátricos: fisiopatología, diagnóstico y manejo. **2011**, 14, 167-179 ○
- 151 A case of multiple sclerosis with a tumefactive lesion during long-term treatment with fingolimod, leading to decompressive craniotomy. **2022**, ○
- 150 Incidence and prevalence of multiple sclerosis in Spain: a systematic review. **2022**, ○
- 149 Microstates in multiple sclerosis: an electrophysiological signature of altered large-scale networks functioning?. ○
- 148 The economic impact of comorbidity in multiple sclerosis. ○
- 147 External validation of a clinical prediction model in multiple sclerosis. 135245852211360 ○
- 146 Single-Cell Transcriptomics Identifies Brain Endothelium Inflammatory Networks in Experimental Autoimmune Encephalomyelitis. **2023**, 10, e200046 ○
- 145 MULTİPL SKLEROZDA KOGNİTİF ETKİLENMENİN DEĞERLENDİRİLMESİ ○
- 144 Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial. **2022**, 4, ○
- 143 Relevance and Impact of Social Support on Quality of Life for Persons With Multiple Sclerosis. **2022**, ○
- 142 Similar neural pathways link psychological stress and brain health in health and multiple sclerosis. ○
- 141 Balance Impairments in People with Early-Stage Multiple Sclerosis: Boosting the Integration of Instrumented Assessment in Clinical Practice. **2022**, 22, 9558 ○
- 140 Is There Reduced Hemodynamic Brain Activation in Multiple Sclerosis Even with Undisturbed Cognition?. **2023**, 24, 112 ○
- 139 Machine learning for exploring neurophysiological functionality in multiple sclerosis based on trigeminal and hand blink reflexes. **2022**, 12, ○

- 138 A novel eye-movement impairment in multiple sclerosis indicating wide-spread cortical damage.
- 137 Exonic variants of the P2RX7 gene in familial multiple sclerosis. **2022**,
- 136 Emotional Recognition and Its Relation to Cognition, Mood and Fatigue in Relapsing&Remitting and Secondary Progressive Multiple Sclerosis. **2022**, 19, 16408
- 135 Mitochondrial DNA haplogroup analysis in Saudi Arab patients with multiple sclerosis. **2022**, 17, e0279237
- 134 Leistungsffigkeit der McDonald-Kriterien von 2017.
- 133 Evaluation of the determinants of cognitive dysfunction in patients with multiple sclerosis. **2022**, 29,
- 132 Clinical Neuroimaging in Pediatric Dysimmune Disorders of the Central Nervous System. **2022**,
- 131 Preliminary validity of the Draw a Shape Test for upper extremity assessment in multiple sclerosis.
- 130 Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference. 10.1212/WNL.0000000000206774
- 129 Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis. 135245852211342
- 128 Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis.
- 127 More than the sum of its parts: disrupted core-periphery of multiplex networks in multiple sclerosis.
- 126 A case for including optic nerve lesions in the McDonald criteria.
- 125 A Whole-Genome Sequencing Study Implicates GRAMD1B in Multiple Sclerosis Susceptibility. **2022**, 13, 2392
- 124 Motor, cognitive, and combined rehabilitation approaches on MS patientsâ cognitive impairment.
- 123 The importance of acknowledging cognitive representations among children and young people with a chronic illness: An illustration from paediatric multiple sclerosis. **2018**, 27, 12-16
- 122 Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis.
- 121 Glcopeptides derived from myelin-relevant proteins and hyperglucosylated nontypeable Haemophilus influenzae bacterial adhesin cross-react with multiple sclerosis specific antibodies: A step forward in the identification of native autoantigens in multiple sclerosis.

120	Identification of astrocyte regulators by nucleic acid cytometry.	2
119	Early Predictors of Disability and Cognition in Multiple Sclerosis Patients: A Long-Term Retrospective Analysis. 2023 , 12, 685	○
118	MRI detection of brain gadolinium retention in multiple sclerosis: Magnetization transfer vs. T1-weighted imaging.	○
117	Dimethyl Fumarate Treatment Reduces the Amount but Not the Avidity of the Epstein-Barr Virus Capsid-Antigen-Specific Antibody Response in Multiple Sclerosis: A Pilot Study. 2023 , 24, 1500	○
116	Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: A prospective analysis. 2023 , 9, 205521732211511	○
115	Association between exposure to combustion-related air pollution and multiple sclerosis risk.	○
114	Bladder training and Kegel exercises on urinary symptoms in female patients with multiple sclerosis.	○
113	Predicting disease severity in Multiple Sclerosis using multimodal data and machine learning.	○
112	Clinical-Radiological Mismatch in Multiple Sclerosis Patients during Acute Relapse: Discrepancy between Clinical Symptoms and Active, Topographically Fitting MRI Lesions. 2023 , 12, 739	○
111	Determining the Prognostic Characteristics of People with Multiple Sclerosis with Bowel and Bladder Dysfunction as the Initial Presentation: A Cohort Study. 2023 , 2, 62-67	○
110	Cerebrospinal fluid proteomics indicates immune dysregulation and neuronal dysfunction in antibody associated autoimmune encephalitis. 2023 , 135, 102985	○
109	Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study. 2023 , 70, 104518	○
108	Assessment of intelligence quotient in patients with neuromyelitis optica spectrum disease and multiple sclerosis. 2023 , 70, 104492	○
107	Multiple sclerosis-related heat sensitivity linked to absence of DMT prescription and subjective hand impairment but not autonomic or corticospinal dysfunction. 2023 , 70, 104514	○
106	Neuro rehabilitation effectiveness based on virtual reality and tele rehabilitation in people with multiple sclerosis in Argentina: Reavitelem study. 2023 , 70, 104499	○
105	Chinese herbal medicine for people with multiple sclerosis: Protocol for a systematic review and meta-analysis. 2023 , 58, 102220	○
104	Neural stress processing, glucocorticoid functioning, and body mass in lean to obese persons with multiple sclerosis.	○
103	Integrating Rehabiliomics into the Multi-Omics Approach in the Management of Multiple Sclerosis: The Way for Precision Medicine?. 2023 , 14, 63	○

- 102 Mood symptoms and chronic fatigue syndrome due to relapsing remitting multiple sclerosis are associated with immune activation and aberrations in the erythron. ○
- 101 Functional alteration due to structural damage is network dependent: insight from multiple sclerosis. ○
- 100 Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis. 135245852211437 ○
- 99 FittsâTapping Task as a New Test for Cognition and Manual Dexterity in Multiple Sclerosis: Validation Study. **2023**, 59, 29 ○
- 98 Correlation between disability status and serum IL-2 and IFN-  levels and other parameters in iraqi multiple sclerosis patients. **2023**, ○
- 97 What is a clinically isolated syndrome in the 21st century?. 135245852211498 ○
- 96 Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis. ○
- 95 Insufficient sleep during adolescence and risk of multiple sclerosis: results from a Swedish case-control study. jnnp-2022-330123 ○
- 94 Corneal axonal loss as an imaging biomarker of neurodegeneration in multiple sclerosis: a longitudinal study. **2023**, 16, 175628642211187 ○
- 93 Association between improved metabolic risk factors and perceived fatigue during dietary intervention trial in relapsing-remitting multiple sclerosis: A secondary analysis of the WAVES trial. 13, ○
- 92 The spectral slope as a marker of excitation/inhibition ratio and cognitive functioning in multiple sclerosis. ○
- 91 Lesion network localization of depression in multiple sclerosis. **2023**, 1, 36-44 ○
- 90 Concurrent multi-session anodal trans-cranial direct current stimulation enhances pelvic floor muscle training effectiveness for female patients with multiple sclerosis suffering from urinary incontinence and pelvic floor dysfunction: a randomized clinical trial study. ○
- 89 Retinal layer thickness predicts disability accumulation in early relapsing multiple sclerosis. ○
- 88 An Updated Evaluation of Intrathecal IgG Synthesis Markers in Relation to Oligoclonal Bands. **2023**, 13, 389 ○
- 87 Analysis of the effect of cortisone on the QT interval. **2023**, 78, 44-48 ○
- 86 Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs. **2023**, 3, 6-13 ○
- 85 Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study. **2022**, 5, ○

- 84 In vivo characterization of microglia and myelin relation in multiple sclerosis by combined 11C-PBR28 PET and synthetic MRI. ○
- 83 Cognitive rehabilitation and mindfulness reduce cognitive complaints in multiple sclerosis (REMIND-MS): A randomized controlled trial. **2023**, 71, 104529 ○
- 82 Evaluation of transorbital sonography measures of optic nerve diameter in the context of global and regional brain volume in multiple sclerosis. **2023**, 13, ○
- 81 In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab. **2023**, 72, 104616 ○
- 80 The Value of Various Post-Processing Modalities of Diffusion Weighted Imaging in the Detection of Multiple Sclerosis. **2023**, 13, 622 ○
- 79 A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience. **2023**, 74, 104712 ○
- 78 Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study. **2023**, 74, 104711 ○
- 77 Abnormal expression of MAPK14-related lncRNAs in the peripheral blood of patients with multiple sclerosis. **2023**, 8, 335-339 ○
- 76 NUTRISEP: Assessment of the nutritional status of patients with multiple sclerosis and link to fatigue. **2023**, 179, 282-288 ○
- 75 Efficacy of ultraviolet B radiation versus vitamin D3 on postural control and cognitive functions in relapsing-remitting multiple sclerosis: A randomized controlled study. **2023**, ○
- 74 Remyelinating activities of Carvedilol or alpha lipoic acid in the Cuprizone-Induced rat model of demyelination. **2023**, 118, 110125 ○
- 73 The Vaccines Induced Autoimmunity. **2022**, 19-55 ○
- 72 Pregnancy planning and management for women with multiple sclerosis: what has changed over the last 15 years? An Italian single-center experience. **2023**, 70, 104526 ○
- 71 Multiple Sclerosis: Where Do We Go From Here?. 84-95 ○
- 70 Observed associations between indicators of socioeconomic status and risk of multiple sclerosis in Sweden are explained by a few lifestyle-related factors. **2023**, 30, 1001-1013 ○
- 69 A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients. ○
- 68 The effect of Transcutaneous Electrical Nerve Stimulation (TENS) and Interferential Currents (IFC) on pain, functional capacity, and quality of life in patients with multiple sclerosis: A randomized controlled, single-blinded study.. **2023**, 71, 104541 ○
- 67 Gene-Environment interactions increase the risk of paediatric-onset multiple sclerosis associated with household chemical exposures. jnp-2022-330713 ○

- 66 Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis. **2023**, 24, 2720 ○
- 65 Analysis of Humoral and Cellular Immunity after SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Immunomodulatory Drugs. ○
- 64 S1PR1 modulators in multiple sclerosis: Efficacy, safety, comparison, and chemical structure insights. **2023**, 250, 115182 ○
- 63 Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison. **2023**, 71, 104551 ○
- 62 Retinal Blood Vessel Analysis Using Optical Coherence Tomography (OCT) in Multiple Sclerosis. **2023**, 13, 596 ○
- 61 Saliva and Serum Acetylcholinesterase Activity in Multiple Sclerosis. **2023**, 60, 2884-2888 ○
- 60 Multicenter Evaluation of AI-generated DIR and PSIR for Cortical and Juxtacortical Multiple Sclerosis Lesion Detection. **2023**, 307, ○
- 59 Microchimerism in multiple sclerosis: The association between sex of offspring and MRI features in women with multiple sclerosis. 17, ○
- 58 Study for the validation of the FeetMe[®] integrated sensor insole system compared to GAITRite[®] system to assess gait characteristics in patients with multiple sclerosis. **2023**, 18, e0272596 ○
- 57 Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study. **2023**, 9, 205521732211442 ○
- 56 Long-term clinical, imaging and cognitive outcomes association with MS immunopathology. **2023**, 10, 339-352 ○
- 55 Ceramide is implicated in humoral peripheral and intrathecal autoimmune response in MS patients. **2023**, 71, 104565 ○
- 54 Predictive factors of multiple sclerosis relapse after the first demyelinating event: A 5-year follow-up. **2023**, 71, 104566 ○
- 53 High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. **2023**, 30, 1389-1399 ○
- 52 Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study. **2023**, 37, 275-289 ○
- 51 Mood symptoms and chronic fatigue syndrome due to relapsing remitting multiple sclerosis are associated with immune activation and aberrations in the erythron.. ○
- 50 Neuropsychiatric Status of Patients With Multiple Sclerosis Across Disease Duration Intervals. ○
- 49 The interplay between T helper cells and brain barriers in the pathogenesis of multiple sclerosis. 17, ○

- 48 Cerebrospinal fluid-related tissue damage in multiple sclerosis patients with iron rim lesions. 135245852311556
- 47 Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis. 135245852311514
- 46 Genetic regulation of IL-8 influences disease presentation of multiple sclerosis. 135245852311550
- 45 Gut microbiome composition is associated with long-term disability worsening in multiple sclerosis. **2023**, 15,
- 44 A Case of Anti-GAD 65 Autoimmune Encephalitis Associated with Focal Segmental Stiff-Person Syndrome. **2023**, 13, 369
- 43 Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis. **2023**, 10, e200091
- 42 Distinct Neuropsychological Correlates of Apathy Sub-Domains in Multiple Sclerosis. **2023**, 13, 385
- 41 Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence. **2023**, 12, 1768
- 40 A decade of fingolimod in multiple sclerosis: Insights from a large real-world cohort study. **2023**,
- 39 Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience. **2023**, 72, 104582
- 38 A 10-Year Single-Center Study of the Clinical Characteristics of Optic Neuritis-Related NMOSD, MS, and Double Seronegative Optic Neuritis, Together with Factors Predicting Visual Outcomes. **2023**, 7, 16
- 37 The radiologically isolated syndrome: revised diagnostic criteria.
- 36 MAGI2-AS3 and miR-374b-5p as Putative Regulators of Multiple Sclerosis via Modulating the PTEN/AKT/IRF-3/IFN- β Axis: New Clinical Insights. **2023**, 14, 1107-1118
- 35 Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis.
- 34 Changes in Retinal Thickness and Brain Volume during 6.8-Year Escalating Therapy for Multiple Sclerosis. **2023**, 2023, 1-8
- 33 Detecting Structural changes in the retina of neurodegenerative patients through OCT supervised segmentation.
- 32 Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study. 14,
- 31 Longitudinal Optical Coherence Tomography Measurement of Retinal Ganglion Cell and Nerve Fiber Layer to Assess Benign Course in Multiple Sclerosis. **2023**, 12, 2240

- 30 A Preclinical Investigation on the Role of IgG Antibodies against Coagulant Components in Multiple Sclerosis. **2023**, 11, 906 ○
- 29 Inflammatory Activity After Diverse Fertility Treatments. **2023**, 10, e200106 ○
- 28 HLA-DRB1 polymorphism and risk of pediatric-onset and adult-onset multiple sclerosis: a case-control study. **2023**, 28, 33-40 ○
- 27 A virtual reality program to assess cognitive function in multiple sclerosis: A pilot study. 17, ○
- 26 Validation of Persian Multiple Sclerosis quality of life-29 (P-MSQOL-29) questionnaire. ○
- 25 Potential Protective Role of Pregnancy and Breastfeeding in Delaying Onset Symptoms Related to Multiple Sclerosis. **2023**, 59, 619 ○
- 24 Performance of McDonald 2017 multiple sclerosis diagnostic criteria and evaluation of genetic ancestry in patients with a first demyelinating event in Argentina. 135245852311572 ○
- 23 Multiple Sclerosis and Other Idiopathic Inflammatory-Demyelinating Diseases. **2013**, 909-943 ○
- 22 Multiple Sclerosis Disease Evolution Assessment in Brain MRI Lesions Based on Texture and Multi-Scale Amplitude Modulation-Frequency Modulation (AM-FM) Features. **2023**, 11, 29918-29933 ○
- 21 First-in-human clinical trial of the NKT cell-stimulatory glycolipid OCH in multiple sclerosis. **2023**, 16, 175628642311621 ○
- 20 Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment. ○
- 19 Comparison of OX40 expression in patients with multiple sclerosis and neuromyelitis optica as an approach to diagnosis. **2023**, 19, ○
- 18 Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) Add-On Therapy to a Standard Treatment in Individuals with Multiple Sclerosis and Concomitant Symptoms of Depression—Results from a Randomized Clinical Trial and Pilot Study. **2023**, 12, 2525 ○
- 17 Metabolic Insights into Iron Deposition in Relapsing-Remitting Multiple Sclerosis via 7T Magnetic Resonance Spectroscopic Imaging. ○
- 16 Wall-Eyed Bilateral Internuclear Ophthalmoplegia as an Early Presentation of Multiple Sclerosis. **2023**, ○
- 15 Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity. **2023**, 23, ○
- 14 Vascular Disease Risk Factors in Multiple Sclerosis: Effect on Metabolism and Brain Volumes. **2023**, 104675 ○
- 13 Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression. jnp-2022-330848 ○

- 12 Magnetic resonance imaging approaches for studying mouse models of multiple sclerosis: A mini review. ○
- 11 Multiple Sclerosis: A Review with a Focus on the Middle East and North Africa Region. **2023**, 1-22 ○
- 10 1,25(OH)2D3 Differently Modulates the Secretary Activity of IFN-DC and IL4-DC: A Study in Cells from Healthy Donors and MS Patients. **2023**, 24, 6717 ○
- 9 Functional Connectivity and Disability in Multiple Sclerosis: a Cross-sectional Study. ○
- 8 Microfibrillar-associated Protein 4 as Potential Marker of Acute Relapse in Inflammatory Demyelinating Diseases of the Central Nervous System: Pathological and Clinical Aspects. ○
- 7 Reduced cone density is associated with multiple sclerosis.. **2023**, 100308 ○
- 6 The prevalence and risk factors of anxiety in multiple sclerosis: A systematic review and meta-analysis. 17, ○
- 5 Validation of the Spanish version of DYsphagia in Multiple Sclerosis questionnaire (DYMUS). **2023**, 74, 104724 ○
- 4 Altered Lnc-EGFR, SNHG1, and LincRNA-Cox2 Profiles in Patients with Relapsing-Remitting Multiple Sclerosis: Impact on Disease Activity and Progression. **2023**, 13, 1448 ○
- 3 Using quantitative magnetic resonance imaging to track cerebral alterations in multiple sclerosis brain: A longitudinal study. ○
- 2 Socioeconomic, Clinical, and Laboratory Parameters Differentiating Pediatric Patients With MOG Antibody-associated Disease and Multiple Sclerosis. 088307382311702 ○
- 1 Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging. **2023**, 29, 741-747 ○